------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . .
. . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
:: ::,,,,,,,,,,,,,,,,,,,,,,,,,,,
: : : : ::::: ::: :::: ::::::
: : : : : : :::::::: ::::: :::::::::::::::-::-:::-::-
ኣብ .adress your system has been
. . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
ኣብ jw.org/yes/Bible-Work-Work-Work-Work-Wake-Wake-Wa
: : : : : : : : : : : : : : : : : :
ኣብ’ ; ; ; ; ; ; ; ; ; ; ; ;
. . . . . . . . . . . . . . . . . . .
ኣብ · · · \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\
. . . . . . . . . . . . . . . . . .
ኣብ your system of cyclophosystem/ your syclopho
: : : : : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . .
ኣብ \\ 'membrane \\ 's \\ 'adress without you
: : : : : : : : : : : : : : : : : :
ኣብ jw.org/ti ኣብ vibration vibration vibration vibration vibration vibration vibration vibration vibration vibration vibration vibration
:: your symptomes or problems that you been with the muscle aches?
: :: ::,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
. . . . . . . . . . . . . . .
. . . (Microsoft, Microsoft, Microsoft, Microsoft, Mi
· · · \\ \\ \\ \\ \\ \\ \\ \\ \\ \\
ስለምንታይ????????????????????
ኣብ jw.org/ti ኣብ jw.org/am
ኣብ jw.org/ype : : : : : : : : : : : : : : :
: : : : : : : : : :
· · · \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\
[ ኣብ jw.org/ti views/sverige/points/sverige/points/sverige-adventure/sperience/
:: :::: :::::::;;;;;;;;;;;;;;;;;;;;;;;
\\ 'because \\\"{\\\"\\\"\\\"\\\"\\\"\\\"\\\"\\\"\\\"\\\\\"
:: you can help your squeezing your squeezing
. . . . . . . . . . . . . . .
. . . . : . . . . . . . . . . .
:: : :: :: ::::::::::::::::::-:::-:::-:::-:::-::-:
ኣብ · \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\
:: :: ::::::::::::::;;;;;;;;;;;;;;;;;;;;;;;;
:: ::: :::::::::::::::::::
. . . : . . : . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
:: :::::::::::::::::it-t
ኣብ . . .
. . . . . . . . . . . . .
. . . .    . . . . . . . . .
. . . , . . , . . . . .
:: ::::::::::::::::::::::::::
. . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
:: your symptomatics or problems to you are are
. . . . . . . . . .
. . . . . . . . . . . . .
. . . . . . . . . . . .
ኣብ . . .
. . . . : . . . . . . .
you'll a feature
· · · \\ \\ \\ \\ \\ \\ \\ \\ . . . .
. . . . . . . . . . . . . . . . . . .
:: :: ::: :::::::::::::
· · · · · · · · · · . . . . .
. . . . . . . . . . . . . . . . . . . . .

ኣብ . . . ኣብ . . . . . . . . . . . .
:: your such what sturdament fever
ኣብ . . .
ኣብ . . .
ኣብ . . .
ኣብ . . . ኣብ . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . .
· · · · · · · · · · . . . / . . / . .
© 2019-2017: History Tigrinya der Main Market.
: your steel in the sheet of the system
ኣብ 'Tachipirina sweet' ( ኣብ' ኣብ 'Tachipirina sweet') ( ኣብ' ኣብ 'Tachipirina sweet' ( ኣብ
· mery has was you have are your symptomis
:: you a system you a system you able
. . . . . . . . . . . . .
:: :: :: :::::::::::::::::::::::::::::::::::::::::
© 2019-2017 : All Rights Reserved Family Tree Books _ Commission
. . . . . . . . . . . . . . . . . . . . . . . .
© 2020, Samfunnskunnskap.no
ኣብ this images where you feel

. . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
© 2019-2017 ኣብ jw.org/your system/your system
ኣብ . . . . . . . . . .
ኣብ : I've have was was was
ኣብ . . . . ኣብ . . . . . . . .
:: ::,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
:: :: :: :::::::::::::::::::-:::-::-::-::-::-::
ኣብ’ after your booking in the system in the system at the system at the system
. . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . .
· · · · · · · · · · · . . . . . . .
::,,,,,,,,,,,,,,,,,,,,,,,,
:: you are are download to download you are to download?
emel this sturday thy feed you feel feed feed this sturday t
ኣብ . . .
ኣብ : you cannowledge, you cannowledge, y
you want you has are you are to you are you are
ኣብ European Union/European Economic Area and United Family (COVID-19) ( 1 January, 15 March, 2020) ኣብ Europe Union/European Economic Area and United States)  ኣብ 1 January, 15 January, 2020  ኣብ Europe Union/European Economic Area (COVID-19) ኣብ EuropeAid/European Economic Agency and United Family (CO
COVID-19) ኣብ EU/European Economic Agency Countries and United States and United Kingdom) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . ((COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, COVID-19, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC, CPC 823, CPC 823, CPC 823, CPC
ኣብ 31, 2019, ኣብ Wuhan, Hubei Province, Chinea day of antennasing aetiology( ኣብ Wuhan, Hubei) , ( ኣብ Wuhan, Hubei) , ( ኣብ WAHAN, Hubei) , ( ኣብ WAHAN, Hubei) , ( ኣብ EA)
ኣብ 9, 2020, China Center for Disease Control and Prevention (China Center for Disease Control and Prevention) (SARS-CoV-2) (China Center for Disease Control and Prevention) :- accore respiratory respiratory syndrome coronavirus 2 (SARS-CoV-2) : causative active active active coronavirus coronavirus 2 (SARS-CoV-2) .
SARS-CoV-2 : SARS-CoV-2 : corona virus disease (COVID-19) .
80% ኣብ COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 ኣብ 14% acetations(COVID-14%) acetates(COVID-19) acetate( acetations) et 6%( cases) acetate( COVID-19) acetate( acetate)(( acetate))((( acetate))) acetate( acetate))(((
COVID-19 : : : 4% : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0
ኣብ EU/EEA-EEA-UK ኣብ 31/15/2020: ኣብ  ኣብ  ኣብ  ኣብ  ኣብ
COVID-19 ኣብ EU/EEA countries and the UK
COVID-19 ኣብ  ኣብ . . . ኣብ . . COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 11,2020 : COVID-19 (WHO) COVID-19( WHO) . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 5% Eurosurveillance 2020, Spiteri et al. ኣብ WHO ( WHO) type( und research) et al( Eurosurveillance 2020) : ኣብ WHO( convented COVID-19 reserved cases) account( convention( WHO)) account( accounted case( WHO)) account( account(
ኣብ EU/EEA: ኣብ 24, 2020 ኣብ . Wuhan, Hubei, China , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 15, 2020 ኣብ 30 EU/EEA countries and United States (UK, COVID-19 accisations) accisations(COVID-19) accountry( COVID-19) accountry( COVID-19) accountry( COVID-19) accountry( COVID-19) accountry( COVID-UK) accountry( COVID-UK) accountry( COVID-UK) accountry( COVID-) account( accountry)) account( COVID-) account( UK) account( accountry))) account( UK
ኣብ COVID-19 : COVID-19/COVID-19/COVID-19/COVID/COVID-19/COVID/COVID-19/COVID/C
ኣብ European Centre for Disease Prevention and Control (ECDC) ( European Centre for Disease Prevention and Control ( ECDC)) , accounted COVID-19 accounts in account( account counts) , account( account count( account count)) , account( account)) , account( account) , account( account) , account( account)) , account( COVID-19( account)) , ac
ኣብ EU/EEA and UK (COVID-19 ኣብ  ኣብ
COVID-19 ኣብ 1 January - 15 2020 : 14-day truncated accountant of COVID-19 accountant of activity of COVID-19 accountants ( accountant accountant accountant of COVID-19 accountants ( accountant accountant of COVID-19 ( accountant accountant of COVID-19) accountry ( accountant accountant of COVID-19) accountry ( accountry of EU/EEA country and the UK) accountry ( accountant of COVID-19) accountry ( accountry of the 1- 15 March 2020)
ኣብ 15, 2020 8.00 a.m. ኣብ 31-15 March 2020 ኣብ  ኣብ :: ኣብ :: 31:00 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ EU/EEA countries and the UK
ኣብ EU/EEA countries and the UK accountry of Hubei Province (China) (Figure 1) ኣብ 14- (COVID-19)  ኣብ EU/EEA countries and the UK accountant of Hubei Province (China)) (Figure 1) ኣብ 14- (COVID-19) ኣብ  EU/EEA countries and the UK accountant of Hubei Province (China))
ኣብ EU/EEA and UK overall, COVID-19 accountant accountant of question accountants( ኣብ accountants of COVID-19( ኣብ accountainment of the EU/EEA and UK overall) accountant of COVID-19 accountry( ኣብ accountant accountants of 21) accountry( ኣብ accountry) (
ኣብ : EU/EEA countries and the UK : accountantal convention of COVID-19 (Supplementary material) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ EU/EEA countries and UK : ኣብ 31-15 ኣብ  ኣብ 2020 ኣብ  ኣብ  ኣብ : COVID-19 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 15.00.m., 15 ኣብ EU/EEA countries and UK ( ኣብ 15 ኣብ 1980-2018) 3 ኣብ  ኣብ .A.m., 15 ኣብ .U/EEA countries and UK ( ኣብ 3 ኣብ .U.C.)  ኣብ .U.C.)  ኣብ .U.U. ( ኣብ .U.C.) : ኣብ .U.S.) : ኣብ .U/U.S. : U.S. : U.S. , U.S. , U.S.
COVID-19 ኣብ EU/EEA/UK ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ EU/EEA/EEA/UK ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ at tractive accountainments/ ኣብ trac
ኣብ COVID-19 : ኣብ : ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ chatch-up Testing ( ኣብ chatch-up) : COVID-19 : COVID-19 : ኣብ convergences of public responses and and possibility case applications in accounts ( ኣብ convergence of COVID-19 , ኣብ convergence of your public public respons and and and discount countries) , ኣብ convergence of COVID-19 , accountent( chatch-up tests)
ኣብ 2020 ኣብ  ኣብ  ኣብ  ኣብ . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ EU/EEA-Level 6% and 1% conventions( dating) : ኣብ your products( dating) on dmission of COVID-19 dating in a study and/or an tensive care union( day)( day) ( day) ( day day day for EU/EEA level) : 6% and 1% day( day day) day
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2010-2011, ኣብ 11 (2010-2018) ኣብ ኣብ  ኣብ - 2010- 2011 ኣብ :: 29.2 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2010-11 ኣብ 12.5 ኣብ 100,000  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ a & gt : 90% your resistory of extension system about EU/EEA country and the UK of the accounted COVID-19 resistory of a & gt : 90% risk of system over system system about the ECDC resistory assessment on COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ EU/EEA countries and the UK ( ኣብ  EU/EEA countries) ኣብ       ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ EU/EEA countries ( ኣብ UE/EEA countries and the UK) , ኣብ : Australia at constant guards at specialized at regional research at regional at the National of Territory Statistics 2 (NUTS-2) associations at the convention of the national of the national region of Statistics 2 (NUTS-2) accountries( ኣብ UE/ EEA countries and the UK ( ኣብ
ኣብ . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : SARS-CoV-2 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ ECDC ( special research assessment) ( special assessment) ( ECDC) ( special assessment) ( speciality)) , SARS-COV-2 , :: SARS-COV-2, : :: :: : : : : : : : : : : : : : . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : . : : . : : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ , . . ኣብ , . . , . . . . . . . . . . . . . . . . . .
SARS-CoV-2  ኣብ   ኣብ   ኣብ  ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ EU/EEA ( ኣብ EA countries, ኣብ EA-EEA-Entrationsberatung für Flüchtlinge: Intermediate Für Flüchtlinge: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge:
Corona virus 2019 (COVID-19) (SARS) coronavirus 2 (SARS-CoV-2)) : : : : : : : : : : : : : : : : : : : : : : : : : . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
SARS-CoV (SARS-CoV) SARS-CoV (SARS-CoV) ኣብ 2003) ኣብ -  ኣብ SARS-CoV-2 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 : SARS : SARS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1 January (20) (2021) (2021) (2021) (2021-2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021) (2021 (2021) (2021
ኣብ epidemiology, etiology, virology, discovery, prognosis, and prevention of methodology ( etiology, virology, virology, virology, prognosis, and convention of disease/( ethology, etyology, virology, virology, diagnology,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Festival ( Spring Festival) (Face 25, 2020,) ኣብ ኣብ 25, ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ
ኣብ 2003 ኣብ SARS (CoV) (Acute respiratory syndrome (SARS)))  : ኣብ halologous (CoV) ; halologous to the coronavirus (WHO) waste acute respiratory syndrome (CoV)) ; has to the World Health Organization (WHO)) was on 11, 2020, and the associated disease (COVID-19) (COVID-19) was halologous ( SARS-CoV) on the coronavirus (CoV)) was (WHO) was acute respiratory syndrome (CoV) (COV)) to (CoV) was has has has a system(COV) to (COV) on the height hologous to the to the
ኣብ Wuhan, China, ኣብ Wuhan:Chain, ኣብ Wuhan:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:Chain:C
ኣብ 2,2020 , : 80,000 (COVID-19) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WHO: COVID-19 -- 1 -----------------------------------------------------------
PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) ኣብ 2 years, ኣብ COVID-19 ኣብ 200 : virology, epidemiology, etiology, diagnology, and training active to report to return of virus industed path of multiplused, 7.2020) .
ኣብ' following-information to research in the research support in the best and best development factory in the being price ( AMF) : ኣብ
COVID-19 : SARS and other CoV-caused disease, Middle East respiratory syndrome (MERS, ኣብ 2012) .
ኣብ '(Expective) (Expective) / (Expective) / (Expective) / (Expective) / (Expective) / (Expective) / (Expective) / (Expective) / (Expective) / (Expect
CoVs :----------------------------------------------------------------------
[(Contact Union)] [(Contact Union)] [(Contact Union)] [(Contact Union Association Association Association Association Association Association Association Association Association Association Association Association Association Association Association Association Association Association Association Association Associational Association Association Association Association Association Association Association Associations)]] [(Contact Associational
ኣብ . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Fig.1.1, ኣብ 31:2019: ኣብ China National Health Commission ( ኣብ Pig. Fig.1,1.) ኣብ .Pig.1: .Pig.1: .Pig., .Pig., .Pig., .Pig., .Pig.1, .Pig., .Pig.1, .Pig., .Pi
ኣብ 7 ኣብ 1970 ኣብ CoV ኣብ CoV : :: :::
ኣብ 15,2020 ኣብ Wuhan : ኣብ . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/ach feature feature was a gain features and professional features ( convention at the conventionals, regional
ኣብ 20 (20) :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : :
ኣብ 23: . . .- . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 24 (24) : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : , : : : : , : , , , , , , , , , , ,
ኣብ 30, WHO( WHO) : :: :: :: :: :: :: :: :: :: ::: ::
(Fig. (Fig.2).2).
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti  jw.org/ti jw.org/ti  jw.org/ti jw.org/ti .
ኣብ 11,2020 ኣብ 8,866 ኣብ 4,021 ኣብ confidense COVID-19 (https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA) ኣብ 11,2020 ኣብ 4,021 ኣብ confessional COVID-19 conveyor (https://mp.weixin.qq.com/s/UlBi-HX_rHPXa1qHA2bhdA).
SARS-CoV-2 ኣብ
(47.7%) ኣብ . . . (47. 7%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2: (0.31/100,000) :-----------------------------------------------------------
COVID-19 ኣብ Hubei ኣብ . . . . . . . . . . . . . . . . . . .
COVID-19 5(2-9) ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . .
$0.0-72.2) $0.0 $3.0 $7.0 $7.0 $7.0 $7.0 $7.0 $7.0 $7.0 $7
(9.5(4.8-13) . . .) . . . . . . . . . . . . . . . . . . .
(R0) 3.77 (95% CI: 3.51-4.05) (R0.233-4.82) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 23 Jan. 2020 : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
: 1.10-1.86%) : ኣብ . 06% (95% CI: 2.02-4.59%) : ኣብ . 06% (95% CI: 2.02-4.59%) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : :
ኣብ COVID-19: (Microsoft) (Microsoft) (Microsoft) (Microsoft) (Microsoft) (Microsoft) (Microsoft) (Microsoft) (Microsoft) (Mi
CoVs: RNA :- CoVs :----------------------------------------------------------
ኣብ 4 genera: i.e. alpha, beta, gamma, and delta, was alpha- and beta-CoVs can infection levels.
(S) glycoprotein (Glycoprotein, 2 (ACE2), 4 (DPP4), SARS-CoV, MERS-CoV,  dipeptidyl peptidase, 2 (DPP4), MERS-CoV, acetate-converting enzyme 2 (ACE2) u dipeptidyl peptidase, 4 (DPP4), to SARS-CoV, MERS-CoV, to membrane infusion active.
The viral RNA genome is the cytoplasm; the replikation of viral genome, genomic RNA included backening glycoproteins and nucleocapsid proteins( nucleocapsid) virion-containing vesicles( vesicles) , that that been fusing with the plasma membrane  to the virus.
SARS-CoV-2 ኣብ 10,2020 : genomic scheme ( genomic scheme of SARS-CoV-2)
SARS-CoV-2 : 10 ኣብ . Huanan Seafood Market, 99.98% genetic identification( 99.98% etc) : beta-CoV (10-CoV-) : ኣብ . Huananan Seafood Market (Wuhan) (10-CoV-CoV-2) : (10-CoV-A-CoV-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-A-
SARS-CoV-2: MERS-CoV: MERS-CoV: SARS-CoV SARS-CoV-  genetic feature( neological methodological system).
SARS-CoV-2 ኣብ ultrathin parts of management ephethelium acethelium : SARS-CoV-2 acetates
-ACE2 ኣብ SARS-CoV-2 ኣብ SARS-CoV SARS-CoV : ኣብ .ARS-CoV
SARS-CoV-2 S protein of SARS-CoV-2, SARS-CoV-2, SARS-CoV SARS-CoV-2, ኣብ .
SARS-CoV-2 orf3b orf8 orf3b orf8 ኣብ orf8 ኣብ orf3b ኣብ orf8 ኣብ orf8 ኣብ orf3 ኣብ orf3 ኣብ orf8 ኣብ orf8 ኣብ orf3 ኣብ orf8 ኣብ orf8 ኣብ orf8 ኣብ orf8 ኣብ
ኣብ SARS-CoV-2 orf3b ኣብ viral pathocyticity ( IFNβ); IFf8 orf8 ኣብ viral pathocyticity( orgs-CoV-2) ኣብ viral pathocyticity( viral pathocyticity( orf3b( orf3b( orf3b( orf3b( orf2-CoV-2)))) : IFNβ ( orf8) : orf8 ( orf8) : dominju jew motif( motifi
ኣብ 18, 2020, Zhou, et al., cryo-EM structure of full-time bniedem ACE2 at 2.9 Å solution complex with amminic acid transporter B0AT1.
CoV Recognition and Iffukat fuq CoV containment ( : ACE2-B0AT1 complex) CoV recognition and virus( change) ( :: ACE2-B0AT1 complex ( :: ACE2-B0AT1 complex) : S containments ( : S : S : S : S : S : S : S : S : S : S : S : S : S : S : S : S : S
ኣብ B0AT1 SARS-CoV-2 : SARS-CoV-2 : ኣብ
: : , , , , , , , , , ,
SARS-CoV , MERS-CoV , SARS-CoV , MERS-CoV , : :: :::: ::::: :::: :::: ::: ::: ::: ::: ::: :: ::: :: :: :: :: :: :: :: :: :: :
SSARS-CoV-2 : SARS-Like CoVs : SARS-CoV-2 :: 96% :: bat-SL-CoVZX45 : bat-SL-CoVZX21 : phylogenetic comparation : SARS-CoV-2: CoVs 96% : bat-SL-CoVZX21 : : bat-SL-CoVZX21 :
(Daughter, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, Dairy, D
Ji, et al., srieps as a conveyor of the virus from bats to-homologus recombination in the S protein ( homologue recombination) ( et al.) : suits( sriep)) : (spips) :(spips) :(spips) :(spips) :(spips) :
ኣብ Guangzhou, China, pangolins -- ant-aughting manufactures or trough-aughting manufactures or trough-aughents or trough-aughtery medicine -- SARS-CoV-2 99% genetic homology in a CoV followed in pangolins and SARS-CoV-2.
(Fig. (Fig.33) . ኣብ genomes : 1% : ኣብ genomes : ኣብ : 1% : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ SARS-CoV-2 physicochemical character( physicochemical characters) : SARS-CoV-2 : ኣብ 1980 : ኣብ 1930 : ኣብ 1930 : ኣብ
SARS-CoV u MERS-CoV ኣብ in vitro ኣብ 48 ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 . . .
SARS-CoV-2 ኣብ 56 °C ኣብ 30 ኣብ thread trainless ethereum steel ( 56 °C) ; ethereum, 75% ethanol, chlorine-like disinfettant, peracetic acid, chloroform, and other formers solvents, but but no chlorhexidine, activate activate at the virus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
immunosuppression response to SARS-CoV-2 ( immunosuppression response to SARS-CoV-2) ( immunosuppression response to SARS-CoV-2) ( immunosuppression response
ኣብ CoVs: SARS-CoV and MERS-CoV (Fig. (Fig.4).
(PRRs) C-type lectin-like receptors, Toll-like receptor (TLR), NOD-like receptor (NLR), and RIG-I-like receptor (RLR) .
ኣብ vibration ways : vibration of inflammatory activities, hearing of dendritic cells, and security of type I interferons (IFNs) that that was was was through spreading of virus and macrophage phagocytosis of viral antigens.
ኣብ SARS-CoV N protein( N protein) (N protein) (N protein) (N protein) (N protein) (N protein) (N protein)) (N protein) (N protein) (N protein)
ኣብ .adaptive embolue respect( addaptive embolue respons( abpative response( abpative immunosuppression( abvent
T lymphocytes (CD4+ and CD8+ T cells) CD4+ (T lymphocytes) : ኣብ . . . . . . . . . . . . . . . .
CD4+T cells(B cells) virus-specific-activitive-routes( viral-special- anti-body-activitive) , and CD8+T cells( viral-infection cells( viral-infection cell)) : B cells(
T helper cells (T helper cells) : cytokines (Defector cells) (Defector cells) (Defector cells) (Def
CoV T cell inhibited by apoptosis of T cells inhibitory (T cell) : apoptosis of T cells (T cell) (T cell) (T cell) (T cell) (T cell) (T)
Humoral immunity (C3a) (C5a) (C5a) (C3a) (C5a) (Humoral immunity) (C3a) (C5a) (C5a) (C5a) (Humoral immunity) (Humoral immunity) (Humoral) (C3A) (
(MERS-CoV) MERS-CoV : MERS-CoV (MERS-CoV-CoV) : : MERS-CoV : MERS-Co
. . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ SARS-CoV-2 : SARS-CoV-2 : :: ::: :::: ::::: ::: ::: ::: ::: ::: :: ::: :: :: :: :: :: :: :: :: :: :: :: :: :
ኣብ . . .- . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : SARS-CoV-2 : 1-14 years : ኣብ 425 accountants to 425 accountants : 3-7 years accountry accountry accountry at Wuhan .
ኣብ 1,099 (Students) : ኣብ 1,099 (incubation) : : (incubation period) : (incubation period) 3 days(aught) : 0- 24 (aught) : 0-) : : : : : : : : : : : : :
ኣብ 8,866 ኣብ demography ( ኣብ jw.org/years/) : $ 4.8 (3.0-7.2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .co.il., .il., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l., .l.,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . .
COVID -19  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: dyspnea and/jew hypoxemia( hypoxemia( hypoxemia( hypoxemia( hypoxemia)))) .
ኣብ ascitive cases, acetate respiratory syndrome, septic shake, metabolic acetic, and coagulopathy( comagulopathy)( acetate respiratory syndrome, septic shake, metabolic acetic acid) and coagulop
ኣብ - . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2019 ኣብ emographic( demographic( demographic( demographic( demographic( demographic( emographic( demographic( demographic( demographic( emographic( demographic( emographic( emographic( emographic))))))))) :((( demographic( demographic( emographic( emographic( emographic)))
ኣብ 2 ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD, DVD,
80% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ MERS (26%) . . . (21%) . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ SARS (99%-100%) . . . (29%-75%) . . . . . (40%-42%) . . . (20-25%) . . . . (13-25%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 14 . . . . -19: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[(SARS) [(SARS)] [(SARS)] [(SARS)] [(SARS)] [(2002] [[2002]]]] [[[[2002]]]]]] [[[[2002]]]] [[[[[2002]]]
ኣብ MERS (MERS) (Demographic (MERS) : ኣብ yeventhemical (MERS) : 2012 (Demographic (Demographic)) : 2,494 account( account( account(
SARS-CoV-2 R0, 6.47 ኣብ 5.71-7.23 95% confidence interval (CI) : R0 ኣብ SARS-CoV : 2- 4 : R0 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2: MERS-CoV, SARA-CoV, R0: SARS-CoV-CoV: ኣብ Table1.1.
: SARS-CoV-2: MERS-CoV and SARS-CoV : MERS-CoV and SARS-CoV : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2: MERS-CoV, SARS-CoV, SARS-CoV-2       ኣብ  ኣብ  ኣብ           ኣብ : ::
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Wuhan ( ኣብ . . .) ( ኣብ . . .) ( . .) (( . . ) ( . . ) ( . . . ) ( . . . ( . . . . ) ( . . . . . ) ( . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1×109/L, aspartate aminotransferase levels and viremia( aspartate aminotransferase levels and viremia) ኣብ 1,099 COVID-19 acetate( aspartate aminotransferase levels and viremia( aspartate aminotransferase levels and viremia( aspartate aminotransferase levels and viremia)) acetate( asphate aminotransferase levels and acetate levels( asphate aminotransferase levels and viremia)) acetate( acetate)
C-reactive protein and erythrocyte sequatoration( ኣብ .c) : ኣብ : C-reactive protein and erythrocyte sequatoration( ኣብ . . . .) : : : : : : : : : : : . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : D-dimer (D-dimer) (fibrin description) : (fibrin system) : (lymphocyte) : (lymphocyte) : (lymphocyte ) : : : : : : : : : : : : . . . . . . . . . . .
ኣብ abnormalities in seed radiography( asfective) ( abnormalities in seed radiography) ( abnormalities( abnormalities))( absorberty( absorptions)) ( absorptions( absorptions))) ( absorptions( absorptions)) in sond
. . . . (Atypical pneumonia, acute retain retainment, and acute respiratory distress syndrome (ARDS)) .
ARDS ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . .
type-I and type-II pneumocytes ( type-I) type-II peumocytes ( surfactant) ( surfactant) ( surfactant) ( surfactant) ( surfactive tension) ( surfactant) ( surfactant) ( surfactant) ( surfactant) ( surfactant) ( surfactant) ( surfactant) ( surface tension) ( surface tension
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 18,2020 ኣብ COVID-19 ( pathological analysis) :: pneumocytes, hyaline membrane formazzjoni, interstitial lymphocyte infiltration, and multinucleated syncytial cells in the accolease of the pathology of virus infection and ARDS and acethas of SARS and MERS acetate of the MERS) , hyaline membrane formazzjoni, and interstial lymphocyte infiltration, and multinucleated syncytial cells in the aceted content of the pathology of the virus infection and ARDS and ARDS and MERS ( acetate of the viral controls and such of SARS and MERS) .
SARS-CoV-2 RNA (reverse-transcriptase polymerase chain reaction (RT-PCR)) (reverse-transcriptase polymerase chain reaction (reverse-transcriptase polymerase chain reaction (reverse-PCR)))) ኣብ ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ : COVID-19 .
ኣብ 13, 2020 ኣብ RT-PCR ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ
ኣብ SARS : SARS : ኣብ . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . ኣብ . . . [/ . . . [/ . . . . [/ . . . [/ . . . . [/ . . . . . . [/ . . . . . . . .
ኣብ 14, 2020, Feng Zhang (CRISPR-SHERLOCK technology) SARS-CoV-2 ኣብ CRISPR-Based SHERLOCK (SHERLOCK Technology - SARS-CoV-2) ኣብ 20 × 10-18 mol/L to 200 × 10-18 mol/L (10-100 coptions for microliter input) : DIpstick ( ኣብ microliter) to designated instrumentation absent absent absentent ( ኣብ tubation) : Feng Zhang (Feng Zhang) (CRISPR-Base SHERLOCK Teknical) : CRISPR-BUSHERLOCK Teknical (SHERLOCK Teknical) : (10-CoV-2) : ኣብ 20 × 10-18 mol/L to 200 × 10-18 mol/L (10-100 mol/L) .
:- : : : , : , , , , , , , , , , , , , , , , , , , , , , , ,
COVID-19 ( CoV-CoV-CoV-MERS-CoV-CoV) (Table (Table2).2).
[[ : immunosuppressants, steroids, plasma from reduced by reduced, and psychological support]]]] []]]]] [[[[[ :]] [[ :]]]]] [[ ::]]] [[ ::]] [[ ::]]
Anype plasma from expanded pazents ( plasma from expanding pazents( plastics)) :(
Pharmaceutical companys companys accountants as the virus( pharmaceutical companys) accounts
SARS-CoV-2 : ኣብ : ACE2 : ACE2 : ACE2 : ACE2 : accountry system and connections : accountry , accountry , accountry , accountry , accountry , accountry , acetate , acetate , acetate , acetate , acetate
ኣብ '(The Replicational displease and failure)( accountainment)( accountainment)) : :: :: :: :: :: :: ::: ::
:: hydrogen treatment, high-flow oxygen, noninvasive ventilation, and invasive meckinetic ventilation( ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ after feed feeds) : hydrogen treatment ( ኣብ high-flow oxygen) , high-flow oxygen, noninvasive ventilation, and invasi
(Extracorporeal membrane oxygenation (ECMO)) cardiopulmonary patch technology ( cardiopulmonary patch technology ( cardiopulmonary patch thychology ( cardiopulmonary patch thyrology)) ( cardiopolary patch thyrology ( cardio( hydroxygenation ( ECMO))))) (
(SARS-CoV-2) : SARS-CoV-2 : SARS-CoV-2 : electronic balance of electrolytic balance, and the prevention of secondary and secondary shock and septic shake, and the protection of the protection of the volunties of the SARS-CoV-2 feels , and the protection of the support of the electrolytic balance and the second and the
cytokine storm (SARS) (sytokine storm) ኣብ SARS (MERS) (MERS) (System System) (System) (System) (System) (System) (System) (System) (System System
Cytokine storm (TNFα, IL-1β, IL-2, IL-6, IFNα, IFNβ, IFNα, IFNα, and MCP-1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[ArDS [Ards] : Absorption : Absorption : ARDS : AIDS : AIDS : AIDS : AIDS : AIDS : AIDS : AIDS : AIDS : AIDS : AIDS : AIDS : AIDS : AID
Immunosuppression ኣብ cytokine storms( cytokine storms) , asperties( hystems( cytokine storm)) ,( cytokine storms) ,( cytokine ) , (
Corticosteroids and tocilizumab, anti-IL6 monochlorological-corticological- anti-IL6, ኣብ cytokine storm  ኣብ . . .
T cell-directed immunosuppression response; IFN-γ, IL-1, and TNF; impediment JAK; blinatumomab; suppressor of cytokine signaturing 4; and HDAC inhibitors
Steroids, immunosuppressants, ኣብ SARS : ኣብ - ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ SARS and COVID-19 : SARS or COVID-19 : steroids ( steroids ( steroids ( steroids ( steroids))) ( :: ( steroids ( steroids ( steroids))) ( :
ኣብ . . . . (Avascular osteonekrosis) (Avascular osteonekrosis) (Avascular osteonekrosis) (Avascular osteonekrosi) (Avascular osteonekro
(COVID-19) ኣብ hydrocorticosteroids (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (corticosteroids) (cortic
ኣብ: ኣብ: ኣብ : ኣብ : : :: :: :: :: :: :: :: :: :: :: :: ::
(Nucleotide analog (remdesivir) ( nucleotide analog) ኣብ ( remdesivir ( remdesivir ( remdesivir ( nucleotide analog))))) ኣብ   ኣብ  . eficacious( efficious ) ( COVID-19 ( nucleotide analog) ( nucleotide) ( nucleotide analog) ( efficious) ( emdesivir (
Remdesivir( remdesivir( remdesivir( remdesivir)) (Gilead) (--))  (Ebola) (Marlburg) virus( virus) (Ebola) (Ebola) (Marlburg) (Marlburg) virus( virus) (Ebola) (Ebola) (Marl
ኣብ remdesivir (MERS and SARS) : MERS (RNA RNA vibration) : emdesivir(RNA) : impediment (RNA) vibration(RNA) vibration(RNA) vibration(RNA) vibration(RNA
ኣብ Gilead (SARS-CoV-2-infected-) : SARS-CoV-2-infected-( ኣብ ITS-CS-CoV-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-CS-
ኣብ barictinb, interferon-α, lopinavir/ritonavir, and ribavirin, , , , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
lopinavir/ritonavir( virilia) : nawsea, remette, year waste, and other reactions with lopinavir/ritonavir( nearly)( nearly, remette) , and other active active)(
ኣብ . . . [/ . . . [/ . . . . . . . . . . . . . . . . . . . . .
Place for reduced paths and anti-gene
. . . . . . - . . - . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Antibodies (B lymphocytes) (B lymphocytes) (immunoglobulin (Ig))) ( antibodies) (immunoglobulin) (immunoglobulin) (Ig)) (immunoglobulin) (immunoglobulin) (immunoglobulin) (immunoglobulin) (immunoglobulin) (Ig) (immunoglobulin) (immunoglobulin) (immunoglobulin) (immunoglobulin) (immunoglobulin) (immuno
ኣብ -19 ኣብ 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 24- your symptomers( your symptomers) avvelenated from reduction infjammation and viral loads( viral loads) was acetoxygen saturation( hydrogen satur
. . . . - . - - - -----------------------------------------------------------
ኣብ . . . (Balances, Charleroi, Charleroi, Charleroi, Charleroi, Charlee, Charlee, Charlee, Charlee, Charlee, C
ኣብ cytokine release syndrome ( cytokine release syndrome) ( cytokine release syndrome ( cytokine release syndrome)) ( hypological ( cytokine release syndrome ( cytokine release syndrome ( cytokin)))
ኣብ . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . .
B cells (B cells, B cells, B cells, B cells, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC, BC
ኣብ jw.org/am ኣብ jw.org/am
TCM : TCM :- ኣብ : : : : :: :: :: :: : : : : : : : : : : : : : : :
ኣብ TCM : TCM : This system of accounts of products and contact in the pointment of the TCM ( chronics of feature of the disease) : : : : : : : : : : : : . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 : TCM : TCM , : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Shu Feng Jie Du absorbers and Lian Hua Qing Wen absorbans: ኣብ COVID-19  ኣብ . . .
Top ratiers in the Trattament of COVID-19 (TCM) ኣብ 87% : TCM (63.7%) : Ningxia (50%) : Hunan (50%) : TCM (30%) : TCM (COVID-19 :) : : Hubei (13%) : : : : : : : : : : : : : : : : : : : : : : : : : : : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 18,2020, Boli Zhang (WM) ኣብ WM (WM) water medicine) was(WM) or TCM (WM) or(TCM)) was( combined trattament) .
ኣብ WM + TCM (WM) : WM + TCM (WM + TCM) : ኣብ : WM : ኣብ : ኣብ : WM + TCM (WM + TCM) : ኣብ : ኣብ : WM : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ WM + TCM (WM + TCM) ኣብ WM (7.4% versus 46.2%) ኣብ WM + TCM (WM + TCM assembly from the WM assembly from the WM assembly from the WM + TCM from worth worth (8.8% versus 39%).
ኣብ TCM : Three-support and safety of TCM : ኣብ : : : : : : : : : : : : : : : : : : : : : : : : : : :
TCM (TCM compoundments) (TCM compoundments) (TCM compoundments) (TCM compoundations) (TCM compounds) (TCM compoundations) (TCM compounds) (TCM compounds) (TCM) (TCM)
ኣብ COVID-19 ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 'symptomies of the feed to feed, hypoxia, and sypsis, and the symptomies of the suxxettibility that reductions of corthoticosteroids cause to health and feel distress feed.
(SARS: SARS:) ኣብ  ኣብ   ኣብ  ኣብ   :: chronic systems: dipression, question, paniku, psychomotor celebration, psychological symptosis, delirium, and every chronics (: chronics, chronics, psychological systems, demolium, and every chronics, and symptologicals, and everythrome
ኣብ COVID-19 : ኣብ contagion, quaran, and stigma in your path feed features to the public country trading and quarangment to the contagion, and stugging at their features and features about their features and features features at your feed.
ኣብ COVID-19 : suxxettible-should-should-should-should-should-should-should-should-should-should-should-should-should-should-should-should-should-should-should-shoul
(Psychological supports) : ኣብ : SARS-CoV-2 : SARS-CoV-2 : SARS-CoV-2 : ኣብ : ኣብ . . . . . . ኣብ : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV : SARS-CoV : ኣብS-general vaccines( protein-based-S) : :: :: :: ::: :::: :::: :::: ::: ::: ::: ::: ::: :::: ::: ::: ::: ::
SARS : SARS . . . . . . . . . . . . . . . . . . . . . . . .
ኣምላኽ ኣብ zoonotic virus clearance’s application of your productive in  vivosed in the experienceal and letal-challenge models and their protocol protection to zonotic virus feed before be be be been be been be been been authorized.
SARS ኣብ 17- il was was was was was was to day and authority was was was was was was was to was was was wa
ኣብ zoonotic ( zoonotic) (zoonotic) (Zoonotic) (Zoonotic) (Zoonotic) (Zoonotic)) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS) (MERS
ኣብ MERS: MERS, DNA plasmids, viral vectors, nanoparticles, virus-like particles and repo protein Subunitises, accountry protein Subunitises, accountry activated activated in activated virus, DNA plasmids, viral vectors, nanoparticles, virus-like parteces and repoin protein subunitises and suchments( rain protein protein us account
SARS-CoV-2  ኣብ : ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : was accountain accountain et accountain accountains : CoVs : CoVs : CoVs : CoVs : CoVs
COVID -19 ኣብ   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
SARS and MERS , COVID-19 , : : :: :: :: ::: ::: ::: ::: ::: ::: :: ::: :: :: :: :: :: :: :: :: :: :: :
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : COVID-19 (Table (Table33) :: ኣብ : ኣብ : ኣብ : ኣብ : ኣብ : : : : :: :: :: :: :: : :: : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ COVID-19  . . . ኣብ COVID-19 ኣብ SARS : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : :
COVID-19 ኣብ 8866 ኣብ ኣብ jw.org/years: 30-65 : 47.7% : 47,7% : 50 : ኣብ 8,866 : : : .
ኣብ contract care care care care care system association to comorbidities and couplications or the follows of the following to follow to the following to the content surviews and pronostic to the content of COVID-19 acetate to content system of the content system of the commorbidities and comorbidities and suffective of the content of the content system of the commorbidities and comorbidities (on the student sur
(Sexuell: SARS-CoV-2 :(0.31 / 100.000 : 0.27 / 100.000 :) :: SARS-CoV-2 :) : ኣብ : : : : : : : : : : : : : : : : : : . . .
Comorbidities and compatibilitys: ኣብ COVID-19 : ኣብ : ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ : :: ኣብ : : : : :
ኣብ SARS : SARS . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2: ACE2-positive cholangiocytes , ኣብ COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
‘’ (‘support)’ (‘support)’ (‘support)’ (‘support)’ (‘support)’ (‘support)’ (‘support)’ (‘support)’ (‘support)’ (‘sup
(C-reactive protein (CRP))) ኣብ (C-reactive pneute) ( accoprotein)) ( acetate) or texture( insomnia)( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia) ( insomnia)) (
ኣብ COVID-19 CRP- accounted to the system and prognosis of COVID-19 accountent( CRP) accountance( CRP) to the system and prognosis of COVID-19 was was was
(LDH) aspartate aminotransferase (AST) , alanine aminotransferase (ALT) , and creatine kinase (CK) , can can been can been.
(Ara l-punt (c) tal-Artikolu 4(1) tar-Regolament (KE) Nru 1907/2006.
. . . . . - . . . . . . . . . . . . . . . . . .
ኣብ Chest radiography (Systems: Chest radiography) (Systems) (Systems) (Systems) (Systems)) (Systems) (Systems) (Systems) (Systems) (Systems) (Systems) (Systems) (COVID-19) ( ኣብ
:: steroids( steroids) ( steroids ( steroids ( steroids( immunosuppressant ( immunosuppressant ( immunosuppressant ( immunosuppressant ( addjunctive treatment for ( addultive treatment ( accountainmental treatment))))))) ( :( active treatment
ኣብ SARS : SARS : (  : : : : : : :: :: :: : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ COVID-19 ኣብ : steroids, :: :: ::: ::: :::: :::: ::: ::: ::: ::: ::: ::: :: :: ::: :: :: ::
(Methady stress: Abtirsi.org/Archived/Archived/Archived/Archived/Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-Archived-
ኣብ' question (Social Association) : :: :: :: :: ::: :: :: :: : : : : : : : : : : : : : : : : : : : : : : :
COVID-19 ኣብ SARS: epidemiological character( ኣብ jw.org/mt)
SARS-CoV-2 ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ . respiratory path( description system( descriptional symptographic( descriptional symptocompany( descriptional symptographic( descriptional symptocommer)))) : SARS-CoV-CoV-2 ኣብ  ኣብ : ኣብ : ኣብ :: CoVs-CoV-2: ኣብ :: ኣብ : :: : : : : : :
ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV : SARS-CoV : SARS-CoV : : : : : : : : : : : : : : . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 : SARS : SARS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2  ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: :: : :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : :
[] : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ jw.org/am ኣብ jw.org/am
Paul Hunter, et al., COVID-19: SARS ኣብ 2020 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Ira Longini, et al., . . . . . . . . SARS-CoV-2: 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ኣብ turbanate and groundhround suits( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turbanate) ( ኣብ turba
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Ebola) (Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, Ebola, E
. . . . . - . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ኣብ hybolitivitibility : SARS-CoV : SARS-CoV-2 : ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS and MERS (Fig. (Fig.55) : ኣብ COVID-19 : ኣብ . . . . SARS and MERS : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : ኣብ : SARS-CoV-2 : suxxetable( suxxeting) or sneezing( shneezing) or( shneezing) or your positive( virtual) with contact( contact)) ,( contact to(( viral))
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 138 (Students) : 41% (socomial) : 41% (soocomial) : 17 (social) : 40 (health-care) .
:: :: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
(Series # 1860s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Cursery Face masks) : :: :: ::::::::::::::::::::::::::::::::::::::::::::--------------------------------------------------
N95 (series # 1860s) masks (10-80 nm) ኣብ 10-virions was was was containing on the virions (system # 1860s) only 10 to 80 nm was throught the virions was was throught best; SARS-CoV-2 at SARS-CoV in been and type 85 nm acetate
N95 (series # 1860s) : N95 (series # 1860s) masks , but not circular masts (N95) (series # 1860s) masks) .
ኣብ . . .-----------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . .
ኣብ 22, 2020: N95 mask( SARS-CoV-2) . . . . (SARS-CoV-2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Bundesamt für Migration für Migration und Flüchtlinge: FAQ: Integrationskurse für Migration und Flüchtlinge: Integrationskurse für Migration und Flüchtlinge
ኣብ : : Absorption of the public and feature basket basket in absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent absorbent ab
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti
ኣብ .b./c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/d/c/c/c/c/c/c/c/c/c/c/c/
SARS-CoV-2 ኣብ 7, 2020 ኣብ 2003: SARS-CoV SARS-CoV SARS-CoV 2 : ኣብ 2003 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 19 ኣብ 2020 ኣብ .The Center of Disease Control of Wuhan( ኣብ .Network of the Diseases Control of Wuhan) : ኣብ .The Research Analysis of the Research of the Research of the Diseases Control of Wuhan ( ኣብ .The Research of the Disease Control of Wuhan) : ኣብ .The Research Analysis ( ኣብ .The Research of the Network of the Network of the Network of the Network of the Research of the Student of the Diseases( ኣብ .
ኣብ Wuhan : ኣብ' , ኣብ' , ኣብ ' Spring Festival' : ኣብ' :- ኣብ' : ኣብ' :' : ኣብ' :' :' :' :' :' :' :' :' :' :' :' :' : : : : : . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2: COVID-19  :: ኣብ 30/09/2019 :: :: :::::::::::::::::::::::::::::::::::::::::::::::::::::::
ኣብ 1 January, 2014, text adjusted from your products from your products from your following from your products from your following to your feature from your feature to
SARS-CoV : SARS-CoV : ኣብ COVID-19 : SARS : ኣብ COVID-19 : ኣብ COVID-19 : COVID-19 : SARS repetition years .
[(COVID-19) and SARS( SARS) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS COVID-19 (10.91% versus 1.44%).
COVID-19: ኣብ : COVID-19: ኣብ . . . SARS: SARS, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ስለምንታይ SARS-CoV-2 SARS-CoV SARS-CoV : SARS-CoV-2 : ኣብ . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 RNA assay ( RNA assay for SARS-CoV-2) : :: COVID-19 rays to products (COVID-19 rays) : : :: :: :: :: :
. . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 : ኣብ : COVID-19 : : :-
SARS-CoV-2 ? . . . . . . . . . . . . . . . .
96% genetic homologue( SARS-CoV-2) ኣብ (SARS-CoV-2) (Bay SARS-like CoVs) : SARS-CoV-2 (Bayer-CoV-2) (Bayer-CoV-SARS-CoV-CoV-2) (Bay SARS-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-C
. . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ #1 and 2 . . . , . . ( #1 and 2 . .) , . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ACE2 : Authority vibration cells and after pathological changes? · · · · · · · · · · · · · · · · · · · · · · · · · · · · . . . . . · · · . . . . . . . .
ACE2-expressing cells in other organisational( ACE2-expressing cells) : :
ኣብ jw.org/ti ኣብ jw.org/ti
. . . . . . . . . . . . . . .
. . . , . . . . . . . . . . . . . . . . .
[(SARS) : SARS : SARS : SARS : Authority Refugee : Influenza , Authority , Authority , Authority , Authority , Auth
ኣብ’ . . . ((((((((((((((())))))) :(((((((())))) :((((((((()))) :(((((((
. . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
© 2019-2017 : Zoonotics Arbeits für Migration und Flüchtlinge und Information und Information om
CoVs, Co-Vs, Co-V-V, Co-V-V-, Co-V-V-, Co-V-V-V-, Co-V-V-V-V-, Co-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-V-
ኣብ 2003 ኣብ CoVs (HCoVs) (- CoVs)--------------------------------------------------------------
SARS (Act acute respiratory syndrome (SARS)) and the Middle East respiratory syndrome (MERS)) : HCoV virus (HCoV virus) was applications (HCoV)) : :
SARS-CoV-2 ኣብ .central following in the central following in accoVs in the following of CoVs in the spotlight error to the her traffic trażmissibility but reductive pathocyticity to has wother SARS-CoV.
HCoVs : HCoVs : HCoVs : zoonosis ( zoonotic ( zoonotic ( zoonotic ( oronotic ( zoonotic ( HCoVs))))) : ኣብ zoonotic ( zoonotic ( HCoVs ( zoonotic ( zo
[HCoVs : HCoVs: HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, H
ኣብ HCoVs: HCoVs . . . . . . . . . . . . . . . . . .
. . .  . . . . . . . . . . . . . . . . . . . . . .
CoV-host active( ኣብ : CoV-host active) : :: CoV pathogenesiation( :: CoV pathogenesius( : : : . . . . . . . . . .
ኣብ :: HCoVs (HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HC
(HCoVs) (HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoV, HC
CoV disease 2019 (COVID-19) epidemy( ኣብ COVID-19) : :: :: :: :: :: :: :: :: :: :: :: :: :
. . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Coronaviruses (CoVs) Coronaviridae, contacted, positive-sensed, single-stranded RNA viruses .
(CoVs, corphology)-like morphology( morphology( morphology( morphology( morphology( morphology( morphology( morphology( morphology( morphology( morphology))))))) ኣብ RNA viruses( morphology( morphology( morphology( morphology))))
CoVs CoVs, regmented genogens, such-segmented genogens, such-segmented genogens, coVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoV
ኣብ ORF1a and ORF1b( ORF1a and ORF1b) ኣብ pp1a and pp1ab polyproteins( orf1a and ORF1b) or two thirdthyversive reductive frequency free free free free free free free free free free free free free free free free free free free free free f
Nsp1~16 : 16 : polyproteins( polyproteins( polypropylene( polyprotein( polyprotein( polyprotein( polyprotein( polyprotein( polyprotein( polyprotein( polyprotein( polyprotein
ORFs (S) (E) (membrane (M) (nucleoprotein (N)) : orfs (S)) : orfs (S) : orfni (N) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ CoVs : CoVs : CoVs : CoVs : Company Association Associational proteinors , Company , Company , Company , Company , Company ,
CoVs (alpha-CoV, beta-CoV, gamma-CoV, delta-CoV, gamma-CoV, delta-CoV) ኣብ 4 genera (alpha-CoV, beta-CoV, beta-CoV, gamma-CoV, and delta-CoV)) genra (beta-CoVs, HCoVs) genra) genera (HCoVs, Subdivided) at 4 lineages (A, B, C and D) lineages (A, C, D) .
gamma-CoVs, delta-CoVs, phenyl alpha-CoVs, beta-CoVs, phylogenetic eventies: gamma-CoVs, dalat-CoVs, gama-CoVs, game-CoVs, game-CoVs, game-CoVs, game-CoVs, game-CoVs, game-CoVs, game-CoVs, game-CoVs, game-CoVs, ga
CoVs . . . . . CoVs . . . . . . . . . . . . . . . . . . . . . . . . . . .
7. CoVs (HCoVs) joint-manual CoVs (HCoVs) specificed.
HCoV-229E and HCoV-NL63: alpha-CoVs: HCoV-229E and HCoV-NL63.
Beta-CoVs: HCoV-OC43, HCoV-HKU1 asy acute respiratory syndrome coronavirus (SARS-CoV), Medium East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV-2.
HCoV-229E, HCoV-OC43, HCoV-HKU1 and HCoV-NL63 .
SARS-CoV, MERS-CoV and restory identificated SARS-CoV-2 hafna pathocytics (ARDS) and expulmonary features (SARS-CoV, MERS-CoV, MERS-CoV, and restorive identificated SARS-CoV-2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV-229E strain B814 ኣብ 1960- ኣብ 1960- ኣብ  60 : ኣብ 1930-1960 : ኣብ 1930-2000 : HCoV-229E strain : B814 : ኣብ 1960- ኣብ 1960- ኣብ : ኣብ 1930- ኣብ 1960- ኣብ : ኣብ 1960- 1960- 1960- : ኣብ 1960- 1960-
ኣብ HCoV-229E (HCoV-OC43) ኣብ HCoV-229E (HCoV-OC43) : ኣብ : :: : : : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ SARS : ኣብ HCoVs ( HCoVs)  ኣብ
ኣብ 2003 ኣብ SARS  ኣብ . . .: ኣብ $ 8.000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(MERS) (MERS) (MERS) (MERS) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (Merħba) (
ኣብ 2019 HCoV (2019-nCoV) SARS-CoV-2, SARS-CoV-2, ኣብ 3, 2020 ኣብ 3,2020 3,120 ኣብ : 3,11,000 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[HCoVs : HCoVs: HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, H
HCoVs : HCoVs : ኣብ . . . HCoVs : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 : : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ኣብ HCoVs zoonotic ( zoonotic ortocological) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) ( zoonotic) (
[(SARS-CoV-2)]: ኣብ  ኣብ : ኣብ .uild splussorbers( amplification authention(s) of SARS-CoV-2) : ኣብ :: ኣብ : ኣብ : ኣብ : ኣብ : ኣብ :: ኣብ : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ : HCoVs: zoonotic ( zoonotic ( zoonotic ( zoonotic ( zoonotic )) ( zoonotic ( zoonotic ( zoonotic ( zoonotic )))) ( pathogenesity ( pathogenesism ) ( pathogenesism ) ( pathogenesism )
[HCoVs : HCoVs : HCoVs : : . . . . HCoVs : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ HCoV : HCoV evolution( : HCoV evolution( :: HCoV evolution ( :: HCoV : : : : : : : : : ) : : : : : : : : : : : : : :
SARS-CoV-2 : ኣብ jw.org/am : : : : : : : : : : : : : : : : : : : : : : :
(CoVs, Corp, Corp, Corp, Corp, Corp, Corp, Corp, Corp, Corp, Corp
HCoV-229E strain B814 rain B814 acquired consumer( orney system) , CoVs( rain B814 rain B814 rain) , rain, rain, cat and kelb( elected) , rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain, rain,
ኣብ . . . 7 HCoVs . . . . . . . . . . . . . . . . .
HCoV following in the chronicle of the HCoV (Table 1) be information and adjusted( feature)( ኣብ 1) be are information and adjusted( following)) .
HCoV-229E rain( HCoV-229E rain) ኣብ 1966: ኣብ third respiratory train( training) path( feed) features( feed) features( feed) was( feed) was( WI-38 need cell( need)) features( rain) features( version) features( version) features( version) features)
HCoV-229E ኣብ 10 ~ 20% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1967, HCoV-OC43 ኣብ .business culture and research serial pass in brains of feeding systems
ኣብ HCoV-OC43 : HCoV-229E : HCoV-229E : HCoV-229E : :: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV-229E (HCoV-229E) and HCoV-OC43 (HCoV-229E) (HCoV-OC43) : :: :: :: ::: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : :
ኣብ $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
ኣብ jw.org/am : HCoV-229E : HCoV-229E : ኣብ : ኣብ : ኣብ your found found found content : HCoV-229E : ኣብ : your found found con
ኣብ immunocompromised accomised accomised accism respiratory tractor fever
SARS : asymptype pulmonite (HCoV-caused pandemic) : accoV-caused pandemy in or the etiological active  is SARS-CoV, the third HCoV detected.
ኣብ SARS : SARS : 2002 : ኣብ Guangdong Professional of China . . .
SARS epidemic( : :: :: :: :: :: :: :: :: :: :: :: :: :: : :: : : : : : : : : : : : :
ኣብ $2.6 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 $2.3 .
SARS-CoV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ SARS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diffuse alveolar waste, epitelial cell convergence and a active of macrophages( ኣብ SARS) account( epitelial cell convergence) account( epithelical convergence) and a active of macrophages( acco
ኣብ 20-30%: ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . .
ኣብ : compomised to respiratory track, accounted versions in the gastrointestinali track track and kilwary( gastrointest)( gastrointest track) , chive and kilwa( convention)) , ኣብ cytokine storm( staple) , ኣብ immunocompromised path( immunocompromised et( immunocompromised)) .
. . . [/ : : : : : : : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ኣብ HCoV Research (HCoV) (HCoV Research) (HCoV Research) (HCoV Research) (HCoV)
HCoV-NL63 ኣብ 2004 ኣብ 7- ኣብ . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ  ኣብ  ኣብ : immunocompromised psychotherapeuts( ኣብ :: immunocompromised psychotherapeuts) : ኣብ (: immunocompromised psychotherapeutics) : ኣብ :: :: ::
ኣብ HCoV-NL63 : coryza, conġunctivitis, and broncholitis( coryza, conġunctivitis) , and bronkolitis( boronkolitis) : HCoV-NL63 .
ኣብ  ኣብ         : 8--  ኣብ : ኣብ 8--- : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : :
ኣብ  ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . . . . . .
HCoV-NL63 4.7% : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV-NL63 croup : HCoV-NL63: ormive larinġitis( octive laryngitis) ( chroup) ( chroup) ( chrongitis ( croup)) ( chrongitis (
ኣብ . . . HCoV-HKU1 ኣብ ኣብ 71- ኣብ ኣብ ኣብ ኣብ ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoV-HKU1 HCoV-HCoV-HKU1  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ HCoV-NL63, HCoV-229E and HCoV-OC43, HCoV-HKU1 ኣብ -  : HCoV-229E and HCoV-OC43 : HCoV-HKU1 : ኣብ : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs : 4 common community-engine HCoVs: HCoV-NL63 : ኣብ third community-engineering HCoV-NCoV-NL63 : ኣብ third community-engineering HCoV-NCoV-NL63 : ኣብ third respiratory feed features features activity activity in the chaigh following again following a hCoVs : ኣብ third are reading againstance of HCoV-NL63 : ኣብ third reading areading areading areading are augh
:: HCoVs: HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoV, HCoV
MERS-CoV ኣብ2012 ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2015 ኣብ-South Countries 186 accounted
ኣብ MERS : MERS : SARS : SARS : acetate pneumonia acetate acetylase acetylase acetylase acetate acetylase acetate
SAR SARS : MERS : MERS : MERS : HCoV- caused diseases : MERS : MERS : MERS : MERS : MERS : MERS : MERS : MERS : MERS : MERS : MERS : MERS : MERS : MERS
ኣብ 30% . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 14,2020: 2500 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2019 : ኣብ Wuhan, Hubei, County, China , SARS-CoV-2 : SARS-CoV-2 : ኣብ .Huhane, Hubei, Countries, Countries, Countries, Countries, Countries, Countries, Countries, Countries, Countries, Countries, Countries, Countries, Countries, Coun
World Health Organization ( WHO) SARS-CoV-2 SARS-CoV-2 : SARS-CoV-2 :- Company Health Emergency of International Concentral Concentral Concentral ( Compension ( Compension of International Concentration ( European Health ( European Health Emergency of Concentration ( Global Organization)
ኣብ 3,2020, 90,053 (0.053 (0.5%)) : ኣብ voltage case fatality (3.4%) :
ኣብ jw.org/year-info/year-info/year-info/year-info/year-info/year-info/year-info/year-info/year/year-info/year-info/year-
SARS-CoV-2: SARS-CoV and MERS-CoV, SARS-CoV and MERS-CoV, : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . . . . . . . . . . . . . . . .
Pneumonia (Pneumonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia) (Pulmonia)
SARS-CoV, and SARS-CoV-2, 82% nucleotide scheme homology, your nucleotide scheme homology, you are in the phylogenetic schere, you are from the phylogenetic scheor. : SARS-CoV and SARS-CoV, and SARS-CoV-2, you are love to nucleotide scheme homology ( homo
SARS-CoV-2: SARS-CoV and MERS-CoV : SARS-CoV-CoV-2: ኣብ .
Symptomatics (SARS-CoV-2) : SARS-CoV-2 : : : : :: : : : : : : : : : : : : : : : : : : : : : :
SARS-CoV-2 : SARS-CoV-2 : ኣብ : HCoVs : ኣብ : HCoVs: ኣብ : HCoVs: ኣብ : HCoVs : ኣብ : HCoVs : ኣብ : HCoVs : ኣብ : HCoVs :
(HCoV disease) . . . . . (HCoV disease) . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2: HCoVs.
(i.e. HCoV-229E, HCoV-OC43, HCoV-HKU1 and HCoV-NL63) ኣብ COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : SARS-CoV-2 : ኣብ . . . . HCoVs : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV : SARS-CoV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(SARS-CoV-2 : SARS-CoV-CoV-Community-requirement HCoVs and SARS-CoV : ኣብ : SARS-CoV-CoV : SARS-CoV-CoV : ኣብ : ኣብ : HCoVs : ኣብ : HCoVs : HCoVs :
“SARS-CoV-2” ኣብ “SARS-CoV-2” (SARS-CoV-2) : common-infection HCoVs (HCoVs)
SARS-CoV and MERS-CoV : SARS-CoV-2 : SARS-CoV-2 : ኣብ- ኣብ- ኣብ : SARS-CoV , MERS-CoV .
(HCoVs, SARS-CoV-2) ኣብ -  ኣብ -  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : SARS-CoV : SARS-CoV-2 : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ኣብ common-engineering HCoVs : SARS-CoV-2 : ኣብ common-engineering HCoVs :: ኣብ common-engineering HCoVs : ኣብ common-active HCoVs : ኣብ Commony-Equity-Equipment HCoVs
(SARS-CoV-2 : SARS-CoV-2 : trasmissibility, pathocyticity and sostenibility dispersibility speaking after in the slots) : ኣብ : COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs ኣብ . HCoVs ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs: ኣብ-, mutazzjonijiet adaptive mutations : mutazzjonijiet adaptive that including restriction factories, mutations : HCoVs : HCoVs : mutations : HCoVs : mutations : HCoVs : mutations : mut
SARS-CoV-2 : SARS-CoV-2 : ኣብ :: ኣብ :: ኣብ :: ኣብ :: :: ኣብ :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : :: : : : : : : :
ኣብ .burokrazy control miżuri/ et/broadcasting/ accountainment/ accountainment// accountainment// accountainment// accountain// accountain/(
CoVs 4 common community-equipment CoVs ኣብ common cold in immunobility suggets accountants : common cold in immunobility suggets ( common cold suits) ( common cold suits) ( common
(16.02.02.02.02.02.02.02.02.02.02.02.02.02.02.02.
(SARS-CoV) (MERS-CoV) (MERS-CoV, MERS-CoV, MERS-CoV, CRS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MERS-CoV, MER
ኣብ .oonotic ( zoonotic ( zoonotic ( : : : : : : : : : : : : : , : , : , , , , : , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
SARS-CoV-2: SARS-CoV/MERS-CoV and the erba’ community-requirement HCoVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs : Commonwealth-Year HCoVs : Commony-Year HCoVs : Common Initiative HCoVs : Common Initiative HCoVs : Com
ኣምላኽ ኣብ HCoVs (HCoVs, HCoVs, HERS-CoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, MERS-CoV, HCoV, HCoV, HCoV, HC
ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ nucleotides : ኣብ . . . , . . , HCoV : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . , . . . . . . . . . . . . . . . . . . . . . . .
HCoV : : HCoV : : HCoV : : HCoV : : HCoV : : HCoV : : HCoV :
ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(HCoV) (HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCoV, HCo, HCo, HCo, HCo, HCoV, HCoV, HC
(MVCs) (MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs, MVCs
ኣብ HCoV : ኣብ : HCoV : ኣብ : HCoV : ኣብ : HCoV : HCoV : ኣብ : HCoV : HCoV : ኣብ : HCoV : ኣብ : HCoV
HCoVs : HCoVs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/years/Anhörung/Anhörung/Anhörung/Anhörung/Anhörung
(Epidemiological) ኣብ SARS: ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Seroprevalence) (Sepliner seroprevalence) (Seplication) (Seplication) (Seplication) (Seplication) (Seplication) (Seplication) (Seplication) (Seplication) (Seplication) (Seplication) (Seplication) (Seplication)
SARS-CoV-like SARS-CoV : SARS-CoV SARS-CoV : SARS-CoV (Paguma larvata) (Paguma larvata)) (Racoon dog)) (Racoon dog) (Racoon dog) (Rakoon dog) (Rakoon dog) (Rakoon dog) (Rakoon dog) (Rakoon dog) (Rakoon dog) (Rakoon dog) (Rakoon dog (Rakov) (Rako
SARS : SARS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ SARS-CoV : SARS-CoV : SARS-CoV : ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Guangzhou (80%) ኣብ .Anti-SARS-CoV-corplus (80%) : ኣብ .Anti-SARS-CoV-corpuses(SARS-CoV-corptions) : ኣብ .Applifications(SARS-CoV) :- :- SARS-CoV :----------------------------------------------------------------------------
[[[SARS-CoV]] [[SARS-CoV]]]] [[SARS-CoV]]] [[SARS-CoV]]]] [[[SSA]]]] [[
SARS-Rhinolophus bat CoV HKU3 (SARSr-Rh-BatCoV HKU3) (SARSr-Rh-BatCoV HKU3))  ኣብ ኣብ  ኣብ  ኣብ - shellshoe baths ( : SARS-CoV-CoV-Rh-BatCoV-HKU3) : ኣብ : SARS-Rhinolophus bat CoV HKU3 ( : SARSr-Rh-BatCoV HKU3 : ኣብ shellshoe bats ( : : : : : : : : : : : ) : : : : : : : : : : : : : : : : : : : : : :
[SARS-CoV-Anti-BatCoV-Anti-Anti-SARSr-Rh-BatCoV HKU3 [] : SARSr-Rh-BatCoV] [[3]]] [[3]]]] [3]]]]] [3]]]]]]]]]]]]]]] [3]]]]]]]]
(Batch CoVs) 88-92% nucleotide sequence homology (SARS-CoV)
ኣብ jw.org/mn ኣብ jw.org/am . . .
SARS-like CoVs (SL-CoVs) : ኣብ 1980-2002 (SL-CoVs) : ኣብ 1980-2002 (SL-CoVs) : ኣብ 1980-2002 (WIV1 : WIV1 : WIV1) : ኣብ 1980-2002 (WIV1 : WIV1 : WIV1 : WIV1 : WIV1 : WIV1 : UV) : UV : UV : UV
(ACE2) ኣብ SARS-CoV: SARS-CoV acetate 2 (ACE2) ኣብ acetate-convertition enzyme 2 (SARS-CoV) : ኣብ acetate-convertition enzyme 2 (A
WIV1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS sera convalescent convalescent systems : WIV1 newtralizzantiabilising .
WIV1: SARS-CoV 95% nucleotide system homology (95% nucleotide system homology) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WIV1 ኣብ SARS-CoV : SARS-CoV : WIV1 hair feature system of Shares-CoV : water feature systems of SARS-CoV : was authority system system of SARS-CoV : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
MERS-CoV MYLOGENETY ABT CoV-HKU4 and bat CoV-HKU5 MYLOGENETY ABT CoV-HKU4 : MYLOGENETY ABT CoV-HKU5 : MYLOGENETY ABT CoV-HKU4 , bat CoV-HKU5 : MERS-CoV :
Bat CoV-HKU4 or MERS-CoV on the hosting receptor, dipeptidyl peptidase 4 (DPP4), for virus inserit.
RNA-dependent RNA polymerase sequences of MERS-CoV : phylogenetically accountantally to countries in bat beta-CoVs from Europa and Africa .
MERS-CoV ኣብ : MERS-CoV : MERS-CoV : ኣብ :: :: :: :: :: :: :: :: :: :: ::
MERS-CoV (MERS-CoV) (Batch CoV-HKU25) : 87% nucleotide system homology (MERS-CoV) .
ኣብ MERS-CoV : MERS-CoV : MERS-CoV : : MERS-CoV , MERS-CoV , MERS-CoV , MERS
. . . (MERS-CoV-Specializing-Special anti-biological) (MERS-CoV-specializing anti-biological (MERS-CoV-special-special-biological) , . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MERS-CoV : MERS-CoV : : MERS-CoV : :: MERS-CoV: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ MERS-CoV: MERS-CoV : Most symptomues, : :: : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . . [/ . . . . [/ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV
SARS-CoV-2: 96.2% nucleotide homology( nucleotide homology( nucleotide( nucleotide( nucleotide ( nucleotide homology( nucleotide( nucleotide ( nucleotide ( homology))))))) ኣብ CoV RaTG13 ኣብ raHinolophus afficinis( emfinis (
ኣብ SARS-CoV and MERS-CoV: ኣብ- SARS-CoV-2-RaTG13 : ኣብ simultanju divergence( selective divergence)( change divergence( special system divergence( specially divergence)))( designation( special system))( special system divergence( special syst
SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Huanan Seafood Marketing Market ( SARS-CoV-2) : ኣብ Huanan Seafood Bejgħ bl-ingrossa (Byvision Market) : ኣብ COVID-COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 85-92% nucleotide system homology with SARS-CoV-2 : 85-92% nucleotide system homology ( homology)
ኣብ neucleotide(RaTG13) 90% : ኣብ neulotide( nucleotide( nucleotide(  ኣብ nucleotide(  ኣብ  ኣብ . . . . . . . . . . . . . . . . .
ኣብ 2 SARS-CoV-2-like virals( SARS-CoV-like) ኣብ phylogenetic speech( phylogenetic speech) : ኣብ RBD-like SARS-CoV-2, 97.4% acid scheme identity ( 97.4% amino acid scheme identification( RBD)) : 97.4% amino acetate scheme identification
(RBDs of SARS-CoV-2 and RaTG13) : RBDs (RBDs of SARS-CoV-2 and RaTG13) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : :: : : : : : : : : : :
ኣብ pangolins (Brandled pangolins) (Brassica contigs) (Brassica contigs) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica) (Brassica)
(Ara l-Anness I) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : SARS-CoV-2 : ኣብ jw.org/years-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-C
[(SARS-CoV-2)-2-related beta-CoVs.]
[(SARS-CoV-2-related beta-CoVs)]
SARS-CoV-2 ኣብ , pangolins and other manufactures beet beet movement of SARS-CoV-2 ( ኣብ pangolins ( ኣብ pangolins) ( ኣብ pangolins) ( ኣብ pangolins) ( ኣብ pangolins) ( ኣብ pangolins
SARS-CoV-2-related beta-CoVs, SARS-CoV-2 and RaTG13 : SARS-CoV-2 : SARS-CoV-2 : SARS-CoV-2 : RaTG13 : genome-link system homology : ኣብ RBDs : :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ pangolin SARS-CoV-2-related beta-CoVs and SARS-CoV-2 (RBDs) (RBDs of bangolin SARS-CoV-2-related beta-CoVs and SARS-CoV-2) (Selettivithy-mediated convergent evolution) (Selective-mediated convergent evolution) (RBDs) (RBDs of bangolin SARS-CoV-CoV-2-related beta-CoVs) (
ኣብ pangolin SARS-CoV-2-related beta-CoV and RaTG13 ኣብ third wild species combination( ኣብ pangolin SARS-CoV-2-related beta-CoV) and RaTG13 ( ኣብ third wild species).
ኣብ beta-CoVs :- ኣብ .beta-CoVs : ኣብ . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ኣብ jw.org/year
(HCoVs, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 zoonotic original orestance) : HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 or zoonotic original or or zoonotic or or zoonotic or or zoonotic or HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU
HCoV-NL63, HCoV-229E, HCoV-229E, CoVs, HCoV-OC43, HCoV-HKU1, childgesets, HCoV-OC43, HCoV-HKU1, childgetics and HCoV-HCoV-HKU1, childgetics, HCoV-OC43, HCoV-HCu1, childgetics, HCoV-HCoV-HCu1, childgetics, HCoV-HCoV-HCoV-HCu1, HCoV-HCoV-
ARCoV.2 (Appalachian Ridge CoV) (ArCoV.2) CoV (Appalachian Ridge CoV) ኣብ norther American tricolored bat with HCoV-NL63 .
HCoV-229E: Hipposideros/GhanaKwam/19/2008 : HCoV-229E: CoV proteological( pathological battle CoV) : was throught hipposideros/GhanaKwam/19/2008 : was was at Gana, at Gana, at Gana, at Gamelids( gamelids) was throught( feedback) at at hepros( et al.) .
ኣብ HCoVs (HCoVs)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1890 HCoV-OC43 : ኣብ 1890 HCoV-OC43 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(HCoV-229E) ( ኣብ special system surface of HCoV-229E) : :: :: :: :: :: :: :
Alpha-CoVs: HCoV-229E  ኣብ : HCoV-229E : ኣብ : HCoV-229E : ኣብ : HCoV-229E : ኣብ : HCoV-229
ኣብ? alpaca alpha-CoV.
. . . . - . . . - . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . .
(HCoV-229E-research bat alpha-CoVs) : HCoV-229E-research abt alpha-CoVs : : alpaca alpha-CoV , : alpaca alpha-CoV : : : : : : : : : : : . . . . . . . . . . . . . . . . . . . . .
Fl-aħħar nett, alpaca alpha-CoV ኣብ  ኣብ - underal feeds( electrica alpha-CoV) [[ electrica]] [[ electrica]]
:: alpacas HCoV-229E-retaced alpha-CoV : ኣብ-- alpha-CoV : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ this feedback viruss, Ebola Virus, Nipah Virus and Hendra Virtual, embase accountain accountain accountain accountain accountain accountain accountain accountain accountain accountain acco
HCoV-229E : HCoV-229E : HCoV-229E : ኣብ : HCoV-229E : HCoV-229E : HCoV-229E : HCoV : HCoV :
(Alpha-CoVs) (Alpha-CoVs) (Alpha-CoVs) (Alpha-CoV-CoVs) (HCoV-229E) جنين pool of HCoV-229E (Alpacas) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoVs) (MERS-CoV) (MERS-CoVs) (MER
MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (M
(MERS-CoV) MERS-CoV ኣብ  ኣብ  . . . (MERS-CoV) ኣብ . . . . . . (MERS-CoV) ኣብ . . . . . . . . . . . . . . . .
ኣብ . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Longevity, tensible packed colones, complete social interference and stability to flying available for bats a ideal 'virus spreader' .
MERS-CoV ኣብ daysdays demandary ( ኣብ daysdays) ኣብ daysdays ( ኣብ daysafety gembles) ( ኣብ daysdaysdays) ኣብ daysafety ( ኣብ daysa
ኣምላኽ ኣብ jw.org/am ኣብ jw.org/am ኣብ jw.org/am
MERS-CoV (MERS-CoV) (MERS-CoV) (Mars-CoV) (Mars) (MERS-CoV) (Mars) (Mars) (Mertic) (Mer
MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS-CoV : MERS
ኣብ MERS-CoV : MERS-CoV : SARS-CoV-2 : ኣብ pangolins : ኣብ this was authority : SARS-CoV-2 : ኣብ pangolins : was authority , you authority , you authority , you authority , you authority authority , you authority , you
(Pangolin beta-CoVs) ኣብ pangolins (Pangolin beta-CoVs) ኣብ pangolins (Pangolins) (Pangolin beta-CoVs).
SARS-CoV-2-retail beta-CoVs : SARS-CoVs : ኣብ :: SARS-CoV : ኣብ civets : SARS-CoV : ኣብ civets : was authentification : SARS-CoV : : : : : : : : : : : : : : . . . . . .
SARS-CoV-2 ኣብ - ኣብ - ኣብ : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[(SARS-CoV-2-related virus) [Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-Huwa l-H
ኣብ jw.org/ti ኣብ . . . ኣብ jw.org/ti . . . . . . . . . . . . . . . .
(Pangolins) (Pangolins) (Amplification) (SARS-CoV-2-related virus)  ኣብ .(SARS-CoV-2) . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . .
SARS-CoV-2 : ኣብ . . . . . , . . . . . . . . . . . . . . . . . . . . . .
‘’’’’’’’’’’’’’’’’’’’’’’‘’’’‘’’’’’’‘’’’’’’’
[(SARS-CoV-2)] ((SARS-CoV-2)]) : ኣብ third special special specials authentification and pangolins( pangolins) : SARS-CoV-2 : ኣብ 3 special special special features( pangolins) : ኣብ 3 special features( features) : ኣብ 3 fe
SARS-CoV-2 ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ SARS-CoV-2 ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ
CoVs : CoVs : CoVs : CoVs : CoVs , Video , Video , Video , Video , Video , Video , Video , Video , Video , Video , Video , Video , Video , Video
ኣብ RNA mutation( mutation( mutation( mutation( mutation( mutation( mutation( mutation( mutation)))))))
CoVs: ~ 10-4 Subplacement for years 2 waste of coV adaption to coV adaption to retails( containment) , ~ 10-4 computing in years( computing in your suite 2) , at coVs ( containment of containmenting) ( to-high) , ~ 10-4 containment in years ( year 2) , at coVs ( containment of commodation) ( to retaining) ( to retain to retain retaining ( year)) ( : CoVs
CoVs proof-reading exoribonuclease ( CoVs) , · virtual-reading exoribonuclease , application ; · actenuation or even inviability . . . . . . . . . . . . . . . . . . . . . . . . .
neucleotide analog Remdesivir CoV : CoV : inhibitation of exoribonuclease, and the RNA-dependent RNA polymerase : CoV : accountainment of exoribonuclease, and the RNA-dependent RNA polymerase , accountainment of the nucleotide analog remdesivir , accountain , accountain ,
Remdesivir( SARS-CoV-2) :- ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mutation rates of CoVs ( mutation rates of CoVs, mutations of CoVs, mutations of mutations, mutations of coVs, mutations of returns, CoVs, CoV
ኣብ mutation rate( CoVs) (mutation rate) ( ኣብ mutation rate) ( CoVs) ( ኣብ mutation) ( ኣብ mutation rate)) ( CoVs ( ኣብ mutation) ( ኣብ mutation) ( ኣብ mutation
SARS-CoV-2 mutation rate with the SARS-CoV accounted to SARS-CoV motion rate of SARS-CoV-2 accounted active to reading accountainment accountainment with in the world
. . . . . . . - . - . . . . . . . . . . . . . . . . .
ኣብ SARS-CoV-2 : ኣብ MERS-CoV : MERS-CoV : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Theoretically, Genetic genetic groundhandling, SARS-CoV-2) : SARS-CoV-2 : ኣብ . . . . . . . . . . . . . . . . . . . . . .
(RNA genome) ኣብ CoVs (RNA genogen) ኣብ mutations( mutations) (RNA genogen) (RNA genogen)) ኣብ CoVs (RNA genogen) (RNA genogen) (RNA genogen) (RNA genogen)) (RNA genogen) (RNA genogen) (RNA genogen) (RNA genogen) (RNA genogen) (RNA) (RNA genogen) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA) (RNA
ኣብ 3’ (end of the genogen) : causious special reading special which following and protein factory ( change of the genome) : 3-( end of the genome)) .
CoVs ኣብ RNA-copy-choice----------------------------------------------------------------------
ኣብ CoV RNA trascription ( ኣብ CoV RNA) : ኣብ tractoration ( ኣብ CoV RNA tractoring) : :: CoV RNA ( ኣብ tractoring) : : : : : : : :
(RNAs RNAs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, RNAs, RNAs, RNAs, RNAs, RNAs, RNAs, RNAs, RNAs, RNAs, RNAs, RNAs, RNAs
ኣብ HCoV-HKU1 and HCoV-OC43 : HCoV-OC43 : ኣብ bat SL-CoV and batCoV-HKU9 : HCoV-OC43 CoVs : HCoV-HKU9 : HCoV-HCoV-OC43 : ኣብ HCoV-HKU9 : HCoV-HCoV-OC43 : HCoV-OC4 : HCoV CoVs : BatSL-CoV and batCoV-HKU9 : HCoV-HCU9 : HCoV-HCU9 : HCoV-HCU9
ኣብ (Virus-host story) ኣብ .(Virus-host)
3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV : SARS-CoV : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoVs: SARS-CoVs: mutations in the RBD of S protein : SARS-CoVs, mutants in the rBD of S protein, absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent absent
ኣብ CoV S protein of a CoV (RBD) (Cellulose receptor) (RBD) (S protein) (RBD) (RBD) (RBD) (RBD) (RBD) (RBD) (RBD) (RBD) (RBD) (RBD) (RBD) (RBD)
ኣብ SARS-CoV, RBD ኣብ 318- 510 ኣብ S1 ኣብ S1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RBD of SARS-CoV : ACE2 receptors of feedbacks: cavet, maws and raccoon kelb : acetates : acetate , acetate , acetate , acetylate , acetate , acetate , acetate , acetate , acetate , acetate , acetylate , acetylate , acetate , acetate , acetate ,
ኣብ RBD ( 6 amino acid reversions) ኣብ RBD (6 amino acid reversions) (6 amino acid reversions) ኣብ RBD (4 accessory) (6 acetate reversions) (ACE2 receptor) (6 acetates (6 acetate)) (4 acetates) (ACE2 receptor) (4 to receptor) (ACE2 receptor) (6 acetates) (ACE2 receptor) (6 acetates (6 acetations) (6 acetations) (
Civet SARS-CoV K479N and S487T mutations in the RBD, that active of spike protein with-Human ACE2 receptor acetate, K479N and S487T mutations in the RBD.
ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ኣብ SARS-CoV: SARS-CoV.
ኣብ S1 union of S protein 30%: S containment of S protein with machine ACE2, SARS-CoV-CoV-CoV-CarS-CarS-CarS-CoV-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-CarS-Car
ኣብ cryo-EM ( cryo-EM) 10- 20- (dopper- accountability) : ኣብ------------------------------------------------------------------------------------
ኣብ SARS-CoV-2 ( SARS-CoV-2) ኣብ  ኣብ  ኣብ  ኣብ :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : :
HCoV-NL63, HCoV-NL63, ACE2 but with a part of S.
ኣብ HCoV-229E, 9-O-acetylated sialic acid to HCoV-OC43 ኣብ HCoV-OC43 ኣብ HCoV-229Daphthal HCoV receptors ( HCoV-229E) ኣብ HCoV-229Daphthalatesialic acid (HCoV-229E) ኣብ HCoV-229E ኣብ HCoV-229Daphthalatesialic acid (HCoV-OC43 ኣብ HCoV-229E) ኣብ HCoV
ክርስትያናት ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HCoVs ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[HCoVs: HCoVs: HCoVs: HCoVs, dromedary gembled and roads, convergences, convergences, convergence, convergence, convergence, convergence, convergence, convergence, convergence, convergence, convergence, convergence, convergence,
HCoVs (HCoVs, contability factores, contability factores, and display hosting hosting factories) : :: HCoVs, : : : : : : :
ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ኣብ US-OF-THE-ART TECHNOLOGY TAX-XEJJENT DEFINIZZJONIJIET UNBIASED GNOME-WIBLE PROVENZJONI TAX-XEJN CRISPR PROVVITIONS PROVVITIONS AND REstriBUTIONS SARS-CoV-2 PROVESTIONS AT-OF-OF-TH-ART-ART
Tigrinya HCoVs: ኣብ landsverige error: FAQ: FAQ: FAQ: FAQ: FAQ: FAQ:
(bat CoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs
ኣብ HCoVs : HCoVs : HCoVs , HCoVs , HCoVs , HCoVs , HCoVs , HCoVs , HCoVs
ኣብ mutation( mutation)( genetic recombination)(HCoV evolution( HCoV) : HCoV (HCoV) pool( HCoV) pool( HCoV) pool(HCoV) pool(HCoV) pool(HC
. . . . . . . ((((((((((((((((((((((()-)-((()-)-)-((((()-)-)-)-)-(((((())-)-)-)-)-(((((())
SARS-CoV ORF8: SARS-CoV: SARS-CoV: ኣብ ORF8: ኣብ ORF8: ኣብ ORS-CoV: ኣብ orf8 proteines ::
SARS-CoVs 29-nucleotide clearing character: ኣብ : accountry-CoVs, :: :: :: :: :: ::: :: ::: :: :: :: :: :: :: :: :: :: :: :
ኣብ ORF8a and ORF8b (ORF8a) ORF8a (ORF8b) ORF8b ORF8b ORF8b ORF8b : mutation( compative mutation)( mutation) : ((availability mutation) :(available mutation) : (availability)
SARS-CoV ኣብ RNA-dependent RNA polymerase (RNA-dependent RNA polymerase)  ኣብ  ኣብ .alpha- and gamma-CoVs (RNA-dependent RNA-dependent RNA polymerase)  ኣብ .
ኣብ nsp9 : nsp10 : nsp14 : ኣብ nsp14 , ኣብ nsp10 :  ኣብ . nsp10 : . . . . . . . . . . . . . . . . . . . . .
“MERS-CoV” (MERS-CoV) : MERS-CoV (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-CoV) (MERS-C
SARS-CoV and MERS-CoV : ኣብ HCoVs : HCoVs : HCoVs : HCoVs : accoVs , accovance CoVs , accovances , accovances , accovances , accovances , accovances , accovances , accovances , accovances , accovances , accovances , accovances , accovances , accovs ,
ኣብ . genome ( viral genogens( viral genomes)) ( chemical selection) ( chemical selection) ( chemical selection) ( chemical selections ( viral genogens( viral systems )) ( chemically) ( chemical systems ( viral systems ( viral systems ))) (
ኣብ HCoV-229E-lactual trainment( ኣብ HCoV-229E traintainment strain)( orf-nucleotide training))  ኣብ HCoV-229E (HCoV-229E rain-nucleotide detainment) (HCoV-229E rainboard trainment) (HCoV-229E rain-nucleotide detainment) .
ኣብ HCoV-229E: ORF4 ኣብ .HCoV-229E: ኣብ .Alpaca alpha-CoV: nucleotide inserit ( nucleotide inserit) ኣብ framechift ( orfnia ORF4) : ኣብ : HCoV-229E , : alpaca alpha-CoV : nucleotide inserit( nucleotide inserit) : ኣብ framechift . . . . . . .
ኣብ (HCoVs) : HCoVs (HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs, HCoVs
ኣብ CoVs : CoVs : CoVs: CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs : CoVs :
ኣብ CoVs natomically ( CoVs) psychologically ( ኣብ CoVs) ( ኣብ jw.org/yperiological/phylological/phychological/soficilic/sofronic/)
(Pathology( CoVs) activation( prop-inflammatory response)) : activation pro-inflammatory response( activating)( ኣብ activation pro-inflammatory response) ( CoVs) ( pathology(
(NKG2 / CD94) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(ROS) metabolic activity of bats( CoV replikatory) CoV reading (Exoribonuclease) (RoS)) : CoV reading (Exoribonuclease) : contact the proofreading types(RoS) , that you available straents( viral straents( rails( viral( viral( viral( hydrogen( viral( hydrogen)))))) : : : : : : : : : : : : : : : : : : : :
Cropcological CoV straps you can be combination by recombination to recombination, to building and protein should changes for hosting addattation ( combination) .
3. HCoVs ኣብ 1 עשורים : : HCoVs: : :: :::::::::::::::::::::::::::::::::::::::------
CoVs : pathogenics or your symptomers in the shadown symptomatics and gembes at with shadown symptomatics and gembes ( CoVs) .
. . . - . . - . . . . . . . . . . . . . . . . .
: asymptomatic controllers( asymptomatic symptomatics) : ስለምንታይ :: :: :::::::::::::::::::::::::::::::::
ኣብ hyperactivation of immune response and the cytokine shape ( cytokine shape) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ asymptomatic travelers (A asymptomatic travelers) : ኣብ asymptomatic( asymptomatic travelers) : CoV replication( CoV replication( asympto
ኣብ-SARS-CoV-2 : ኣብ -SARS-CoV-2 :- ኣብ -SARS-CoV-2  ኣብ  ኣብ  ኣብ :- ኣብ :: ኣብ ::- ኣብ ::- ኣብ ::- ኣብ ::- ኣብ ::- ኣብ ::- ኣብ :-
(Alp interferon response) : (Alpone response) : (Alp) : (Alp) :
:: type I interferon( SARS-CoV-2) ኣብ-- ኣብ ኣብ  ኣብ  ኣብ  ኣብ  ኣብ---------------------------------------------------------
NLRP3 activation inflammasome in the bacteria is defactive. . . . . . . . . . . . . . .
ኣብ COVID-19 : NLRP3 ኣብ MCC950 inhibitation( inhibitation) accognition( NLRP3 inflammasome) .
SARS-CoV-2 ኣብ .: SARS-CoV and MERS-CoV was following ( SARS-CoV) : ኣብ . . . . . . . . . . . . . . . . . . . . . . .
ኣብ SARS-CoV 95% nucleotide homology (Bath-CoV nucleotide homology (Bath-CoV)) ኣብ SARS-CoV-2 96% nucleotide homology (Batch-CoV)
SARS-CoV . . SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pangolin beta-CoVs homologue to SARS-CoV-2 was was was was to found that pangolins or pangolin beta-CoVs : SARS-CoV-2 : ኣብ : ኣብ : SARS-CoV-2 : ኣብ : ኣብ : ኣብ : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CoVs: SARS-CoV-2 : SARS-CoV-2 : CoVs : was yourlight was are to the treadlight to the ready light to the was.
CoVs ( CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoVs, CoV
SARS-CoV, MERS-CoV, and SARS-CoV-2, ኣብ .ARS-CoV-CoV-, SARS-CoV-, ኣብ .ARS-CoV-CoV-, ኣብ .ARS-CoV-CoV-2, ኣብ .Anhance-CoV-CoV-CoV-CoV-, MERS-CoV, MERS-CoV, SARS-Co
SARS-CoV : SARS-CoV : :: :: :: ::: :::: ::::: :::: ::: :::: ::: ::: ::: :: ::: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : :
[(Pangolin beta-CoVs, SARS-CoV-2, bengolin beta-CoVs, zoonotic travelings)] :: zoonotic( zoonotic travelance)] : ::: [/] :: changolin beta-CoVs : SARS-CoV-2 : : : : : : : : : : : : : .
(SARS-CoV-2 : SARS-CoV-2 : : : :: :: :: :: :: : : : : : : : : : : : : : : : : : : , , , , , , , , , , , , ,
MERS-CoV ኣብ emblemary gembles day day day day
(Migrationsberatungs-Stelle) (Migrationsberatungs-Stelle) (Migrationsberatung) (Migrationsberatungs-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (M
ኣብ . . . . . . . . . . . . . . . . . . . .
SARS-CoV and SARS-CoV-2 : SARS-CoV-2 : SARS-CoV-2 : MERS : ኣብ  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ MERS-CoV (MERS-CoV) ኣብ     ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ .MERS-CoV (MERS-CoV) : MERS-CoV (MERS-CoV)  ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/ach-informations/returns-administrative-informations/system-administrative-active-active-active-active-active-acti
CoVs zoonotic ( zoonotic CoVs) : :: :: :: :: :: :: :: :: :: : : :
(bat CoVs with zoonotic potentic) (Batch CoVs) be available (Batch CoVs with zoonotic potential
“ zoonotic CoVs” (CoVs) (CoVs, CoVs, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS, CS,
ኣብ . . . ኣብ . . : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS, MERS, and COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:- ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . .
. . . . : . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . . - - --------------------------------------------------------------------------------------------------------------------
CoVs ( Ecology of Ecology of Ecology of Ecology of Ecology of Ecology of Ecology and Ecology of Ecology of Ecology of Ecology and System System System Systems) ( : :( : : . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ኣብ zoonotic or or zoonotic or or your productive of SARS-CoV-2 or zoonotic or or zoonotic or or or zoonotic or or or or or
(SARS-CoV-2) ኣብ pangolins : SARS-CoV-2 : :: :: :: :: :: :: ::: ::: ::: ::: ::: ::: :: ::: ::: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : :
(Business Business Business Business Business Business Business Business Business Business Business Business Business Business Business Business Business Business Business Business Busin
(3-) ኣብ jw.org/mt/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switcht/switch-
ኣብ . . .- SARS-CoV-2, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : SARS-CoV-2 : SARS-CoV-2 , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 ኣብ : ኣብ : COVID-19 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19’ssuspected case’ and’-confirmed case’s required’s et
ኣብ 6,2020 ኣብ 2019 (2019-nCoV) (2019-nCoV) : ኣብ 2019 ( 2019) (2019-nCoV) : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ 2019 (COVID-19) : coronavirus disease 2019 (COVID-19) : :: :: ::: ::::: ::::: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ኣብ jw.org/your follow-information/should-information/should-info@country.org/court-info-info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/information_info/
ኣብ 2019 ኣብ 2019 ኣብ 2019-nCoV (2019-nCoV) ( 2019)- ኣብ 2019 (COVID-19)- ( 2019)-)--------------------------------------------------------------------------------------------------------------------------------------------------------------------
ኣብ 11, 2020, WHO (COVID-19)  ኣብ . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2  ኣብ : SARS-CoV-2 : ኣብ 06 February 2020 : ኣብ Surfacture Medicipal Research on your following to research to your system privacy privacy Association on 06.
ኣብ jw.org/am ኣብ jw.org/am
COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(http://www.nhc.gov.cn/), 16 2020-32, 2020-32, 2020, 7-32-32-32-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-44-48-44-48-44-48-44-48-44-48-48-44-44-7)-------------------------------------------------------------------------------------------------------
:: Zhou et al., :: :: :: ::: :::: :::: :::: :::: ::: ::: ::: ::: ::: :: ::: :: :: :: :: :::
. . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . .
. . . ኣብ . . ኣብ . . . ኣብ . . . . . . . .
(COVID-19 (Antilly seventh version)) ኣብ   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ this seventh production (3 March 2020) : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(1) ኣብ Wuhan clearance( ኣብ 14- il your story) account( et) account( positive nucleic acid test); (3) ኣብ Wuhan( account( positive nucleic acid test)) accountant( positive neuroc acid( positive activities)) accountants( positive neuroc acid( positive activitive)) accountants( positive nuclearic acid test) : (1) ኣብ 14- il account( neughan account( neucleic acid test)) :) accountants( accountants)) accountants( to respiratory symptomatic systems)) account( accountants)) account( accountants) accountants( accountants)) accountain(( acet)) acet((( et))) acet(((((( et)))))))) acet((((((((((((((((((a)))))))))))))))))) ab(((((((((((((((((((((((((((a))))))))))))))))))))))))))) ob(((((((((((((((((((((((((((((((((((((((a)))))))))
(CPC) (1) . . . , (CPCPC) (2) , (CPCPCPC) , (CPCPCPCPC) , (CPCPCPCPCPC) , (CPCPCPCPCPC) , (CPCPCPCPCPCPC) , (CPCPCPCPCPCPCPC) , (CPCPCPCPCPCPCPC) , (CPCPCPCPCPCPCPC) , (CPCPCPCPCPCPCPCPC) , (CPCPCPC 87) , (PCPCPC 87) , (PCPCPC 811
(1) real-time PCR test positive for SARS-CoV-2; (2) viral whole genome sequencing with high homogeneity to the chronaviruses; (3) positive for thespecific IgM antibody and IgG antibody to SARS-CoV-2 in serum test; or a SARS-CoV-2-specific IgG antibody to nearly to positive, or titer joy to ≥4 positive to being at the acute phase at the acute phase.
Real-time PCR test for nucleic acid in respiratory track or love people active active active to the novel active to the novely active to real-time PCR test for nucleic acid in respiratory track or bood ignition to the 2 (18, 2020) and 3 (22, 2020) election(22, 2020) features) fe
ኣብ 07.2019 ኣብ 220-2019 ኣብ 220-2019 ኣብ 220-2021 ኣብ 1930 ኣብ 1980-2000-2000-( ኣብ 1980-2000)-(831-2)-(8-9)-(8-9)-(8-9)------------------------------------------------------------
(Anti-positive results) : (Anti-positive reviews) ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
. . . (Symptomatics and asymptomatics) . . . . (Symptomatics) (Symptomatics) (Symptomatics) (Symptomatics (Symptomatics
ኣብ Zhou et al. ኣብ flow chart (Zhou et al.) : :: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
(Speed system) ኣብ’ ኣብ’ (Socialsystem) ኣብ’ (Socialsystem) ኣብ’ (Socialsystem) ኣብ’ (S
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ \\ 'ssuspected case\\' and'confirmed case\\ 's ኣብ \\ 's \\ 's \\ ' s \\ s \\ ' s \\ s \\ ' s \\ ' s \\ s \\ ' s \\ ' s \\ s \\ s \\ s \\ s \\ s \\ s \\ s \\ s \\ s \\ s \\ s \\ s \\
ኣብ jw.org/your privacy/author/author/author/author/author/author/au
© 2020-2017 ኣብ jw.org/ti ኣብ jw.org/am .
:- ኣብ 1980-2000: COVID-19:5 (Bangladexx) : COVID-19:5 (Bangladexx) ::- “Bangladexx (Bangladexx) :COVID-19:
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . .
:(IEDCR, Ippydemiology Institute of Epidemiology, Disease Control and Research)) : : :: :: :: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ኣብ 17- il at totale years registrations.
ኣብ 1 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03 03
Dr. Meerjady ( ኣብ 60 ኣብ . . .) : ኣብ 51-60 ኣብ . . . . 41-50 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . .
WHO) COVID-19 ኣብ 11 ( Global Health Organization ( WHO) : ኣብ WHO
ኣብ Anadolu (Anadolu Agency) ( ኣብ . . .) (Anadolu Agency) ( ኣብ . . . . . . . . . .) (( . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt ኣብ jw.org/years/Anglish/Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Anglish_Angli
ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 236-Citrus und Initiative Association Association Association und Initiative Association Association Association des Authority Association
:: : , , , , , , , , , , , , , , , , , , , , , , ,
COVID-19 : : : :: :: :: :: :: :: :: :: :: :: : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ 1914 ኣብ 1930-1999 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1980-2002/2002 ኣብ 1980-2002/
SARS-CoV-2 : : : :: :: ::: ::::: ::::: ::::::
Johns Hopkins University ( ኣብ 1980-2002) : Johns Hopkins University ( ኣብ 1970-2000) : :: Johns Hopkins University ( ኣብ 1970-1999) :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . [[ . . . [/ . . [/ . . . [/ . . . [/ . . . [/ . . . [/ . . . . [/ . . . . [/ . . . . [/ . . . .
ኣብ $0.00 ኣብ $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-1999-1999-1999 ኣብ 1970-1999-1999-1999-1999-1999-1999 ኣብ 1970-1999-1999-1999-1999 ኣብ 1970-1999-1999-1999-1999 ኣብ 1970-1997-1999-1999-1999-
ኣብ . . . ኣብ . . ኣብ . . , 244 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Johns Hopkins University ( CBS News) : Johns Hopkins University , 1,000 U.S. : 1,000 U.S. : : : : . . . . . . . . . . . . . . . . . . .
ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1980-2000 (Sergei Sobyanin) (Sergei Sobyanin) (Sergei Sobyanin) (Sergei Sobyanin) (Sergei Sobyanin) (Sergei Sobyanin) (Sergei Sob
ኣብ 20 يونيو/كانون الثاني 1977 ኣብ 1987 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
---------------------------------------------------------------------------------------------------------------------------
ኣብ 10 p.m.- 4 a.m.  ኣብ  ኣብ .a.- 10 ap.m. . . . . . . . . . . . . . . . . . .
Mike DeWine, ኣብ 1980-2000: ኣብ 1930-2002: ኣብ 1978: ኣብ 1930-1999: ኣብ 1930-1999: ኣብ 1930-1999: ኣብ 1980-1999: ኣብ 1980-1999: ኣብ 1980-1999: ኣብ 1980-1997: ኣብ 1980-1999: ኣብ 1980-1997: ኣብ 2001: ኣብ
ኣብ ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ atleta paper lists. . . . . . .
ኣብ : Woolworths and Coles, ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ALDI ኣብ ALDI ኣብ $ 1-pack or on the You Time day.
ኣብ .burokrazija (Facebook pages), ኣብ .broadcasting (Facebook pages), ኣብ .broadcasting on check outs, ኣብ .broadcasting (
COVID-19 : :- : : , , , , , , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ኣብ Woolworths ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . .
[(Woolworths and Coles)] [(Woolworths and Coles)] [[4-pack]] [[4-pack]]] [[5]] [[4-pack]]] [[4-pack]]] [[5]] [[4-pack]]] [[5]]
ALDI ALDI ALDI ALDI , ኣብ Facebook postable , ``---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ኣብ 1914-1914 ኣብ 1930-2002 ኣብ 1930: ኣብ 1930 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1930- ኣብ 1930- 1970- 1978- 1978 ኣብ 1930- 1978- 1978 ኣብ 1970- 1978- 1978- 1978- 1978- 1978- 1978- 1978- 1978 ኣብ 1970- 1978-
ኣብ . . . (Costco’s basket für erwachslagend für Flüchtlinge: FAQ: FAQ: FAQ: FAQ: FAQ: FAQ: FAQ:
(Coles) : Colleges (Colleges, Colleges, Colleges, College, College, College, College, College, College, College, College, College, College, College, College, College, College, College, College, College, College, Col
ኣብ Australian Retailers Association (Australian Retailers Association) , Ross Zimmerman (Australian Retailers Association) , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . : . . . . . . . . . . . . . . . . . . . . . . . .
Aldi ALDI : ኣብ 1980 : ኣብ 1930 : ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI: ALDI:
ኣብ The News.com.au research, ኣብ News.com.au: ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
---Coles and Woolworths ኣብ .bl-info@watchtower.org/colles and Woolworths.ch/ ኣብ .bl-info/star-bl-info-info/star-bl-info-info-info-bl-info-info-info-bl-info-info-bl-info-information-bl-info-bl-info-information-bl-info-information-bl-info-bl-info-bl-info-bl-info-bl-info-bl-info-bl-info-bl-info-info-bl-info-info-info-info-info-info-
Who Gives a Crap product returned rotatory productor (Who Gives a Crap) : ኣብ 20/03/2017 : : : : . . . . . . . . . . . . . .
ኣብ News.com.au report.
Domain.com (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.com) (Domain.) (Domain.com) (Domain.
NT News (NT News) ኣብ Darwin (Nearwin) (NT News) (NT News) (NDarwin)) ኣብ 8-(Public(NT News) (NT News)) (NT News) (NT-News) (NT-News) (NT-News) (NT-News (NT-News
ABC Australia( ABC Australia)( ABC Australia) ( ABC Australia) ( ABC Australia) ( ABC Australia) ( ABC Australia) ( ABC Australia) ( ABC Australia) ( ABC Australia) ( ABC Australia) ( AB
. . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1930 ኣብ 1930 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1930-2002-2002-2002-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi-Wi
COVID-19 ኣብ 1980-1999 ኣብ 1980-1998 ኣብ 1970-2000 ኣብ COVID-19 ኣብ COVID-19 ኣብ COVID
(WHO) COVID-19 -- SARS-CoV-2 --------------------------------------------------------------------------------------------------------------
WHO:- . . . : . . : . . . : . . . . . . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------
ኣብ WHO (Tedros Adhanom Ghebreyesus) (Tendros Adhanom Ghebreyesus, WHO, WHO) :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ : :: ኣብ : :: ኣብ : :  ኣብ : : : : : :: ኣብ :
:: : : : : : : : : : : : : : : : : : :: : : : : : : : : : : : : : : : : : : : : : : :
(Dr. Tom Frieden) ኣብ 1980-1999 ኣብ 1930-1999 ኣብ 1930-UNHCR (Dr. Tom Frieden, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR
ኣብ CNN :------------------------------------------------------------------------------------------------------------
- ghebrayesus ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
---------------------------------------------------------------------------------
(WHO) ኣብ . . . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
---------------------------------------------------------------------------------------------------------------------------------------------------------
Associated Press( Associated Press) : 126,000 (COVID-19) accountants( Associated Press) accountants( Associated Press) accountants( Associated Press) accountants( Associated)
ኣብ 2019-20 ( 2019-20) ኣብ coronavirus pandemy ( 2019-2018) ኣብ coronavirus disease 2019 (COVID-19) : acetate respiratory syndrome coronavirus 2 (SARS-CoV-2).
ኣብ 2019 ኣብ Wuhan: China, ኣብ Wuhan: China, ኣብ 30, 2020, “Public Health Emergency of International International Concludence” ( ኣብ .fr.fr., 2020) : ኣብ 11,2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 10,2020 ኣብ 1.61 ኣብ 1.8 ኣብ 210 ኣብ .countries and treatries ( ኣብ 210 ኣብ 1.4 ኣብ .co.il.) ኣብ 2.7 ኣብ .co.il.
364000 . . .
ኣብ . . . 4% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
Complexs( complexs)( complexs)( pulmonite)( acute respiratory distress syndrome) (
. . . . - . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .b./c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/
(Treatment is symptomatic and support therapy.Recommented preventional methods including your google’s symptomatic, following’s factory, being of other being, and controllectment and-isolution for the feature of the should following des designed ( suits) (-) , (-) , (-) , (-) , (-) , (-) , (-) , (-)
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Phasebookschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftsch
ኣብ 193 (Bundesamt für Migration und Flüchtlinge: Integrationskurse für Flüchtlinge: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge:
(Migrationsberatung für Asylbewerber) (Migrationsberatung für Asylbewerber (Migrationsberatung für Asylbewerber (Migrationsberatungsberatungs-Schutz))) : (Migrationsberatung für Asylbewerber (Migrationsberatungs-Schutz für Flüchtlinge) :: (Migrationsberatung für Flüchtlin
. . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Wuhan, China (Hubei continue) (Hubei convention) ኣብ 31, 2019,  ኣብ .Hubei (Hubei contributions) : ኣብ .Hubei (Hubei contributions)) :----------------------------------------------------
ኣብ zoonotic( zoonotic)  ኣብ zoonotic( zoonotic) was to Huananan Seafood Bejgħ bl-ingrossa Commerce ( ኣብ zoonotic) ( ኣብ zoonotic( ኣብ zoonotic))) ( ኣብ zoonotic( ኣብ zoonotic( ኣብ zoonotic))) (
SARS-CoV-2, ኣብ 1,2019 ኣብ : ኣብ : 1-2019 ኣብ :: SARS-CoV-1, SARS-CoV-2, ኣብ 1CoV-Coronaviruses, pangolin coronaviruses, and SARS-CoV- accountry feature feature feature feature feature feature feature feature features in 1 February 2019 feature feature feature feature feature feature feature feature feature feature feature feature feature feature feature feature feature feature featured feature featured featured features
ኣብ 2019 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 13, 2020: ኣብ South China Morning Post (South China Morning Post) ኣብ 17 ኣብ 2019 ኣብ 55-il sena ኣብ ITS (South China Morning Post) ኣብ 26 ኣብ 2020 ኣብ WHO (South Morning Post) ኣብ ITS (South Market Post) ኣብ ITS (South Morning Post) ኣብ ITS (South Market Post) ኣብ ITS (South Market Post) ኣብ ITS (South Market Post) ኣብ ITS (South Market Post) ኣብ ITS (South Market Post) (South Market Post) (South Market) ኣብ ITS (South Market) (South Market) ( ኣብ ITS) ( ኣብ ITS) ((South Market) (South Maturing Post) ( ኣብ ATS) (Nationales) (Nationach 2019) ( ኣብ ATSAT) (55) (55) ((55)) (((55)))) (((NE))) (((((CO))))) ((((CO))))))) (
ኣብ  ኣብ' ` : ኣብ' ` . . . . . . . . . . . . . . . . . . . . . .
ኣብ 26 ኣብ 1980 ኣብ 1980-2000 ኣብ 2.4% ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-1997 ኣብ 1980-1997 ኣብ 1980-1997 ኣብ 1980-1997 ኣብ 1980-1997 ኣብ 1980-1997 ኣብ 1970-2000 ኣብ 1970-1997 ኣብ 1980-1997 ኣብ 1970-1997 ኣብ 1980-1997 ኣብ 1980-1997 ኣብ 1980-1997 ኣብ 1970-1997 ኣብ 1980-1997 ኣብ 1970-1997 ኣብ 1970-1997 ኣብ 1970-1997 ኣብ 1980-1997 ኣብ 1970-1997 ኣብ 1980-1997 ኣብ 1980-1997 ኣብ 1970-2000 ኣብ 1978-2000 ኣብ 1970-2000 ኣብ 1978-1978-1978-1997 ኣብ 1978-1978 (1923) ኣብ
:- : COVID-19 , : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ኣብ 23 (March, 23) 3% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 16 (February, 23 (Bay, 23)) 86% ኣብ COVID-19 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 30, ኣብ 1980 : ኣብ : 30, ኣብ : ኣብ :: ኣብ :: :: :: :: :: :: :: : : : : : : : : : : : : :
ኣብ COVID-19 (R0) : 1.4-2.4 : ኣብ COVID-19 : ኣብ 1.4-0.4 .
ኣብ US Center for Disease Control and Prevention( US Center for Disease Control and Prevention( US Center for Control and Prevention)) ( ኣብ US Company) ( ኣብ :: ኣብ :: “
ኣብ COVID-19 ኣብ . . .
ኣብ . . .: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 10,2020 : 97,000 ኣብ : COVID-19 . . . .
ኣብ . . . 50% : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19  ኣብ : afterförsäkringsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsför
ኣብ : ኣብ : ኣብ yesears: ኣብ yesears: ኣብ yesears: ኣብ yesears: yesears: yesears, yesears, yesears, yesears, yesears, yesears, yesears, yesear
ኣብ 2009: H1N1 plein influenza epidemics features: ኣብ Wuhan ኣብ 9 April 2020: ኣብ U.S. Centers for Disease Control and Prevention (CDC) ( US. Science  for Disease Control and Prevention ( DC)) ( US. Science for the Disease Control and Prevention ( Commonvention ( CCD))) ( : [(  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . ( . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1 : ኣብ . . . 1 : 1 : 1 : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ 28 . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1980-2002 ኣብ 1980-2000 ኣብ Antract. Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz-Schutz
(Migrationsberatungs-Stelle) (Migrationsberatungs-Stelle): (Migrations-Stelle): (Migrations-Stelle): (Migrations-Stelle): (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrations-Stelle) (Migrati
ኣብ Johns Hopkins University (Johns Hopkins University) ኣብ 10,204 ኣብ 10,204:6% (97,039/1,617,204) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .
ኣብ · ኣብ · 17.3% (symptomatic 1-10 December 2020) · 0.7% (symptomatic acetate acetate 1 February 2020) ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
[[Trypt]] [[Trypt]]] [[Trypt]]] [[Trypt]]]] [[Trypt]]] [Trypt]] [Trypt
ኣብ jw.org/am ኣብ jw.org/am
University of Oxford’s Centre for Evidence-Based Medicine ( University of Oxford's Centre for Evidence-Based Medicine) ( University of Evidence-Based Centre for the Evidence-Based Medicine)( University of the University of Axford’s Centre for the Evidence-Based
ኣብ COVID-19: ኣብ CFR : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(WHO) : ኣብ . . . . . . . . . . . . . . .
ኣብ  ኣብ  ኣብ asylum et al., asylum et al., asylum et al., asylum et al., asylum et al., asylum
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------
ኣብ WHO ኣብ  ኣብ --- WHO( WHO)-----------------------------------------------------------------------------------------------------------------------------------------------
- ኣብ 17-il March, Adam Kucharski of London School of Hygiene &amp; Tropherical Medicine: SARS-CoV-2’;-----:----------------------------------------------------------------------------------------------
ኣብ jw.org/am ኣብ jw.org/am ኣብ jw.org/am . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Vanderbilt University William Schaffner : · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · . . . . · · · · · · · · · · · · . . . . . . . . . . : . . . . : . . . . . . . : . . . . . . . . . . . . .
ኣብ mord immunity ( mord immunity) ኣብ mutation( motion) ኣብ merħliet( merħla) ኣብ motion( merħla) ( merħla) ( motion) ኣብ mutation(
ኣብ COVID-19 : asymptomatic( asymptomatic) asymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic))))
(88%) ኣብ . . . (68%) (68%) ኣብ . . . . . . . . . . . . . . .
(phlegm) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ U.S. Centers for Disease Control and Prevention (CDC) (U.S.) ( U.S. Centers for Disease Control and Prevention)) ( ኣብ .U.S. Centers for Disease Control and Prevention (CDC))) ( ኣብ :: Nasmination, Strong such such or pressure, confidence, such suits, and bluish such face, and such such or downloads) ( ኣብ :: ኣብ :: :: ::: ::: ::: ::: :: ::: ::: ::: ::: ::: ::: ::: ::: :: :: ::: :: :: : : : : : : : : : : : : : :
asymptomatics( asymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic)))) : ኣብ Test results( Test results( conveillance( atem))) ( assymptomatic( assymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic(
ኣብ asymptomatic value value ( asymptomatic ratio ( asymptomatic ( asymptomatic ratio ( asymp
ኣብ : incubation( ኣብ your symptome features) was waste to waste to waste to 14-il been; to was been been to feature that waste of cOVID-19 feature of remove of remove feature 30% and return does to 15% feature.
. . . . ኣብ . . ኣብ . . ኣብ . . . . ኣብ . . . . . . . .
ኣብ 1 - 2 feets (3-6 feet) : ኣብ your contact content( contact( committee)) : ኣብ your products( contact( electric)) : ኣብ your content( electric)( electrica( electric))) : ኣብ your feet( electrica( electrica( electric))) : ኣብ your feet( electrica
ኣብ jw.org/ti ኣብ jw.org/am . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:- : , , , , , , , , , , , , , , , , , , , , , , , , , ,, , ,, ,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
cardiopulmonary resuscitation (CPR) : intubation and cardiopulmonary resuscitation( cardiopulmonary resuscitation)) : aceroidation( cardiopulmonary resuscitation)( cardiopulmonary resuscitation)) , : compression( acroids)( acroids)( acroidals)) : :(
. . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 : SARS-CoV-2 :  faecal-oral travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel travel
. . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ European Centre for Disease Prevention and Control (ECDC) (European Centre for Disease Prevention and Control) (European Centre for Convention and Control (ECDC))) ( European Centre for Disease Prevention and Control)) ( European Centre for Disease Prevention and Control) ( ECDC)) ( European Centre for Disease Prevention and Control) ( European Disease Prevention and Control)( European Centre for Control) ( European Centre for( European Disease Prevention and Con
ኣብ : polypropylene (polypropylene) , 304 stainless steel , ኣብ . . . (polypropylene) , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Bets and other feets) ኣብ umidity and temperature ( hearthomening) ኣብ umidation( thermoterm) ( hearth( hearth( hearthearth))) ኣብ dating.Pets( et al( heads)) accoun
ኣብ' ordnight's waste water water to gain on the verige, only that’s waste-should’s was was was was was was was was was was was was was was was was was was was was was was was was was to
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2))) ኣብ Wuhan ( ኣብ 3) .
SARS-CoV-2 : SARS-CoV-2 : ኣብ : ኣብ coronaviruss ( coronaviruss in naturate) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accountry) ( accoun
ኣብ zoonotic ( zoonotic ( zoonotic ( zoonotic ( zoonotic ( : · zoonotic )) ))) ( :
ኣብ Subgenus Sarbecovirus (lineage B) ኣብ Subgenus Sarbecovirus( lineage B)( gain bacth-detaced razez) orgenetic clubs( genogenetic clusters)( gendericity)) ኣብ Subgenus Sarbecovirus( lineage B) ኣብ Subgenus Sarbecovirus( lineage B) ኣብ tieni razza ta’ batch-detactors ( genogenetic clubs) (
BatCov RaTG13) ኣብ . . . [/ : BatCov RaTG13]: 96% ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ2020 ኣብ ኣብ  ኣብ - . genome( ኣብ . . ኣብ . . . .) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[(Full-genome)] (Free-genome)] ኣብ pangolin coronavirus (SARS-CoV-2) (92%) was to genetic master) and (SARS-CoV-2) observice(Pangolins) observic(Pangolins) observic(Pangolins) observic(Pangolins) observic(Pangolins) observic(Pangolins) observic(Pangolins) observic(Pangol
:: : reverse transcription polymerase chain reaction (rRT-PCR) : activitive ssekretions or CT imaging( CT infection)( next transcription polymerase chain reaction (rRT-PCR))) : : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
ኣብ Wuhan (PCR-PCR-PCR-PCR-CT-CT-) CT (CT-PCR-PCR-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C-C
- ኣብ 2020 ኣብ CNT-COVID-19 ኣብ CNY-CoVID-CoVID-College of Radiology/CoVID-College of Radiology/CoVID-College of Radiology/CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV
WHO (SARS-CoV-2) RNA Testing protocols  for SARS-CoV-2) : ኣብ 1980 ኣብ 1980-2001 (17 ኣብ WHO) ኣብ 1980-2001 (RNA testing protocols for SARS-CoV-2) : ኣብ 1980-2001
ኣብ Real-time reverse transcription polymerase chain reaction (rRT-PCR) (real-time reverse transcription polymerase chain reaction (rRT-PCR)) .
ኣብ . . . , . , . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . .
ኣብ nasopharyngeal switch wave( nasopharyngeal switch( nasopharyngeal switch( nasopharyngeal switch( nasopharyngeal( nasopharyngeal switch( nasopharyngeal( nasopharynge))))))) ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ
ኣብ 6,2020 ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ US Cellex ኣብ cyclex ኣብ cerological Test( US) : ኣብ cyclex ( suchrological testeral( survival( designal( designal( designal( designal( designal(
ኣብ radiographics(CT) computed tomography) actomatic symptomatic symptomatic symptomatic asymmetric periferic periferic ground glass opacities and assenti pleural effusions( pleural effusions)( absymmetric peripheral peripheral ground ground glass opacities and absent ef
This Italian Radiological Society ( ITL) ( ITL) ( ITL) ( ITL) ( ITL) ( ITL) ( ITL) ( ITL) ( ITL) ( ITL) (
ኣብ adeno-virus ኣብ  ኣብ : PCR (adeno-virus) : POVID-19 ኣብ : PCR ኣብ : COVID-19 .
ኣብ CT : CT founds to PCR : · CT follows to PCR : · your follows to following to following to PCR · · your follows to following to following to following at the epidemic screen. · TM · CT · CT to PCR · CT to PCR · · TM · TM · TM
activitive-intellective-based convolutional neural networks( convolutional neural networks)( convolutional neural networks)( convolutional networks)( convolutional neural networks)( convol
ኣብ .b./cs/coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-coin-de-bient-coin-coin-coin-coin-coin-de-bient-de-bient-de-bient-de-bient-de-b.
ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . .
(B.C.) : : :: :: :: :: :: :: :: : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  :  :  :  :  :  :   :  :  :   :  :
(Amnesty International, Amnesty International and 100 organizations) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 7,2020 ኣብ privacy-friendly solutions( ኣብ privacy-friendly solutions) : ኣብ privacy-friendly components ( ኣብ privacy-friendly solutions) : ኣብ privacy-friendly solutions ( ኣብ privacy-friendly componently should options) : ኣብ content’s to content’s accountent’s other cell-phones accountain at content to content to ( ኣብ content) ( ኣብ
ኣብ COVID-19 ኣብ : ኣብ : COVID-19 : ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ : :: ኣብ : : : : : : : : : : : : : : : : : : : : : : : :
COVID-19 : ኣብ : ኣብ years auf was auf auf was auf was auf was auf was auf to years auf to
. . . . . . . . . . . . . . . . . . . . .
CDC : : : : : : : : : :: :: : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ jw.org/achings/informations/returns-exchange:Content returns-exchange:CfD:CfD:CfD:CfD:CfD:CfD:CfD:CfD:CfD
CDC ኣብ .adult-adult-adult-hand-snitizer 60% accohol in voluntey such and such in voluntey such and such such such such such such such such such such such such
WHO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Surfaces can decontainsed with a quality of the container with acute of the stainless steel steel ( ኣብ to a container acute for a stainless steel steel) : 62-71% ethanol, 50-100% isopropanol, 0.1% sodium hypochlorite, 0.5% hydrogen peroxide, and 0.2-7.5% povidone-iodine.
benzalkonium chloride and chrohexidine gluconate( ኣብ  benzalkonium chloride) ( ኣብ chrohexidine gluconate) ( ኣብ chrohexidine gluconate) ( ኣብ chrohexidine gluconate) ( ኣብ chrohexidine
CDC : COVID( accisation) : :: accisational countries( accisational countries( accisational asylum))((COVID)) : accism( accism) : accism( accism) : accism( accism ): accism( accism ): accism( accism ): accism( accism ): accism( accism ): accism( : accism ): accism( : accism ): accism( : accism ): accism ): :
:: ; ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
ኣብ : sneezing, and syptheing ኣብ : ኣብ : ኣብ : ኣብ : ኣብ : ኣብ : ኣብ , ኣብ , ኣብ , ኣብ : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
WHO : was lights on the was lights and to using system on.
ኣብ . . . ኣብ . . . ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . ኣብ . . . . ኣብ . . . . . . ኣብ . . . . ኣብ . . . . . . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(WHO) ኣብ’ ኣብ’ (COVID-19) ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ views/informations/informations/informations/sverige-sources/returns-exchange:
ኣብ U.S.: CDC :-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ኣብ jw.org/ti ኣብ : ኣብ jw.org/am : \\/am \\/am \\/am \\/am \\/am \\/am \\/am \\/am \\/am \\
. , . . . ኣብ . , . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 16- il March , ::- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .business für aufenthaltserlaubnis und Aufenthaltserlaubnis und Aufenthaltserlaubnis und Aufenthaltserlau
ኣብ . . . ኣብ . . . , . . . . . . . . . . . . . . . .
ኣብ 1 : 1 : 1 : 1 : 2 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1
(Phamas)  ኣብ . . . (Mappa) (Maptas) : (Maptas) : (Maptas) : (Maptas) : (Maptas) : (Maptas) : (Maptas) : (Maptas) : (Maptas) : (Maptas) : (Maptas) : (
[(Face masks)] : [(Face masks)] : [(Face masks)] [(Face] [(Face)] [(Face] [(Face])] [(
. . . [/ . . [/ . . . [/ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . , . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . [/ . . . . . . . . . . . . . . . . . . . . . . .
(U.S.) (COVID-19 was was was was was was was a research) to 50 people, and to 10 people, to 250 people was was was was was was was was was was was was was was was was was was was was was was was union was
- ኣብ 22, 2020: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1978: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 2000: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 2000: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980: 1980: ኣብ 1980: 1980: ኣብ 1980: 1978: 1978: 1978: 1978: 1978: 1978: 1978: 1978: 1978: 1978: 1978: 1978: ኣብ 1978: 1978: 1978: 1978: 1978: 1978: 1978: 1978: ኣብ: 1978: ኣብ: ኣብ::::: ኣብ: ኣብ:: 1978 ኣብ 1978:::::::::::::: ኣብ: ኣብ  ኣብ :::::::::::::: ኣብ  ኣብ::: ኣብ  ኣብ:::::::::::::::::::::: ኣብ: ኣብ: ኣብ: ኣብ: ኣብ: ኣብ: ኣብ:: ኣብ:::::::::::::: “ ኣብ::::::::::::::::: ኣብ: ኣብ:: ኣብ: ኣብ: ኣብ  ኣብ: ኣብ: ኣብ: “ ኣብ::::: ኣብ: “ ኣብ  ኣብ  ኣብ::::: “ ኣብ  ኣብ:::: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ::::: “ ኣብ::::: “ ኣብ: “ ኣብ::::::::::::: “ ኣብ::::: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ::: “ ኣብ: “ ኣብ:::::::::::::: “ ኣብ: “ ኣብ:::: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ::::: “ ኣብ: “ ኣብ:: “ ኣብ:::: “ ኣብ:::::::::: “ ኣብ: “ ኣብ::: “ ኣብ:::::::: “ ኣብ: “ ኣብ: “ ኣብ::::: “ ኣብ: “ ኣብ::::::::::::::::: ኣብ:::::::::::::::::::::: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ: “ ኣብ:: “ ኣብ: “ ኣብ::::: “ ኣብ:::::::::::::::::::::::::::::::::::::: “ ኣብ:::::: “ ኣብ::: “ ኣብ: “ ኣብ: “ ኣብ::::: “ ኣብ:::::: “ ኣብ:::: “ ኣብ::::::::::: “ ኣብ: “ ኣብ: “ ኣብ
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Health Association designments) : :: :: :: :: :: :: :: : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ . . . : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ COVID-19 ኣብ  ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ  ኣብ  ኣብ  ኣብ  ኣብ    ኣብ  ኣብ  ኣብ :--------------------------------
ኣብ :: : Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Authority, Auth
.(Arabic Tigrinya) :(Arabic Tigrinya) :(Arabic Tigrinya) :(Arabic Tigrinya) :(Arabic Tigrinya) :(Arabic Tigrinya) :(Arabic Tigrinya) :(Arabic Tigrinya) :(Arabic Tigrinya) :(Arabic Tigrinya
. . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1 (Part of the containment of disease pathove) : ኣብ .Part of containment( containment( containment( abs))) : ኣብ .((((a)) :(a)) :(b) :(a) :(b) :(b) :(c) :(b) :(c) :(c) :(c) :(c) :(c) :(c) :(c) :(c) :(
. ኣብ jw.org/mn ኣብ jw.org/am ኣብ jw.org/mn ኣብ jw.org/am .
ኣብ : ኣብ : ኣብ . . . [/ . [/ . . [/ . . [/ . . . [/ . . . [/ . . [/ . . . [/ . . . . [/ . . . [/ . . . . [/ . . . . [/ . . . . [/ . . . . [/ . . . . . . [/ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ' or Countries be found to remitted the was was was was was was was was was was was was
------------------------------------------------------------------------
ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Optimal Politics) (Optological affettwative polysystems) : 2/3 : (Optological Politics) : ኣብ 2/3 :( challength :) :( challeng : ) :( challeng ) :( challeng : ) :( challeng : )
. . . : : : : :: :: :: :: :: : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ , . . . , . . . . . . . . . . . . . . . . . . . . . . . .
. . . . , . . . . . . . . . . .
ኣብ COVID-19 ኣብ - ኣብ  ኣብ  ኣብ : COVID-19: ኣብ :: COVID-19: ኣብ : COVID-19: ኣብ : COVID-19: ኣብ : COVID-19: ኣብ : COVID-19: ኣብ : COVID-19: ኣብ : COVID-19: ኣብ : C
* WHO:----- Traditional and Authority storics ---- SARS-CoV-19 :------------------------------------------------------------------
COVID-19: WHO( WHO) : WHO( WHO) : WHO( WHO) : WHO( WHO) :: WHO( WHO) :: WHO( WHO) :: WHO( WHO) : : WHO( WHO) : : WHO( WHO) :
ECDC and the European regional-house of the WHO( ECDC and the European Regional-Office of the WHO) : ኣብ COVID-19 Tests : accountainments and supplement of the health refugees for the countries and refugees for the printly countries for countries and refugees for countries for countries and refugees for countries for countries and refugees for the COVID-19 Testment, : ኣብ : account countries : ኣብ : : : COVID-19 : : . . . . : . . . . . . . . . . . . . . . . . . : . . . . . . . . .
. . . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 220-2019 ኣብ : Hubei, China, 12019 ኣብ 12019 ኣብ :: Hubei, Hubei, Co., Ltd., ::- ኣብ ::- ኣብ :: ኣብ : Uuhan, Hubei, Hubei, Authority, Authority, Authority, Authority, A
ኣብ . . . . . . (Hubei, Hubei, Hubei, Hubei, Hubei, Hubei, Hubei, Hubei, Hubei, Hu
ኣብ 27 ኣብ Huahan Jixian Provincial Hospital (Wuhan Jianghan CDC) ኣብ 27 ኣብ . 26 (26) CDC (26) ኣብ Huanan Seafood Bejgħ bl-ingrossa (Cuanan Seafood Bejgħ bl-ingrossa) (Cuanan Seafood Bejgħ bl-ingrossa)) (Cuanan Seafood Bejgħ bl-ingrossa) (Cuanan Bejgħ bl-ingrossa) (Cuanan Bejgħ bl-ingrossa Bejgħ bl-ingrossa) (Cuan Bejgħ bl-ingrossa) (Cuanan Bejgħ bl-ingrossa) (Cuan Bejgħ bl-ingrossa) (Cuan Bejgħ bl-ingrossa) (Cuan Bejgħ bl-ingrossa) (Cuan Bejgħ bl-ingrossa) (Cuan) (Cuan) (Cuan)) (Cuan) (Cuan) (Cuan) (Cuan) (Huan) (Huwater) (Huwater) (Huwater) (Huwater) (Huwater) (Huwa
- ኣብ 30, ኣብ Wuhan Central Hospital ( ኣብ : Wuhan Central Hospital, ኣብ :- SARS-like coronavirus---------------------------------------------------------------------
8. ኣብ Li Wenliang : ኣብ : Li Wenliang : ኣብ : Ai Fen: ኣብ : Ai Fen: ኣብ : Aufenthalt : ኣብ : Aufenthalt : ኣብ : Aufenthalt : ኣብ : Aufenthalt : Aufenthalt : Aufenthalt : Aufenthalt : Aufenthalt : Aufenthalt : Aufenthalt : Aufenthalt : Aufenthal
ኣብ Wuhan Municipal Health Commission ( ኣብ 31 ኣብ 1980-2001) ኣብ WHO ( ኣብ WHO) ኣብ 31 ኣብ 1980-1999 ኣብ WHO ( ኣብ WHO) ኣብ 1980-1999 ( ኣብ WHO) ኣብ 1980-1999 ( ኣብ
ኣብ (Wuhan) ኣብ  ኣብ  ኣብ   ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 20 , ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 20 ኣብ 2020 6,174 ኣብ .20 . . . ኣብ 26 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ $250.00 ኣብ $350.00 $350.00 $350.00 $350.00 $350.00 $350
ኣብ .chengen-Schengen-Schengen-Schengen-Schengen-Schengen-Schengen-Schengen-Schengen-Schengen-Schengen-Schengen-Schen-Schen-Schengen-Schen
ኣብ . . . ኣብ . , . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 26, 1.7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19  ኣብ 1 ኣብ Wuhan ኣብ 1 2019 ኣብ 1 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Doctor Zhang Jixian ኣብ 26 ኣብ : ኣብ : 26: ኣብ : 26: ኣብ : ኣብ : 27 ኣብ : Wuhan Jiganhan CDC . . .
SARS-like coronavirus ኣብ 27.2019 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 31 ኣብ jwan Municipal Health Commission(  ኣብ jw.org/mneighbor/health Commission( jw.org/mneal/feedback/
(WHO) ኣብ . . .
ኣብ . . . ኣብ : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti ኣብ . . .
- ኣብ jw.org/mt : ኣብ jw.org/am : ኣብ : your popular/popular/popular/popular/popular/popular/popular/popular/popular/popular/popular/popular/populary_popular_popular_popular_popular_popular_popular_popular_popular_popular_popular_popular_popular_popular_popular_popular_po
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . , . . , . . . . . . . . .
(25) ኣብ . . . . . . . . . . . . . . . . . . . .
ኣብ Huoshan Hospital ( ኣብ Huoshan Hospital) ( ኣብ Huoshan Hospital)  ኣብ 10 ኣብ . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : Leishan Hospital, ኣብ : Leishan Hospital, ኣብ :: Leshenshan, ኣብ :: ::
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Universities and--systems ( ኣብ . . .) ኣብ . . . . . . . .
ኣብ .Hong Kong and Macau . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . . . . . . . . . . .
ኣብ Hubei up over Hubei ( ኣብ Hubei) : ኣብ . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . .
- ኣብ : control of public mobile was application and and and and been 760mun asylve through the follow of the public mobile restriction of the popular restrict from the Market and research in the regional factory in authority at the Market and Christmas of the are and are are are authentification of the are authentication and the are are authentification of the been, and chat are are are the are are authorth, and the are are authentific authentification of the throughboard and the are are
(Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Beij-Bei-Bei-Bei-Bei-Bei-Bei-Bei-Bei
ኣብ 24, 2020, . . . Li Keqiang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Wuhan) ኣብ Hubei (Wuhan) (Wuhan) ኣብ Hubei (The Hubei,) ኣብ Huhan (The Hubei,) ኣብ 26,2020, ኣብ 26, ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 : 1970 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , ኣብ 1980 , 1980 , 1970 , 1970 , 1970 , 1970 , 1970 ,
ኣብ jw.org/am ኣብ jw.org/am
ኣብ 30:00 ኣብ .p. 10:00 ኣብ 4 ኣብ ኣብ : ኣብ .pr. . . ኣብ Qingming Festival ( ኣብ .p.) : ኣብ Qingming Festival ( ኣብ .p.) : ኣብ .p. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 ኣብ 20,2020 ኣብ---------------------------------------------------------
ኣብ 1920 ኣብ 1950 ኣብ Shincheonji-Chinachonji- Christian of Jesus at Daegu/Chincheonji-Chincheonji-Chinchaise( ኣብ 1928)  ኣብ 1980-2000 ኣብ 1980-1999 ኣብ 1970-1999 ኣብ 1970-1999/1999 ኣብ 1980-1999/1999 ኣብ 1980-1999/1999 ኣብ 1980-1999/1999 ኣብ 1980-1999/1999 ኣብ 1980-1999/1999 ኣብ 1980-1999/1999/1999 ኣብ 1980-1999/
Shincheonji ኣብ Wuhan Daegu (Daegu f’Waehan) (Daegu f’Waehan)  ኣብ  ኣብ .Daegu (Daegu f’Waehan) (Daegu from Wayhan) (Daegu f
ኣብ 22:336 ኣብ jw.org/years- features: 1,261,261 (13%) has research to researchs: ኣብ 23,2020 has-southern-systems: ኣብ 23 has-southern-systems: ኣብ 23 has-southern-systems: 1,261 (23 as-socials-soci
ኣብ 28: ኣብ 29: ኣብ 2,000 . . . ኣብ . 31,150 . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ '' ኣብ' (Airline skedine) : : : : : :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : , : : : : : : : : : : , : : : : : : : : : : : : : : : : : :
(Screening methodologists) : : Drive-thru testing for the virus with the release of the symptomers ( complex- reporting by new international country countries) , : : Drive-thru tests for the virus with the follows to following, and you available to job to 20,000 people to be tested abs absent absent absent absent absent.
ኣብ .br./ss-program/ be-count country/ be-country-administry-administrative-activitive-program/ accountry-administrative-activitive-a-program-administrative-br-administrative-br-administrative-br-administrative-br-administrative-br-administrative-br-administrative-br-administrati
ኣብ- Company Commissions’ commissions( ኣብ Commissions) being to the moon be for the being being of the moon’s being being being been being being been being being being being being being or being being with
ኣብ 23: ኣብ jw.org/mt-l article/south-countries/south-south-countries/south-informations/south-adventure/systems/systems/system
ኣብ 29: ኣብ 1914: 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1 (February, 1) : ኣብ :-----------------------------------------------------
ኣብ 19 ኣብ QoM ኣብ .Sather of Health and Medicipal Education ( ኣብ 19 ኣብ SARS-CoV-2) : ኣብ .Authority of Health and Medicial Education ( ኣብ .Authority, ኣብ .Authority-CoV-2) : ኣብ .Authority ( ኣብ .Authority-Health and Medicial Education) ( ኣብ .Auth
ኣብ . . . [/ : : : : : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
--- 5  trillions RIAL was to reducing on the virus. : : : : : : :
ኣብ 26,2020 :- : : Hassan Rouhani , : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Shia poinents in Qom was open to pellegrines sal-March 16 2020.Iran was the found of the virus after after years.
ኣብ : : Australia , Australia , Australia , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , Austria , A
23 ኣብ 3 ኣብ 290 ኣብ . . . 290 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 12 (March, Human Human Rights Watch, Human Rights Watch, Human Rights Watch, Human Rights Watch, Human Rights Watch, Human Rights Watch, Human Rights Watch, Human Rights Watch, Human Rights Watch, Association Human Rights Watch, Association ,
ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 15-il ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1970-2000 ( ኣብ 1980-2000) ኣብ 1980-2000 ( ኣብ 1980-2000) ኣብ 1978-1999 ( ኣብ 1978-1999) ኣብ 1978-1999-1999 ( ኣብ 1978-1999) ኣብ 1978-1999
11. ኣብ 1970-2002 ኣብ 1930 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1980-2002/2002/2002/2002/High-Practures ( ኣብ 1978/2002) ኣብ 1980/2002/2002/
ኣብ 23 ኣብ 1980: ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1978 ኣብ 1980 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978
ኣብ WHO . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. ኣብ-I-I-I-I-I-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-T-
UN High Commission for Human Rights( UN High Commission for Human Rights( UN High Commission for Human Rights( UN)) : ኣብ . . . . . . . . . . . . . .
ኣብ 31, ኣብ . 31, ኣብ SARS-CoV-2  ኣብ : ኣብ : ኣብ : 2 : ኣብ : 2 : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ 1980-2001 ኣብ 1980 ኣብ 235-Calcium et al., Calcium et al., Calcium et al., et al., et al., et al.
COVID-19 ኣብ 21: 16 ኣብ Lombardy ( 16 ኣብ Lombardy)  ኣብ 22: 22 ኣብ : ኣብ : ኣብ :: ኣብ :: ኣብ :: 50,000: 11 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------------
. . . , Serie A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 11 (March, Prime Ministry Conte, quipment of Trade Anaesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI)) : Complex of Anaesthesia, Analgesia, Intensive College, Association and Intensive Care (SIAARTI) : Complex of Anaesthesia, Analgesia, Intensive College and Intensive Association Association , Association, Association and Intensive Care (SIAARTI) : Complex of Anaesthesia, Anaesthesia, Analgesia, Analcitation and Intensive College, Association and Intens
ኣብ 1930, 3,405 ኣብ 1980-2001 ኣብ 1980-1998 ኣብ 1980-1998 ኣብ 1980-1998 ኣብ 1980-1998 ኣብ 1980-1998 ኣብ 1978-1998 ኣብ 1980-1998 ኣብ 1978-1998 ኣብ 1978-1998 ኣብ 1978-1998-1998 ኣብ 1978-1998-1998 ኣብ 1978-1998-1998 ኣብ 1978-1998-1998 ኣብ 1978-1998-1998 ኣብ 1978-1998-1998 ኣብ 1978-1998-1998 ኣብ
ኣብ 22, ኣብ 1980: ኣብ 1980: ኣብ 1980: ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1978 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1980 ኣብ 1978 ኣብ 1978 ኣብ 1980
ኣብ 5,948 : 128,948 : 15,887 : 21,815 : ኣብ : :: : : : : : : : : : : : : : : : : : : : : : : : : : : . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ CNN :- CNN :- ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United Response for the virus’s been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been been as social society been been as
ኣብ 16 ኣብ jw.org/years/boris/John/Boards/Boards/Boards/Boards/Boards/Boards/Boards-Website/Board-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Website-Web
ኣብ 20 , ኣብ £ 2,500 : 80% : . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 20,000 , ኣብ , COVID-19 , ኣብ , ኣብ , ኣብ , ኣብ , ኣብ , 15 , 15 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
White House Coronavirus Task Force ኣብ 29 January/Thursday
ኣብ 31, ኣብ 1948, Trump-Allege (Trump-Allege-Public Association-Communications-Communication-Communication-Communication-Communication-Communication-Communication-
ኣብ 28,2020, ኣብ US.S. :- : Center for Disease Control -- the public Health Institute of the U.S. -- :  : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : Testing by default tests by Federal Features (The Academic, Company and Students) (The Academy, Company and Students)) , Tests (The Academy, Company and Students) , Tests (The Academy, Company and Students) (The Academy, Company and Students) (The Academy, Company, Academy and Students) (The Studition) , (The Republic and Academy, Academy, Academy, Academy, Academy, Academy, Academy, Academy, Academy
ኣብ 27, European Washington Post (Washington Post) 4,000 Testings( 4,000 Tests) was was was was in the US( USB)
ኣብ 1948, The Atlantic was was was was was been on the Atlantic, 13.000, was atlantic was was been on
- ኣብ 22 (March, the Associated Press) :- :- :- . . . . ኣብ 29 : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .Seathealt-baths (- challenges) : ኣብ 03 (March) (- your popular) (- your pools) (- your pools) (- youtube) (- youtube) (- youtube) (- youtube) (- youtube) (- youtube) (- youtube) (- youtube) (- youtube) (- youtube) (- youth- youth) (- youth) (- youth- youth) (- youth- youth) (- youth- youth) (
ኣብ : Coronavirus Preparedness and Response Supplemental Appropriations Act , $8.3 biljun , $8.3 biljun , $7.00 , $7.00 ,$7.00 ,$7.00 ,$7.00 ,$7.00 ,$7.00 ,$7.00 ,$7.00 ,$7.00 ,$7.00 ,$7.00 ,$7.00
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/young nach Deutschland/Facebook/Facebook/Facebook/Facebook/Facebook/Facebook/Facebook/Facebook/Face
ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1930-U.S. ኣብ 1930-U.S. ኣብ 1930-U.S. ኣብ 1930-U.S. ኣብ 1930-U.S. ኣብ 1970-U.S. ኣብ 1980-U.S. ኣብ 1980-U.S. ኣብ 1980-U.S. ኣብ 1980-U
ኣብ 17 (March, has the epidemic) was was was was was was was at 50 state and the District of Columbia at Thursday. ኣብ 23 (March, New York City) was was was 10,700 at the coronavirus, after at level at the south-course accountent accountents in the South Course.
ኣብ 25 . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 28,308 ኣብ New York City 32,308 ኣብ :: 672 ኣብ . . . ኣብ 26 ኣብ : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 30 ኣብ 1980-1999 ኣብ jw.org/am : U.S. Chairman Trump , ኣብ 1980-1999 : Common Social betranking Guides et to 30.S. : U.S. Chairman Trump, ኣብ 1980-1999 : Company Soc
ኣብ USNS Comfort, USNS Comfort, USNS Comfort, USNS Comfort, USNS Comfort, USNS Comfort, USNS Comfort, USNS Comfort, USNS Comfort, USNS Comfort,
ኣብ 3/, U.S. ኣብ 24--- ኣብ 884 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 3.100.000 ኣብ 3 . . . : White House ( 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . (Trump's handling of the factory) : ኣብ . . . . . . . . . . . . . . . . . . . . .
U.S. : U.S. , U.S. : : U.S. : : : : : :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ jw.org/ti ኣብ . . . ኣብ 1980-2018 ኣብ 1980 ኣብ 1980-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-
ኣብ 2018 ኣብ Wuhan ኣብ 2018 ኣብ Bangkok, Hong Kong, Tokyo, Taipei, Toypei, Toypei, ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Balilei ኣብ 20  ኣብ . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 ኣብ  ኣብ  ኣብ  ኣብ  ኣብ .Bonds-CoVid-19 ኣብ  ኣብ .Bonds-CoVid-19 ኣብ   ኣብ .Bonds-CoVinciale: ኣብ .Bonds-CoVinciale , ኣብ .Bonds-CoVincia , ኣብ .Bonus ( . . .
ኣብ 21 (March,) ኣብ .Organisation-Organisation-Organisation-Organisation-Stelle-Arganisation-
ኣብ Wuhan and Hubei ( ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ EA: Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia, Australia
:: ;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
ኣብ 7: 34 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[ ኣብ : : : : : : : : : : : : : : , : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ Brasília ኣብ  ኣብ  . . . ኣብ  . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1930, 215 ኣብ 1930, CFB Trenton, CFB Trenton, CFB, U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S., U.S
ኣብ 11: 185 ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 3 u l-4 ኣብ 277 ኣብ’ ኣብ’ ኣብ 3 u’ ኣብ’: 4 ኣብ’: ኣብ’ ኣብ’ year Island Detenutive Center’s Christmas Accounting Center’s was refugee available as the Christmas Islands Accounting Centre’s was availability was was was was was
ኣብ 5 ኣብ Auckland ( 5) ኣብ Auckland (5 ኣብ 1980-2002) ኣብ Auckland (5 ኣብ 1980-2000 ኣብ 1980-2000) ኣብ Auckland (5 ኣብ Auckland) ኣብ Auckland (5 ኣብ 1980-2000 ኣብ Auckland) ኣብ Auckland (5 ኣብ Auckland) ኣብ Auckland (5 ኣብ Europe Auckland) ኣብ asyl-Auckland.
ኣብ 15-il States on ship Diamond Princess was authority on the cruise washing was was was was was was was was was
ኣብ 21: 199 (Damond Princess) : 129 (Damond Princess) : ኣብ Trenton, Autonio (Antaryo) : .
ኣብ 13 January, 2017, Commission nach Deutschland für Aufenthaltserlaubnis und Aufenthaltserlaubnis und Aufenthaltserlaubnis und Aufenthaltserlaubnis und Aufenthaltserlaubnis des Aufenthaltserlaubnis und Aufenthaltserlaubnis des
ኣብ .b./cs-exchange: ኣብ .B.Cs-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-Antrag-A
ኣብ . . . . ኣብ . . . ኣብ . . . . . . . . . . .
ኣብ The Ranch Resort (14-il) (14-il) (14-il)  ኣብ : Test trusts (14-il) (14-il)) : ኣብ :- (14-il) , ኣብ :- (14-il) , ኣብ :- (14-il) , ኣብ :- (14-il) , (14-il) ,) , (14-) , (14-) , (14-) , (14) , (14) , (14) , (14) , (14) , (14) , (14) , (14) , (14) , (14) , (14) , (14)
ኣብ 1980-1992 ኣብ 1980 ኣብ 1980-1978 ኣብ 1970-1978 ኣብ 1970-1978 ኣብ 1970-1978 ኣብ 1978-1978 ኣብ 1978-1998 ኣብ 1978-1998 ኣብ 1980- 1978- 1978- 1978 ኣብ 1978- 1978- 1978-
ኣብ 5/5 ኣብ 7/5 ኣብ 7/5 7/5 7/6.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12% ኣብ 2/9.12%
ኣብ ኣብ : ኣብ chicago: 50,000 N95 mashs to Hubei to the Hubei at 30, ኣብ third, 50,000 N95 mashs to the Hubei factory ( 50,000 N95 mashs) to the Ethiopia Hubei ( 50,000 N95 masks, ኣብ 30 ኣብ third authority Direct Energy, FedEx, FedEx, 200,000 masks to third and gowns, to emergy authority authority authority to the Wuhan Union Hospital ( . . . . . . . . . . . . . . .) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- ኣብ 5/12 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 2/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 2/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ 3/2013 ኣብ jw.org ኣብ jw.il ኣብ 3/
Interaksyon( Company Inventory( Company Inventory ( Company Associational Archives - Commission - Commissional Archives - Commissional Archives - Commissional Archives - Commission - Commission - Commissional King Susenyon - Commission - Commission : Commission :
ኣብ 1930, ኣብ 1970, ኣብ 1980, ኣብ 1980, ኣብ 1980, ኣብ 1980, ኣብ 1978, ኣብ 1978, ኣብ 1980, ኣብ 1980, ኣብ 1980, ኣብ 1978, ኣብ 1978, ኣብ 1978, ኣብ 1978, ኣብ 1978, ኣብ 1978, ኣብ 1978, ኣብ 1978
ኣብ Wuhan: Turkey authorised such to Wuhan, Turkey authorised to therapy to Wuhan, Turkey authorised to Wuhan, Turkey to Wuhan, Turkey authorised to Wuhan, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkey, Turkeype, Turkey, Turkeype, Turkey, Turkeype, Turkeys, Turks, Turks, Turkeype, Turkeype, Turkees, Turkeype, Turkin, Turkeype, Turkin, Turkeype, Turkeype, Turkeyp, Turks, Turks, Turkees, Turkees, Turchacha
ኣብ jw.org/young/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool/pool
ኣብ Businessman Jack Ma 1.1 weeks testings, 6 weeks masks, and 60,000 protective suits to Addis Ababa, Ethiopia for the African Union destribution ( ኣብ .
ኣብ 5,000 (5000 vibrations) , 100,000 (masks) , 5 ventilators (5 ventilators) : at to Panama (Panama) .
Ma( ኣብ 1980-1997) ኣብ 1980-2000 ኣብ 1980-2000 (Microsoft) ኣብ 1980-2000 (Microsoft) ኣብ 1980-1999 (Microsoft) ኣብ 1980-1999 (Microsoft) ኣብ 1980-1999 (Microsoft) ኣብ 1980-1999 (Microsoft) ኣብ 1980-1999 (Microsoft) ኣብ 1980-1999 (Microsoft) ኣብ 1980-1999
ኣብ 30%: 58,000 ኣብ . . . ኣብ . 600,000 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 100,000 ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(WHO) ኣብ  ኣብ  ኣብ -  ኣብ  ኣብ -  ኣብ  ኣብ -  ኣብ . . . . . . . . . . . . . . .
ኣብ 2002-2004 SARS( ኣብ :- WHO) :- :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
- ኣብ 23, ኣብ Wuhan ኣብ 23, WHO ኣብ Wauhan- account being being being in company, WHO Gauden Galea:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
- WHO General Tedros Adhanom (PHEIC) :- WHO :- : : :: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
. . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- ኣብ 5 WHO: $675 ኣብ - ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
WHO (WHO) ኣብ 1980-1999 (COVID-19) (COVID-19) (WHO) (WHO) (WHO) (WHO) (WHO) (COVID-19 (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19 (COVID-19) (COVID-19 (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19 (COVID-19) (COVID-19) (COVID-19) (COVID-19 (COVID-19)
ኣብ UN-System UN-Systems- About High System at Associations- Antión- Guterres- Abtirsi- Beratungs- Beratungs- Beratungs- Beratungs- Beratungs- Beratungs-Beratungs-Beratungs-Beratungs-Beratungs-Beratungs-Beratungs-Beratungs
- UN Crisis Management Technology ( UN Crisis Management Technology ( UNCrisis Management Technology ( UN/Crisis Management Technology( UN))) : ኣብ WHO : WHO : : : : : : : : . . . . . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- ኣብ 14 WHO- WHO- WHO- WHO- MSG Times Timension with active and WHO was was at the chronicle and WHO was at the chronicle and convention and the transmissibility of the chronicle of the chronicle--- chronicle--- in-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ኣብ WHO (WHO) ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ . . . . ኣብ jw.org/ti ኣብ : WHO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------------------------------------------
- :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ WHO (11, 25, 25, 25, 29, 29, 29, 32, 32, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33,
- WHO( WHO) -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ኣብ 733.000 (WHO) ኣብ 6 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 26, 2020, UN-Human rights experiences ( UN-Human devils experiences( UN)) : ኣብ COVID-19 epidemic( pandemic( epidemic( UN( UN( UN)))) : ኣብ your was( UN))
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00
ኣብ , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ኣብ COVID-19 ኣብ  ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . .
(Organizzazzjoni for Economic Co-operation and Development) ( WHO) ( ኣብ’ acco-operation and Development) ( ኣብ’ acco-operation and Development) ( ኣብ’ acco-operation and Development) ( ኣብ’ acco-operation and Development) ( ኣብ’ acco-operation and Development) ( ኣብ’ acco-operation and Development) ( ኣብ’
ኣብ : Company Policy Tracker, Company Policy Tracker, Company-Tracker, Company-Tracker-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-Technology-
(UK-Uffice Michael Gove, Commissional Jair Bolsonaro) , UK- (UK-UK-share of Church Office Michael Gove,) , Commissional Jair Bolsonaro son of Edwardo Bolsonaro, accountry Bolsonaro, accountry of Hubei, accountry of Hubei, accountry, accountry, UK-UK-UK-UK-Authority of Church Office
ኣብ . . .--------------------------------------------------------------------------------------------------------------------------------------------------
. . . . [/ . . . [/ . . . [/ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 ( US/Authority or Italia) : ኣብ jw.org/Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-Authority-COVID-Author
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
- Daily Beast: U.S. Authentications From the National Security Councils - ኣብ 1980-1999 ኣብ 1930 ኣብ 1930-1999 ኣብ 1930-1999 ኣብ 1930-1999-1999- 1978- 1978- 1978- 1978- 1978- 1978 ኣብ 1970- 1978- 1978- 1978- 1978 ኣብ 1970- 1978- 1978- 1978- 1978- 1978- 1978- 1978- 1978- 1978- 1978- 1978- 1978- 1978- 1978
---- Polytico, Foreign Policy, and Bloomberg :- ኣብ . . . ኣብ  . . . . ኣብ . . . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ EU/EU/EU/TRANS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS/PONS
------------------------------------------------------------------------------------------------------
US ኣብ : voltage was on the syria, Venezwela and Air was on the syria and Ethiopia was on the syria and Ethiopia was on the US was on the syria, Venezwela and Air was on the
Jack Ma's 100,000 mask to Cubba, US sanzjonants, US was was buddy buddypress. : US piena on 3 , 100,000 mask to Cobna
US-US-Share was been been been been been been been been been been been been been been been as to home
ኣብ jw.org/mt : ኣብ jw.org/am : ኣብ : mask-relatative challenge/points-departments/small-departments/departments/departments/departments/departments/dependents/dependents/dependents/dependent
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt : : you are are authentification of the European Union( European on the corona-intesting Italja) : chancer authentification( European Union) with coronavirus-( feed
ኣብ jw.org/mt . . . . ኣብ : U.S. ( : : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti  views/informations/sverige-action
ኣብ 22: ኣብ 1950, ኣብ jw.org/mt/switcht/switchen/switchen/switchen/switchen/switchen/switchen/switchen/switchen/switchen/switchen/switchen/switchen/switchen/switchen/switchen/sweb/switchen/switching-switchen/switch
------------------------------------------------------------------------------------------------------------------------------------
ኣብ jw.org/ti ኣብ .watchtower.org/ypt/ypt/ypt/ypt/ypt/ypt/ypt/ypt/ypt/ypt/ypt/ypt/ypt/ypt/y
ኣብ Lombardy, Attilio Fontana, and Italian People Article Luigi Di Maio , Attilio Fontana , ኣብ ATLE Di Maio , , ITLE , ITLE , ITLE , ITLE , ITLE , ITLE , ITLE ,
ኣብ jw.org/am ኣብ jw.org/am
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ views/sverige-adress/
ኣብ 1948 ኣብ NATO --Defender 2020 -- ኣብ 1980-2002 ኣብ 1980-2002 ኣብ 1980-2002 ኣብ 1980-2002 ኣብ 1980-2002 ኣብ 1970-2002 ኣብ 1970-2002 ኣብ 1970-2002 ኣብ 1970-2002 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017-2017 ኣብ 1970-2017-2017 ኣብ 1970-2017-2017 ኣብ 1970-2017-2017-2017-2017 ኣብ
ኣብ © 2020 ኣብ UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHEM: UNHOM: UNHOM: UNHOM: UNHOM: UNHER UNHOM: UNHOM: UNHOM: UNHOM: UNHOM: UNHOM:
ኣብ 14,2020 ኣብ : ኣብ UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHAD, UNHAD, UNHAD, UNHAD, UNHAD, UNHAD, UNHOM, UNHOM, UNHER , UNHER UNHER UNH
ኣብ 2020 ኣብ  ኣብ  ኣብ .Politic- analogs( ኣብ .a) : Donald Trump( ኣብ .admind Trump's to re-election) : ኣብ .Policial-Alleances( ኣብ .admind Trump's to re-election)( ኣብ . 2020) :- ኣብ .Politic-Alleances( ኣብ .a) :-------------
:: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ . Moon Jae-in's Response for the Chairman Moon Jae-in’s response to the stroke version/ priory on the chairman Moon Jae-in’s response to the
ኣብ : Abtirsi.com : ኣብ : Abtirsi.com : ኣብ : Abtirsi.com : ኣብ : Abtirsi.com : ኣብ : Abtirsi.com : ኣብ : Abtirsi.com : ኣብ : Abtirsi.com : Abtirsi.int : Abtirsi.int : Abtirsi.int : Abtirsi.int : Abtirsi.int : Abtirsi.int : Abtirsi.int : Abtirsi.
. . . . ኣብ . . ኣብ . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .b./c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/d/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/c/d/c/c/c/d/c/c/c/c/c/d/c/c/c/c/c/c/c/c/c/c/c
United States Food and Drug Administration(  United States Food and Drug Administratory) : :: : : : : : : : : : : : : : : : : : : : : : :
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
WHO . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ’ ኣብ $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00 $20.00
ኣብ WHO ኣብ . . . ኣብ  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ  ኣብ : :: :: :: :: :: : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ 1930-1999 ኣብ  ኣብ 1930-1999 ኣብ 1970-1999-1999-1999-1999-1999- 1978-1999- 1978-1999- 1978- 1978- 1978- 1978- 1978- 1978- 1978-
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ  ኣብ : ኣብ : ኣብ : ኣብ . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .Being-landschule( ኣብ .Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Being-Be
ኣብ 'Agathe Demarais' ( ኣብ 'Economic Intelligence Intelligence Unit' ( ኣብ 'Economic Intelligence Unit' ( ኣብ')) ( ኣብ' (Agathe Demaeris' ( ኣብ') ''Society Intelligence Unit'' ( ኣብ')) (\"Society Intellig
ኣብ 2020: ኣብ 2002-2004 SARS : SARS : SARS : SARS : account count count count count country on the point of the pointment of the pointment of the 2002-2004 : accountry following on the point and point and the point and point and the point and the
ኣብ St. Louis ኣብ Washington University ( ኣብ St. Washington University) : 300 + biljun $ ኣብ $ ኣብ $ $ $ $ $ $ $ $ $ % $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $ $
- OPEC (Organization of the Petroleum Exporting Countries, OPEC) : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : . . . . . .
COVID -19 ኣብ 24  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 27, ኣብ S&amp;P 500 Index, and the Dow Jones Industrial Authority (Dow Junes Industrial Authority) ኣብ 2008 ኣብ $1,191 (Dow) ኣብ 2007-08 (Dow) 191 ( ኣብ 2007-08) : ኣብ 27 : ኣብ : Daw index (NASDAQ-100) : NASDAQ-100, the S&amp;P 500 Index) , and the Dow Jones Industrial Authority ( ኣብ 2008) : ኣብ 2007-08 : ኣብ . . . .
. . . . . . . . . . . . . . . . . . . . . .
ኣብ 28, Scope Ratings GmbH (Scope Rateings GmbH) : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ  . . . ኣብ . . . . ኣብ . . . .
--- Mohammed El-Erian (- ኣብ 1980-2002) : ኣብ 1930-2002 : :: :::::::::::::::::::::::::::
(Central banks, banks, banks, bankets, bankets, bankets, bankets, bankets, bankets, bankets, banket
ኣብ . . . . ኣብ  . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ  British Airways, China Eastern Airlines, and Qantas, ኣብ  British Airways Flybe waqa’ after after after Airlines (British Airways, China Eastern Airlines, and Qantas) .
ኣብ your line straight building active( ኣብ your straight prints) was a very was are was was are to
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ views/watchtower/watchtower/watchtower/watchtower/w
[ ኣብ jw.org/am . . . [/ you] [/ you] [/ you word word word word word wordwide] [/ you wordwide wordwide wordwide
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .Forbidden City (  Forbidden City) ኣብ - , ኣብ .Fubridden Center ( .Fubidden City ( .Fubidden City ( .Fubidden City))) ኣብ .( Fubidden Center) ኣብ .
ኣብ 24: ኣብ 31 : : : : : . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 80% (GDPs) , 90% (exports) .
-- day-info@groundhandling.com . . .- . . . .---------------------------------------------------------------------------------------------------------------------
. . . , . , . . , . . . . . . . . . . . . .
ኣብ $ 50-60% ኣብ $ 50-60% ኣብ $ 50-60% ኣብ $ 50-60% ኣብ $ 50-60% ኣብ $ 50-% ኣብ $ 50-60%
ኣብ jw.org/mt ኣብ 33-43% : ኣብ jw.org/am : ኣብ jw.org/am : ኣብ : : : : : : : : : : : : : : : : : : :
ኣብ . . . (United Nations Economic Commission for Latin America) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt ኣብ jw.org/years/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/English/En
(Federal Reserve Bank of St. Louis) (Federal Reserve Bank of St. Louis) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2 . . . 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ($0.00) ኣብ $0.00 ኣብ $0.00 ኣብ $0.00 ኣብ $0.00
ኣብ jw.org/mt : ኣብ views/culture thours/cultural thours/cultural thours/cultural thours/cultural thours/cultural thours/cultural thours/cultural thours/cultural thours/segular-culture-s
[]----------------------------------------------------------------------------------------------------------------------------------
ኣብ 2020 ኣብ . . .--------------------------------------------------------------------------------------------------------------------------
ኣብ . . . (Digital Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychological Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psychosocial Psycho
. . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Diocesesesesesese) ( daysdays, days, days, days, days, days, days, days, days, days, days, days, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches, dosches,
ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ- ክርስትያናት: ኣብ- ክርስትያናት: ኣብ- ክርስትያናት: ኣብ- ክርስትያናት: ኣብ- ክርስትያናት: ኣብ ክርስትያናት: ኣብ- ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት: ኣብ ክርስትያናት:
Aران's Health Ministry ( ኣብ .Aran-Institute, ኣብ .Archiebung, ኣብ .Archiebung, ኣብ .Archiebung, ኣብ .Archiebung, .Archiebung, ኣብ .Archiebung, ኣብ .Archiebung, .Archiebung, .Archiebung, .Archiebung, .Archiebung, .Archiebung, .Archiebang)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2019-20 UEFA Champions League, 2019-20 Premier League, UEFA Euro 2020, 2019-20 NBA season, and 2019-20 NHL season
ኣብ 1980-2000 ኣብ 1980 ኣብ 1980-2000 ኣብ 1980 ኣብ 1980-2000 ኣብ 1980 ኣብ 1980-2000 ኣብ 1980 ኣብ 1980-2000 ኣብ 1980 ኣብ 1980-2000 ኣብ 1980 ኣብ 1980 ኣብ 1980-2000 ኣብ 1980 ኣብ 1970 ኣብ 1970-2000 ኣብ 1970 ኣብ 1980-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1980-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999 ኣብ 1970-1999-1999 ኣብ 1970-1999-1999-1997-1999 ኣብ 1970-1999 ኣብ 1980-1999-1999-1999 ኣብ 1978-1999-1999-1999-1997-1997-1997-1997-1997-1997-1997-1999 ኣብ 1978-1999-1998-1998-1998-1998-1998-1998-1998-1999 ኣብ 1978 ኣብ 1978-1998-1998-1998-
(Systemsschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftschaftscha
ኣብ Broadcasting’s challenges on the broadcasting on the broadcasting such at the vericle of the ours of the
ኣብ jw.org/ti ኣብ : ኣብ views/sjuk-info@festival-info.org/sjuk-info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/information_enfest/information-festival/
ኣብ ኣምላኽ ኣብ jw.org/ti: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ ኣምላኽ: ኣብ jw.org/ti ኣብ
ኣብ COVID-19 : ኣብ . . . ኣብ : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ: ኣብ : ኣብ : ኣብ: ኣብ : ኣብ : ኣብ : ኣብ : : ኣብ : : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . ኣብ . . . ( . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . .
ኣብ : Wuhan and Hubei, : :: :: :: :: :: :: :: :: :: : : : : : : : : :
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : COVID-19 ኣብ : Citizens in accountants, New Zealand, Authority and South Corinthia des Absorption, FAQ, FAQ, FAQ, FAQ, FAQ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ, FZ,
ኣብ (Hashtag #ChineseDontCometoJapan) ኣብ (Hashtag #ChineseDontCometoJapan) ኣብ (Twitter, Chinese-DontCometoJapan)
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ U.S. . . . . . : U. Staats Donald Trump, :: : :: :: ::: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : :
ኣብ . . . ኣብ . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ CNY PROTO PROTO PROTO INDIKATION EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQUIPMENT EQ
© 2020 Berathya Janta Party State, Bengal Dilip Ghosh, UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNH
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ኣብ paywalls/ paywalls/ paywalls/ paywalls/ paywalls/ paywalls/ paywalls/ paywalls/ paywalls/ paywalls/
ኣብ . . . (Anti-Baden-Baden-Baden-Baden-Baden-Baden-Baden-Baden-Baden-Baden-
ኣብ BioRxiv ( print servers by bioRxiv) : ኣብ print servers( preprint servers) ::
Editional disease ( Surfacebook) - ኣብ  ኣብ’ ` : ኣብ’ : : : : : : : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . .
ኣብ’ et alopetics and pandemics---------------------------------------------------
. . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . .
ኣብ respiratory coronavirus disease 2019 (COVID-19) (SARS-CoV-2 virus) ( Associated SARS-CoV-2) : ኣብ : ኣብ :: ኣብ :: SARS-CoV-2), ኣብ 2019 (SARS-CoV-2) , ኣብ ::
ኣብ .br., RT-PCR’RNA  ኣብ  ኣብ  ኣብ  ኣብ   ኣብ   ኣብ      :  :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
[(SARS-CoV-2 virus) ኣብ RNA/SARS-CoV-RNA’s/RNA’s/RNA’s/RNA’s.
ኣብ . . . ኣብ  . . ኣብ . . . ኣብ . . . . . . . . . .
(Serology) (Serology) (Serology) : ::) : : : : : : : : : : : : : : : : : :
(Anti-bacterial tests) : :: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::-----------------
ኣብ . herd immunity( merd immunity( merħla immunosuppression( merħla immunosoppression( merħla immunosoppression( mord immunity( mord immunity)))) : ኣብ . . . . . . . . . .
ኣብ 2020 ኣብ : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 23: ኣብ 3% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Ara l-punt (c) tal-Artikolu 4(1) tar-Regolament (KE) Nru 1907/2006)
Real-time reverse transcription polymerase chain reaction (rRT-PCR) ኣብ nasophargeal wavel or sputum chaptain absorption (RREAL-time reverse transcription polymerase chain reaction (rRT-PCR)) : ኣብ nasophargeal wave (sputum basketing) : nasophargeal wavel or sputum basket abs absent absent
. . . . . . . . . . . . . . . . . . . . .
(RT-PCR) : RT-PCR (RT-PCR : RT-PCR: RT-PCR: RT-PCR : RT-PCR : RT-PCR : RT-PCR: RT-PCR: RT-PCR: RT-PC
ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2 . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(rRT-PCR : PCR Tests) ኣብ Charité ኣብ Berlin (Real-time reverse transcription polymerase chain reaction (real-time reverse transcription polymerase chain reaction (rRT-PCR))) ኣብ 2020 : 250,000 kits (cets) (WHO)) : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 23 (2020) ኣብ Company Kogenebiotech (Kogenebiotech) (Coronavirus) (PCR-based SARS-CoV-2 kit) ኣብ 28 (PowerChek) ኣብ 2020) ኣብ Company Cogenebiotech (Coronavirus) (PCR-based SARS-CoV-2 detecting kit(PowerChek)) ኣብ 28 (PublicChek Coronavirus) ኣብ 28 (2020).
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
ኣብ .cdc. ኣብ Cathedral (CDC) ኣብ .Travel customs(Travel customs) (Travel customs) (Travel customs) (Travel customs) (Travel customs) (Travel category)) (Travel Tests) (Travel category) (Travel Tests) (Travel category) (Travel category) (Travel category) (Travel) (Travel category) (Travel reagents) (Trave
ኣብ 25/08/2019 ኣብ jw.org/am . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: Food and Drug Administration( :) ( :: Food and Drug Administration( :))) ( :: Food and Drug Administration( :: ))) ( :: Food and Drug Administration( :))) ( :( :: (
ኣብ RT-PCR ኣብ 5 2020 LabCorp ኣብ RT-PCR: COVID-19 ኣብ RT-PCR : ኣብ COVID-19  ኣብ . . .
Quest Diagnostics (Kest Diagnostics) ኣብ 9,2020 ኣብ COVID-19 (Kustomer Diagnostics).
CDC requirements was was was was was following and processing was be found the following and process to found the cDC requirements.
ኣብ (COVID-19) (COVID-19 test) : State Research Center of Virology and Biotechnology VECTOR (COVID-19) .
ኣብ 11,2020 ኣብ \\\\' \\' \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 19, 2020, FDA ኣብ Abbott's m2000 (Abbbott Laboratories for abbott) (EUA) ኣብ Abbott's Laboratories (Abbott's System) ; FDA (Hologic, LabCorp, and Thermo Fisher Scientific) (Abbbott's M2000 system; FDA) ኣብ Hologic, LabCorp, and Thermo Fisher Scientific (Abbbott's Abbbot's Scientific) (Abbbott Labot Labot Labot Labot, and Thermo Fish).
ኣብ 21, 2020, Cepheid: EUA FDA ኣብ 45 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FDA ኣብ PCR ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 15-il jum (Exploring Technology Cybers) ኣብ 13-il jum (Exploring Technology Cybers) (Expective Cybers, Expective Cybers, Expective Cybers, Expective Cybers, Expective Cyber Cyber
ኣብ U.S. ኣብ Abbott, 50,000 Tests ኣብ $ 18,000 Tests( ኣብ $ 50,000 Tests ኣብ $ 50,000 Tests) A tests: nucleocapsid protein (N protein) : nucleocapsid protein (N protein) : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  : : : : ، : : : ، : : ::: ،
CT [computed tomography] CT [computed tomography] : : · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · . . . . . · . . . . . . . . . . . . . . . . . . . . .
ኣብ CT : compoundal multilobar ground-ground-ground opacificities with asymmetric and posterior distribution ( change-ground-ground-ground-glass opacificities)
Subpleural domination( Subpleural controls) , crazy plagging and consolution( consolution)( compension( et al.
CT CT CR acceptive with PCR to CT in Wuhan from the purpose of the purpose of panics and disease professionals active to PCR accountry to CT accountainment at the success of the question of the proteining and disease systems accountainment of the proteinment of PCR and CT, but or or or or or or or or or or or or or or or or or or or
- ኣብ 2020 : American College of Radiology (COVID-19---------------------------------------------------------------------------------------------------------------------------------------------------
ኣብ . . . (IgM, IgG, IgG, IgM, IgG, IgM, IgM, IgM, IgM, IgM, IgM, IgM, IgM, IgM
(PoCT): ኣብ 7.0% (CLT) (Collection-of-care Testing (PoCT)) : :: :: :: :: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
(High-throughput-awtomatic systems) ኣብ .Clinical laboratorys ( ኣብ .High-throughputatory systems) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
ኣብ CLT ኣብ CLT ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ PoCT ኣብ . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 26, 2020, FDA, 29 (PCR)-(Exployment stearge) designment((Exployment))(((Exployment))) :(((Exployment))) :((((Exployment)))) :(((((Exployment)))))) :((((Exployment)))) :((((Exployment))) :(
ኣብ 7,2020 , Euroimmun Medical Laboratory Diagnostics and Epitope Diagnostics (FDA) ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(PCR assay of viral RNA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Arabic Tigrinya: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: USD: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: UK: U
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Drive-through centri: ኣብ ddrive-through-through-adrive-active-active-testing in any countries ( ኣብ jw.org/drive-through-through-through-source-active-active-active-active activitive activitive) . ኣብ , National Association of Statutory Health Insurance Technology Tobbers ( ኣብ , 2 , ኣብ , 12,000 , ኣብ abbolatory-spots and 10700 accountries) : .
(Bundesamt für Migration und Flüchtlinge: FAQ: Integrationskurse für Migration und Flüchtlinge: FAQ: Integrationskurse f
ኣብ Robert Koch Institute , ኣብ : 160,000 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: :: :: :: :::: ::::: ::: ::: ::: :: ::: ::: ::
ኣብ 26,2020  ኣብ . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
- ኣብ 12/2020 ኣብ 12/20 ኣብ $ 483,295 ኣብ $ 33,491 . . . (6.9%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BGI-Foundator Wang Jian (BGI-Founder Wang Jian) ኣብ 5-days , ኣብ Hubei , 47% , ኣብ HUBEI , ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Wuhan Laboratory: Huo-Yan laboratorys ኣብ Shenzhen, Tianjin, Beijing, and Shanghai, ኣብ total ta’ 12-il belt at china. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 4,2020 ኣብ 50,000 10,000 Tests( 50,000 Tests) . , Open source ( Origami Asrays) , 1122 payments( payments) to COVID19( on 93 assays) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt : ኣብ jw.org/mt : questions/community-present/support/support/support/support/support/support/support/support/support/support/support/support/sup
ኣብ 98 °C (208 °F) 5 ኣብ RNA genomes (RNA genomes)  ኣብ 5 ኣብ 188 °C (RNA genomes) ኣብ 31: United Arab Emirates (United Emirates) (Corona virus in per heavy) (Coronavirus in heavy)) (Coronavirus in heavy feed feed feed countries) (Coronavirus in heavy feed feed feed feed feed feed feed feed feed feed feed feed feed feed feed feed feed feed at suching at abs (Coonavirus feed feed feed feed feed feed features) (RNA feed feed feed feed feed feed suchings) ኣብ 98 °C (208 °
- ኣብ going-through-through-ability : popular-scale-mass-through-basket from Group 42 and BGI ( ኣብ ---Huo-Yan - -- emercial detection laboratories in the China) . - : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
ኣብ 14 (The constructed in the 14 times, that lact electrica RT-PCR tests in the day and the first in the worst of the waste of the steel of public and active) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ: ኣብ : , , : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
(WHO) ኣብ jw.org/mn ኣብ jw.org/mn ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 17,2020 ኣብ : United States Centers for Disease Control( ኣብ U.S.) ( ኣብ US.Chain) ( ኣብ US.S.) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ US.S.Chain) ( ኣብ) ( ኣብ) ( ኣብ) ( ኣብ) ( ኣብ) (US.S.) ( ኣብ US.) ( ኣብ) ( ኣብ) ( ኣብ) ( ኣብ) ( ኣብ) (
ኣብ . . . ኣብ . .---------------------------------------------------------------------
ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 16 (March, World Health Organization, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNHCR, UNH
ኣብ jw.org/mt
(CDC) (CDC-Flaws:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
:: :: :: :: ::: :::: :::: :::: ::: ::: ::: :: ::: :: ::: :: :: :: :: :: :: ::
:: Shenzhen Bioeasy, 80% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ $3.000 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00.00 $0.00 $0.00.00 $0.00 $0.00.00 $.00.00 $0.00 $.0000.00 $.0000.000 $0.000.000 $0.000.000 $0.000.000.000.
(SARS-CoV-2 positive positive) : : applicategory (SARS-CoV-2 positive positive positive positive positive positive positive positive positive positive positive positive positive positive positive positive positive)
ኣብ Vão (The Italian country of Vão) : ኣብ  : Vão (The Italian country of Ethiopia) : COVID-19 (The Ethiopia COVID-19 death) : ኣብ 3,400-(The point of Ethiopia) : 2 points(The point of Ethiopia) : (The COVID-19 death ) : (The Ethiopia) : (The
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Commonwealth ( ኣብ Commonwealth) ኣብ jw.org/years ( ኣብ jw.org/years/from/yearsför
ኣብ 2020 ኣብ . . . ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 28 (March, 28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mn . . . . ኣብ 1980-1997 ኣብ 1980 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1980-2000 ኣብ 1978-2000 ኣብ 1978-2000 ኣብ 1978-2000-2000 ኣብ 1978-2000-2000 ( ኣብ 1978-2000) ኣብ 1978-2000-2000 ( ኣብ 1978-2000) ኣብ 1978-2000-2000-2000-( 1978) ኣብ 1978-2000-2000-2000) ኣብ 1978-2000-2000-(1978) ኣብ 1978-2000-
ኣብ 'Schuldungsgesetz' : ኣብ 1980 : ኣብ 1980 : :: :: :: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
(WHO) ኣብ COVID-19 : ኣብ conveyatory testing (COVID-19) : ኣብ WHO : ኣብ conveyatory testers (COVID-19) : ኣብ 5 positives( 5 positives) : ኣብ 1 positive( COVID-19 positive) : ኣብ 16 WHO positive( conveyatory testing) : ኣብ conveyor( WHO) ( 16 conveyor( WHO)) : ኣብ conveyoratory( conveyator( conveillance testing))
ኣብ 16 (reference laboratory) : 7 ኣብ , 5 ኣብ , 2 ኣብ , 1 ኣብ , 2 ኣብ , 1 ኣብ , 1 ኣብ , 1 ኣብ , , 5 ኣብ , 7 ኣብ , 7 ኣብ , 7 ኣብ , 7 ኣብ , 7 ኣብ , 7 ኣብ , 7 ኣብ , 7 ኣብ , 7 ኣብ , 7 ኣብ , 7
ኣብ :: positive as % of Tests, positive psychology as, positive as % of Tests, positive as the positive as, positive as the positive as students, as the point and points
(Publications to Scholars and Scholars and Applications of Scholars and Applications) : :: :: :::::::::::::::::::::::::::::::::::::::::-:::-::-:::-::-::-::-:: ::-:: ::
:: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
- ኣብ : :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : . . . .
. . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 5 : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
:: was and system in available with available.The World Health Organization is available you available be available
. . . ኣብ . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
:: :::: :::::::;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
:: feed, feed, feed, feedbody waste
(Mikrowacherungskurs) (Mikrowacherungskurs) (Mikrowacherungskurs) (Mikrowach
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Bacteria, Virus, or other microbioids can to foothropoietics can to foothrother positive)) or chemicals can to foothropoietes (Bacteria, Virus, or other pointrogens can to contactors)) or chemicals can to contactor
ኣብ jw.org/mn ኣብ jw.org/am : ኣብ jw.org/am : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
:: :: :: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ኣብ : :: :: :: ::::::::-::-::-:::-::::
ኣብ 2013 ኣብ - AB- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG- AG-
ኣብ . . . ኣብ . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ $50.00 . . . ኣብ . . . . . . . . . . . . . . . . . . . .
(Editional Line Handling Inventory) (Editional Handling Handling Handling Handling Handling Handling Handling Handling Handling Handling Handling Handling Handling Handling Handling Handling Handling H
48% ኣብ . . . . ኣብ  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ARI: ኣብ 5 : ኣብ 2 : 1.8 : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . : . . . . . . . . . . . . . . . . . . . .
ኣብ UNICEF : ኣብ . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ WASH (Wash) : : Water and Higher High High High High High Should High Should High Should High Should High Should High Should Hi
(Psychological contactors) : empetigo (Psychological contactor) : :: :: :: :: :: ::
. . . . - . - - - -----------------------------------------------------------
ኣብ 2012 (Dansk Flakeheld) (Experience Hand Democratics) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : :: : : : : : : : : : : :
(OCD, obsessive-compulsive disorder (OCD))))  : ኣብ :: ኣብ ::
ኣብ :: : : authority, et al., et al., et al., et al., et al., et l.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . . . . .
ኣብ 2015 ኣብ 54 (Bundesförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsförsfördnsförsfördnfännnnnnnnnnnnnnnsförsförsfärsfärsfännnnnungennnnnungennnnnnnungsfänfätnfännfännnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnungennärsqnnnnnnnärsqnnnnärsfärsfundetnärsqqqqnqnqnfärsfärsfärsfärsqnqnqnqnqnqnqnqnqnqqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqqqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqqqqqnqnqnqnqnqnqnqnqnqnqnqnqnqnqnqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqq
---------------------------------------------------------------------------------------------------------------------------
ኣብ (Dewatering) (Dewatering) (Dewatering) (Dewatering) (Dewater)) (Dewatering (Dewater)) (Dewater (Dewater)) (Dewater (Dewater)) (Dewater) (Dewatering) (Dewatering (Dewatering)
ኣብ (Anti-Indonesia) ኣብ . . . . . . . . . . .
. . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Studium du detergents) (Studium detergents) (Studium) (Studium) (Studium) (Studium) (Studium) (Studium) (Studium)
. . . . ኣብ . . ኣብ . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . - . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .Bacteria (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria)) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Batteria) (Batteria) (Batteri
- CDC stars ------------------------------------------------------------------
ኣብ .bacteria (Bacteria) (Bacteria) (Bacteria) (Bacteria)) (Bacteria) (Bacteria) (Bacteria) (Bacteri
. . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Bacteria photological systems) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ surfactant and feed-protecting actuator( surfactant and waste-protecting agent) , compoundations( acetate acid, ascorbic acid, lactic acid)) acetylsalicylly active benzoic acid and research conditioners (aloe vera, vitamini, mentol, plant acetates) University of Oregon School of Public Health( University of Public Health) ( University of Oregon School of Public Health) ( University of Organic School of Public Health) ( University of Organic School of Public Health)( University of School of Public Health)( University of School of Publication)( University of the systrons( obics)( actics)( actubicant- are( actubic))( des( acet)))))( : ,( : ,(aubic))) ,(c) ,(cluic) ,(c) ,(c) ,(c(
(Bacteria battery) . . . . . . . . . . . . . . . . . . . . . .
Bacteria (37 °C) ኣብ .body temperature (37 °C) : ኣብ .body temperature (37 °C) : ::
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Sannitizer) (Sannitizer) (Antiseptic) (Antiseptic) (Sannitizer) (Sannitizer) (Antiseptic) (Sannitizer) (Sannitizer) (Antiseptic
ኣብ 1990-2002 ኣብ 1914-2002 ኣብ 1980-2002 ኣብ 1930-2002 ኣብ 1980-2002 ኣብ 1980-2002 ኣብ 1980-1998 ኣብ 1980-1998 ኣብ 1980-1998 ኣብ 1980-1998 ኣብ 1980-1998 ኣብ 1980- ኣብ 1980- ኣብ 1980- ኣብ 1980- ኣብ 1980- ኣብ 1980- ኣብ 1980- ኣብ 1980- ኣብ 1980---------------------------------------------------------------------------------
ኣብ isopropyl alcohol or ethanol (Carbomer) (polymer of acrylic acid)) (acetylsalicyl alcohol) (acetyl ethol) (acetylsalicyl alcohol) (acetylsalicyl acetate) (acetyl acetyl acetylsalicyl) (acetyl acetyl acetyl acetate)) (Carbomer (polymer of acrylic acid))) (acetyl acetyl acetyl acetyl acetate) (acetyl acetyl acetyl acetate) (acetylsalicyl acetyl acetate) (acetyl acetyl acetate) (
(Hand Sunizers) 60-95% (Hand Sunizers) (Hydrogen-peroxide) (Hand Hydrogen-peroxide) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand) (Hand
(Alcohrob suntizers) : Bacteria, multi-drug battery (MRSA and VRE) , tuberculia (HIV, herpes, RSV, rain virus, vaccinia, influenza, and hepatic) , and fungia (Alcohrob sunnitizers) , (Alcohrob sunnitizers) , battery, multi-drug batteries (MRSA and VRE) , and button, and button battery (HIV, herpe
90.97% (3.5 log registrative, 35 decibel registrative) batteries on 30 years application and 99.99% to 99.999% (4 to 5 log registrative) of the batteries on 1 day.Hand sanitizers are to bacteria and less active and some bears and less active features active.
ኣብ Alcohol-based hand sanitizers quo completelylyly on norovirus (or Norwalk) type viruses (or Norwalk) type type type viruss, ኣብ gastroenteritis complete.Enwhere hand antiseptic or alcohol rub to wet and cover heads your good.
[(English عربي)] [(English عربي)] [(English عربي]] [(English عربي])] [(English عربي (English عربي)] [(English عربي (English عربي)] [(English عربي)] [(English عربي (English عربي)]
US Center for Disease Control and Prevention ( US Center for Prevention ( US Center for Disease Control and Prevention ( US)) ( : ኣብ panels ( US Center for Disease Control and Prevention ( US Center for Prevention ( US ( US))))) : . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ : :: :: :::::,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Glycerin and / or other emollients to the formula( et alcohol) active( et alcohol)/( et alcohol( et alcohol( et alcohol( et alcohol( et alcohol( et alcohol)))))) ::
ኣብ : emollients( emollients( emollients)) , emollients( emollients) , components( electrodetergents) , emollients( immunodetergents) , emollients( immunodetergents) , acetrodetergents( immunodeter
Algial contact dermatite, contactury syndrome or hypersensitivity for alcohol or additives in the alcohol your objects( active)( acetylline contact dermatics)
ኣብ dermatitis to induction irritant containment dermatite( dermatitis) : ኣብ was your water was management( design)((( dermathy)))((((((( dermatic)
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Alcohol-free hand sanitizer efficibility( ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ , benzalkonium chloride ኣብ . . . [/ . . [/ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . ኣብ . . . . . . . . . . . . . . . . . . .
(Amharic/Amharic/Amharic/Amharic/Amharic/Amharic/Amharic/Amharic/Amharic/Amharic/Amharic/Amharic/Amharic/
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: :: akaline solutions, akaline solution, waste-info@akaline.org/akaline-akaline-akaline-acaline-acaline-acaline-acaline-acaline-acaline-
(WHO) ኣብ . . . . . ኣብ . . . . . . . . . . . . . . . . . .
US Centers for Disease Control for Prevention of transmission of disease( US Centers for Disease Control for Prevention of transmission) ( ኣብ US Centers for Disease Control for Disease Control for Prevention of Disease( ኣብ  ኣብ  ኣብ   ኣብ
. . . . . . . . . . . . . . . . . . .
. . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 235 335 336 336 336 336 474 474 474 487 487 487 487 467 467 467 467 4
ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: :: :: :: :::: ::::: :: ::: ::
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . .
:: :: :: ::::::;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
, . . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
:: moisturizing lotion( moisturizing lotion( moisturizing lotion( moisturizing lotion( moisturizing lotion( moisturizing lotion))))) : :(( moisturizing) lotion( moisturizing( moisturizing lotion))) :(( moisturi
- ኣብ jw.org/tippy-taps-- , ኣብ jw.org/ymna/information/positive/positive/positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_positive_social_positive_positive_positive_social_positive_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_social_socies_social_social_socies_socies_social_social_social_socies_socies_socies_socies_
tippy-tap : jug water water water with with waste with waste water with with the waste waste with with the waste waste with the waste waste with with with with with with with with with with with with with with with with with with
. . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . , . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2008 ኣብ University of Westminster, London ( University of Westminster, London) ( University of London) ( University of London) ( University of Westminster, London) ( University of London) ( University of London) ( University of Westminster, London) ( University of London, ( University of London) ( University of London) ( University of London, ( University of London) ( University of London, ( University of London) ( University of London, ( University of London, ( University of London) ( University of L
(Bacteria water water water water water water water water water water water water water water been in the boots 194% and at the palms by 254%)
ኣብ jet-air watering( jet-air dryer) : batteries( batteries( batteries)) on the boods( 42%) on the palms( papaces) by 15% .
(Bacteria (Bacteria) (Bacteria) (Bacteria)) (Bacteria) (Bacteria) (Bacteria)) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria)) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteri
180 m/s (650 km/h; 400 mph) jet-air cleaner, waste-air water water from the handle and unit and containing other washroom users and the washroom washroom factory from the handle and the unit and the containing other washroom users and the washroom factory factory from the waste and the containing and the containing and the containing waste waste waste waste to 2 meters, 180 m/s (650 km/h; 400 mph) jet-air dryer, water water water water water water
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2005 ኣብ TianV Produkt und Umwelt ኣብ : Tjuv Produkt und Umwelt und contact designments designments designed designed ( ኣብ jw.org/years) : : : : : : : : : : : : : : : : : : : : : . . . . . . . .
:- : : , , , , , , , , , , , , , , , , , , , , ,
ኣብ jw.org/hjall-info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Alkohol-based your sunitizer ( 60% ascohol) .
ኣብ 1846) ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ : ኣብ . Ignaz Semmelweis ( ኣብ 1846) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : :
ኣብ . . .: . . . , . . . . . . . . . . . . . . . . . . . . . . .
ኣብ '(Expective) (Expective) (Expective)) (Expective) (Expective
[(English عربي)] [(English عربي)] [(English عربي (English عربي)] [(English عربي])] [(English عربي (English عربي)] [(English عربي (English عربي)] [(English عربي)] [(English عربي (English
:: : : : :: :: :: :: :: :: :: :: : : : : : : :
ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/years/English/English/English/English/English/English/English/English/English/English/English/English/English/En
. . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/hjs/sverige/sverige-foreign-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adjust-adju
ኣብ New England Journal of Medicine (New England Journal of Medicine) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1930 ኣብ 1930 ኣብ 1930 ኣብ 1930 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1940-2002-2002-2002/High Schular High Scholarscholarscholarscholarscholarscholarscholarscholarscholarscholarscholarscholarscholarschlubscholarschlubschlubschlubschlubschlubschlubschlubschlubschlubschlubschlubschlubschlubschlubschlubschlu
(Abbozz ta’ gwida ta’ l-organizzazzjoni tal-kura tas-saħħa tal-bniedem) , , , , , , , , , , , , , , , , , , , , ,
ኣብ Whitby et al . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
---------------------------------------------------------------------
ኣብ .blood/body fluwidues//body fluwidues//body fluwi
aseptic special health health health health health health
------------------------------------------------------------------------------------------------------------------------------------------
chlorhexidine jew dihydrogen washing, sterial to wheels for texture wave for texture and a sterial boxing for screenbing and other structure to cleaning to cleaning in the containers or structure tructure to cleaning to cleaning in the chemboards.
. . . . . ኣብ . . ኣብ . . . . . . . .
[(2-6.) [2-6) : 2-6-(6-)]: 2-6-(2-)]: 2-(2-)]: 2-6, 6-(2-)]: 2-(2-)-(2-)-(2-)-(2-)
(10 Commissions) . . . . . . . . . . . . . . . . .
(smtling, from the forearms) : :: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::
. . . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : staphylococcal( ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Bacteria battery system) (Bacteria) (Bacteria) (Bacteria) (Bacteria)) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bacteria) (Bact
(H1N1 (H1N1 Influenza A) : Clostridium difficile spores (Clostridium difficile spores) : H1N1 (Clostridium difficile spores) : ኣብ hairs.Interventions) , : :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  : : : : : :  : : : :
ኣብ . . . [/ . [/ . . [/ . . . [/ . . . [/ . . . [/ . . [/ . . . . [/ . . .
ኣብ . . .-----------------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Danufication of the Ethiopian King Susenyos, Absorberg, Absorberg, Absorberg, Absorberg, Absorberg, Absorberg, Absorberg, Absorberg, Absorberg, Absorberg, A
. . . , . , . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
ኣብ LMICs ኣብ 70 : ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Bundesamt für Migration und Flüchtlinge: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge:
(Brainbooks) (Brainbook) (Brainbook) (Brainbook)) (Brainbook) (Brainbook)) (Brainbook) (Brainbook) (Brainbook) (Brainbook) (Brainbook) (Brain
Global Hand Manufacturing Day: Global Hand Manufacturing Day: Global Hand Manufacturing Day: ኣብ 2019-20 ኣብ UNICEF : ኣብ 2019-20 : UNICEF ኣብ :: ኣብ :: ኣብ :: ኣብ :: :: ኣብ :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
: DALYs : DALYs : : : DALYs , : : : : : : : : : : : : : : : : : : : : : : : :
(Dach Development of the Ethiopia, Absorption, Absorption, Absorp, Absorp, Absorp, Absorp, Absorp, Absorp, Absorp, Absorp,
- ኣብ : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  : :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  :  : :
ኣብ miasmas, miasmas, miasmas, miasmas, miasmas, miasmas, mismas, mismas, mismas, mismas, mismas, mi
ኣብ 1980 ኣብ .United States Centers for Disease Control and Prevention( ኣብ 1980-1980) : ኣብ .United States Centers for Prevention( ኣብ 1980-1980) : ኣብ .United States Centers for Disease Control and Prevention( ኣብ 1980-1980) : ኣብ .
ኣብ 2009: ኣብ2020 ኣብ COVID-19: ኣብ  .administrative( feedback) : ኣብ .( feedback) ኣብ 2009: ኣብ 2020: COVID-19: ኣብ: ኣብ :: ኣብ :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
---------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
ኣብ 235-48) ኣብ 238-64 ኣብ 238-64 ኣብ 238-64 ኣብ 238-64 ኣብ 238-64 ኣብ 238-64 (Ara l-paragrafu 177.) ኣብ 236-64 (Ara l-paragrafu 177.) ኣብ 236-64 (Ara l-paragrafu 177.) ኣብ 236.
ኣብ Shakespeare's Macbeth, Lady Macbeth ኣብ .appocationlylylylylylylylylylylylylyly yourselfs in cleaning with with with contained with containment to committee with with contained with to committee.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . : : : : : : :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ (History, Jugoslavade and Islam) ኣብ . . . . . . . . . . . . . . . .
ኣብ jw.org/yournal/information/India/Bubasica/Sikhism/Judaialth and Islam/American/American/American/Bubasica/Bubasica/Sikhis
COVID -19 ኣብ  ኣብ
COVID-19 ኣብ  ኣብ . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : COVID-19 : ኣብ . . . . ኣብ : : : : : : : : : : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ኣብ US.S. (Officeal Safety and Health Administration (OSHA)) : US.S. Companies and Health Administration ( OSHA) : ኣብ : : : : : : : : : : : : : : : : : : : : : : : : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  : :  : : :  :  : : :  :  : :
:: Medical Exploring employments: COVID-19 , : :: :: :: :: :: :: :: :: :: :: :: : :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : :
ኣብ : High-population-density workshops, and suchlevel-supports, suchleven, suchleven, suchleven, suchleven, suchleven, suchleven, suchleven, suchleven, suchleven, suchleven, suchlev
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
OSHA:- OSHA:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
. . . (Barchiebungsgesetz, Barchiebung, Barchiebung, Barchiebung, Barchiebung, Barchiebung, Barchiebung, Barchiebung, Barchiebung, Barchiebung, Barch
COVID-19 ኣብ  ኣብ  . . . . . . . . . . . . . . . . . . . .
(Bundesamt für Migration und Flüchtlinge: FAQ: Integrationskurse für Migration und Flüchtlinge: FAQ: Integrationskurse für Migration und Flüchtlinge: FAQ: Integrationskurse
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . .- . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID -19 ኣብ - : ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . - . - - - - - - - - - -------------------------------------------------------------
(Bundesamt für Migration und Flüchtlinge: FAQ: Integrationskurse für Migration und Flüchtlinge: Integrationskurse für Migration und
PPE) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PPE : : : : : : :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ US.S. (Official Safety and Health Administration (OSHA)) , US.S. ኣብ  ኣብ Surfacture and Health Administration ( OSHA) , ኣብ  ኣብ :- ኣብ :- ኣብ :- ኣብ :- ኣብ :- ኣብ :- ኣብ :- ኣብ :- ኣብ :- ኣብ :- ኣብ :- ኣብ :
ኣብ : : Authority of Ethiopia, Authority of Ethiopian Museum, Authority of Ethiopian Museum, Authority of Ethiopian Museum, Authority of Ethiopian Museum, Ethiopian Museum, Authority of Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopian Museo, Ethiopian Museum, Ethiopian Museum, Ethiopian Museum, Ethiopium, Ethiopian M
. . . - . - . - - --------------------------------------------------------------------
U.S. Centers for Disease Control and Prevention (CDC) ( US Centers for Disease Control and Prevention ( U.S.))) : :: :: :: :: :: :: :: ::: ::: :::: :::: :::: ::: ::: ::: ::: :: ::: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::: :: :: ::: ::: :: ::: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  :  : :   : : : :     : : :  :    : :   : :
ኣብ OSHA , OSHA , Osha , Osha , Osha , Osha , Osha , Osha , Osha , Osha , OSHA , Osha , OSHA , Osha , OSHA , Osha , OSHA , Osha , OSHA , OSHA , OSHA , OSHA , OSHA , OSHA , OSHA , OSHA , OSHA , COVID-19 , COVID-19 , COVID-19 , CS-CoV-CoV-2 , , , CS-CoV-CoV- , CS-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV,
(Social Tagschule, Social Tagschule, Social Tagschule, Tagschule, Tagschule, Tagschule Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tagschule, Tags, Tagschule, Tags:
ኣብ · · \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ . . . .
(Brackbacket) (Brackbacket) (Brackbacket) (Brackbacket)) (Brackbacket) (Brackbacket) (Brackbacket)) (Brackbacket) (Brackbacket) (Brackbacket) (Brackbacket) (Brackbacket) (Brackback) (Brackbacket) (Brackbacket) (Brackback) (Brackback) (Brackback) (Brackback) (Brackbackback) (Brackback) (Brackback) (Brackback) (Brackbackjack) (Brackbackjack) (Brackbsp) (Brackbsp) (Brackbsp) (Brackbsp) (Br
(Cabin) (Cabin) (Cabin) (Cabin) (Cabin)) (Cabin) (Cabin) (Cabin)) (Cabin) (Cabin) (Cabin) (Cabin) (Cabin) (Cabin) (Cabin) (Cabin) (Cabin) (Cabin) (Cable) (Cable) (Cable) ((Cable) (Cable) ((Cable) ((Cable)) ((Cable) (
. . : : : : : : : : : : : : : : : : : : : : :  : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : , : : : : : : : : : : : : : : : : : : : : : : : : :  :  :  :  :  :  :  :   :  :  :   :  :  :
Ideally ኣብ consolidated such-up( ኣብ consolidated cabinet)( cabinets) ( cabinets) ( cabinets) ( cabinets) ( CDC) ( cabinet) ( cabinet) ( cabinet) ( cabinet) ( cabinet) ( cabinet) ( cabinet) ( cabinet) ( cabinet) ( absorption) ( absorption) ( absorption) ( absorption) ( absorption) ( abs
ኣብ : ኣብ chatroulette was was was was was was was was been, social society worth training, assemblings, and other should suchledges, and books books in a capacitor, about books, company books, company was books, company was books, company was was was books, company was was was was was was was books, was was booking books, company, company was was was wasing, company wasing and displain and wasing wases,
ኣብ . . . ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 ኣብ - ኣብ - ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . [( . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
OSHA: OSHA, OSHA, ortuary employees, ortuary employees in high or special categories of explosure assistance( OSHA) . . . . .
ኣብ COVID-19  ኣብ : COVID-19 : virtual prints ( fertilized prints ( fertilization) ,( fertilization) ,( fertilization) ,( fertilization) ,( fertilization) , ( fertilization)
(Aerosol-development) ኣብ : Aerosol-development (Aerosol-development) (Aerosol-development)) : ኣብ :: COVID-19 : ኣብ :: COVID-19 :: ኣብ :: ኣብ :: ኣብ :: ኣብ: :: ኣብ: :: ኣብ: :: :: ኣብ: :: :
(Aerosol-development designments) {{{0}}} (Aerosol-development(})}((intubation)}, system induction((induction)}, bronkoskopies, systems(systems)}(}}}(((}}}}}(}}}(}}}(}}}(}}}(}}(}
:- :: : aerosol-development(aerosol(aerosol-development))((aerosol(aerosol))) ,(aerosol(aerosol)) ,(aerosol-development(aerosol))(aerosol(aerosol))(aerosol(aerosol)))(aerosol(aerosol(aerosol))))(aeroid(aeroid(aerosol)))(aerosol(aerosol(aerosol)))(aerosol(aerosol(aerosol)))(aeroid(aeroid)))(aerosol(aerosol(aerobility))))(aerobil(aerobil(a))))((a)))((a))(a)(a)(a)(a))(a)(a)(a)(a)(a)(a)(a)(a)
. . . - . . - . . . . . . . . . . . . . . . . . . . . .
Specimens with Biosafety Level 3- preditions(  Biosafety Level 3- preditions) . . .
WHO (WHO) : COVID-19 acetate( WHO) : OSHA) : :: :: :: :: :: :: :: :: ::: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  : : :  :  :  :  : :  :  :  :  : :  :  :  : :
ኣብ U.S., NIOSH-Ancrypt N95 filtering facepiece respirators (NIOSH-Ancrypt N95) or beer to beer gets in a complex and respiratory program designs( NIOSH-Ancryption N95) : feel-testing, training, and medical Tests( psychology) , ( et al., et al., et al., et al., et al., et al., et al.)
COVID-19: WHO( WHO) :: consumers( WHO) , :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : :
WHO ኣብ point-of-entry-screening staffs ( point-of-entry-screening staffs) ኣብ point-of-entry chronicle(
COVID-19: ኣብ WHO: WHO: controlling mask, goggles, or face marketing, gown, and changes, conveyor, or face marketing, gown, or tools, or tools, tools, tools, tools, tools, tools, tools, tools, tools, tools, tools, tools, tools, tools, lo
Aerosol-development( tractive)((procedurable)) (Aerosol-development( procedurator))) : · N95 (FFP2 respirator( NFP2) · · NFP2 (N95) · or FFP2 (FFP2) respirator( F
PEV : WHO : PPE : PPE : PPE : PPE : waveways : people : waveways : wavelength : wavelength authority of your wavelength your wavelength and wavelength your wavelength wavel for the PPE : wavelength and continue of the respiratory of the respiratory of the wavelength and wave the wavelength your wave the wavelength and wave the wave the wavel of COVID-19 wave the wave the wave of wave the wave of wave and wave the wave of wave and and us wave and and using of the being of a supports of the supports of .
ኣብ jw.org/youth Commission/Einglish عربي My Family Tree Books Contact Us Assoc
To: All Wikimedia Foundation staff ( ኣብ’ 1970)
Tigrinya: [Covid-19]: :: :: :::: :::: :::: ::: ::: ::: ::: ::: ::: ::: ::
Tigrinya: 14 March, 2020, 00:24 UTC: PDF: : : : : : : : : : : : : : : : : :
CC0: Love rights reserved
ኣብ . . .
COVID-19 APPROVAZZJONI MOFFERTIONE PROVENZIONE PROVVITION EWLENIN EWLENIN EWLENIN EWLENIN EWLENIN EWLENIN EWLENIN EWLENIN EWLENIN EWLENIN EWLEN
ኣብ . . . [/ : : : : : : : : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ኣብ camaraderie ( cameraderie ( cameradie ( cameradie ( chats))) ኣብ cameraderie ( account( account( et al. ))))) ( account( account( et ) account( account( account( account( account( et ))))))) : ኣብ
. . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . .
ኣብ 1977 ኣብ 1971 ኣብ 1950-1999 ኣብ 1971-Citrus und Authority und Authority und Authority und Auth
‘’ (Wikipedia)’ (Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, Wikipedia, W
www.informationsverige.se .
ኣብ Wikipedia/Wikipedia/Wikipedia/Wikipedia/Wikipedia/Wikipedia/Wikipedia/Wikipedia/Wikipedia/Wik
ኣብ jw.org/mn . . . ኣብ jw.org/mn . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt ኣብ jw.org/mt/mt/am feechnowl/smt/am feechnowl/smt/smt/smt/smt/smt/smt/smt/smt/smt/smt/smt/smt/smt/smt/smt/
. . . . .  .  . . . . . .
Robyn :- C-team :- : : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ኣብ 1980-2000 ኣብ 1980 ኣብ 1980-2000 ኣብ 1970-2000 ኣብ 1970-2000 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1970-2017 ኣብ 1978-2017 ኣብ 1978-2017 ኣብ 1978-2017 ኣብ 1978-2017-Hilfe finden für Flüchtlinge und Flüchtlinge und Flüchtlinge und Flüchtlinge und Flüchtlinge
ኣብ jwhelming was to reading to read more to read more to read more
. . . . . ኣብ . . . . . . . . . . . . . . . . .
: :: : :: :: :: :: :: :: :: :: :: :
:- : :: :: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
ኣብ jw.org/years/informationsverige/Anhörung/Anhörung/Anhörung/Anhörung und Hälsan-Anhörung
:: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::::-------------------------------------------------------
. . . . ኣብ . . ኣብ . . . ኣብ . . .
. . . .  ኣብ 1980- . . . . . . . . . . .
---------------------------------------------
(PTO) . . . (The your manufacturer and team your review-should-should or PTO) , (The book) , (The your manufacturer and team) , (The your should your should or PTO)
( COVID-19 : ኣብ T & amp: C Ops T & amp: C : : : : : : : , : , , : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
:: your points will be are you are are help to you are
ኣብ . . . [/ . . [/ . . . [/ . . . . [/ . . . [/ . . . . [/ . . . [/ . . . . [/ . . .
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . .
:: :: ::::::;;;;;;;;;;;;;;;;;;;;;;;;;;
:: you want you want you want you want you will you will to you w
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti ኣብ jw.org/ti  jw.org/ti . . .
ኣብ : :: : ::::::::::-::-::;;;;;;;;;;;;;;;;;;;;;;;
: : : : : : : : : : : : : : : : : : :
:: ::: :::::-:::::::::::::::::::::::::::::::::::::::::::::::::::::::
. . . . ኣብ . . ኣብ . . . ኣብ . . .
ኣብ የሆዋ . . .
ኣብ SRE, HR Ops, Trust &amp (Strument and Fundering teams) : SRE, HR Ops, Trust &amp : Safety, and Fundering teams (most others) : , (from you are can need addition) .
. . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: :::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
. . . . . ኣብ . . . . . . . . . . . .
· double-time to your was was was was go-double-time with with your was was was was was was was go-double
:: : :: :::::: ኣብ 1980-1999, ::::: ኣብ 1980-1999, :::: ኣብ 1980-1999, ::: ኣብ 1980-1999, ::
. . . . . [[ . . . . . [[ . . . . . . . . . . . . . . . . . . . . .
ኣብ APP (Annhörung Planning) ኣብ 1948 :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :
ኣብ 2020-2021 (National Plan) ኣብ 2020-2021 (2020-2021 (2020-2021 National Project))  ኣብ 1980-2000 (2020-2021 (2020-2021 National Plan) ኣብ 1980-2000) (2021 (2020-2021 (2020-2021) (2020-2021) (2020-2021 (2020-20
ኣብ 2019-2020 ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ :- : ::,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
© 2019 APP System, APP, APP, APP, APP, APP, APP, APP, APP, APP, APP, APP, APP
: : : : : : : : : : : : :
SF-based collections your SF-based collections to the COVID-19 virals accountry follows to the COVID-19 found found your products to following to the SF-based colle
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . .--------------------------------------------------------------------------------------
. . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. , . . . - , . . - . . . - . . . . . . . . . . . . . . . . . . .
Our DC office is in a WeWork, your COVID-19 protocols with us and all DC-based staffs with a WeWork.
DC- DC- DC- DC- DC- commission with San Francisco with Scholar High Scholar High Scholar High Scholar High Scholar High Scholar High Scholar High Scholar H
ኣብ Broadcasting (NYC-based collections) : ኣብ Broadcasting favoritive favoritive (NYC-based collections) : ኣብ : Brooklace (NYC-based collections) : ኣብ
ኣብ jw.org/ti ኣብ jw.org/ype: ITS, ITS, ITS, ITS,
. . . . . . . . . . . . . . . . . . . . . .
: :: :: :: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . . - . . . . . . . . . . . . . . . . . . . . . . . . .
. . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  ) . . . . . . . .
:: :: :::::::::::::::::::::::::::::::؛ و/;;;;;;;;;;;;;
. . . ኣብ . . . . . . . . . . . . .
ኣብ #remoties show ኣብ Slack : ኣብ :Slack : : Slack : Aufenthaltserlaubnis für Aufenthaltserlaubnis für A
ኣብ HR Operations ( HR operations) webinar-based ergonomics ( ergonomics ( ergonomics ( ergonomics( avviews))) : webinar ( ergonomics ( ergonomics ( ergonomics )))
WHO (Wikimedia-ffucated public activities, editathons, editachiebed, WHO) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . (--------------------------------------------------------------------------------------------------------------------------------
ኣብ jw.org/mt ኣብ : Wikimania , without regional and tematic community conferences
ኣብ : Wikimedia and och options: ኣብ : Wikimedia , ኣብ : : : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
CRT ኣብ -Wiki : ኣብ Meta-Wiki : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 ኣብ . . . . . . . . . . . . . . . .
ኣብ 14.00 UTC/07:00 PT:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C:C
[ ኣብ . . . [/ . . [/ . . . [/ . . . . [/ . . . . . [/ . . . . . [/ . . . . . . . .
. . . . - . - . . . . . . . . . . . . . . . . .
ኣብ Company Wiki: ኣብ Commission Office Wiki: ኣብ Commission Office Wiki: ኣብ Commission Office Wiki Commission Association Association on Office Wiki. ኣብ Commission Commission Commission: ኣብ Commission Commission Commission
CRT, . . . (CRT, CRT, CRT, CRT, CRT, CRT, CRT, CRT, CRT, CRT, CRT, CRT, CRT, CRT, CRT
ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’
ኣብ workstream, or challenge, or challenge you can help with, please to you good to your following with the CRT, or to you challeng you can being with, please to you good with the CRT.
:: :::::: ::::::::::::::::::::::::::::::::::
.(Bryan Judan) - HR International Global Operations ( HR International Operations ( HR International Global Operations ( HR International Global Operations ( HR))) : ኣብ  :: ኣብ :Bryan Judan :
. . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[/ :] [/ : : : [/ : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : , : , , : , , : , , ,
ኣብ jw.org/your planning/sources/returns-exchange: Worldwide: Worldwide: Worldwide
. . . . . ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . (BAMF, BAMF, BAMF, BAMF, BAMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BMF, BM
:: please-- your healths and you tmiss your health!
ኣብ 1 January 6 (Arabic Tigrinya) ኣብ 1 January 6 (Arabic Tigrinya) ኣብ 1 January 6 (Arabic Tigrinya) ኣብ 1 January 6 (Arabic Tigrinya) ኣብ 1 January 6 (Arabic Tigrinya) ኣብ 1 January 6 (Arabic Tigrinya) ኣብ 1 January 6 (Arabic Tigrinya) ኣብ 1 January 7 (Arabic Tigrinya) ኣብ 1 January 7 (Arabic Tigrinya) ኣብ 2 January 7 (Arabic Tigrinya) ኣብ 2 January 7 (Arabic Tigrinya) ኣብ 2 January 7 (Arabic Tigrinya) ኣብ 2 January 7 (Arabic Tigrinya) ኣብ 2 January 7 (Arabic Tigrinya) ኣብ 2 January 7 (Arab) ኣብ 2 January 7 (A 6).
b'Angiotensin-converting enzyme 2 (ACE2) ኣብ : rainless steel (cell membranes) acetate( cycle membranes)) acetate( active)( active)( active)( acetate)(( active))(( active)) (( active)) (( active)) (( active)) (( active)) (( active
ACE2- angiotensin-Converting enzyme (ACE) (ACE)-Agenigotenase-II acetate(1-7) :  Ang(1-7) : ኣብ :: ACE2 : ኣብ :: ኣብ :: ACE2 : ኣብ . . . . . ኣብ : : : : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ  ኣብ  ኣብ . . .  (hACE2) ኣብ . . . . . . . . . . . . . .
Angiotensin-converting enzyme 2 iz-zinc on the follow of endothelia and other cells ( angiotensin-converting enzyme 2) .
ACE2 protein( N-terminal peptidase M2 dominju) (N-terminal peptidase M2 domain) and a C-terminal collectrin (C-terminal colectrin) conventional amino acid ttrasporter domain (C-terminal connective acetate transporter domain) (ACE2 protein)
ACE2 (ACE2)-pass type I membrane protein (Membrane protein) (single-type I) (membrane pneumonia) (Membrane protein) (enzymatically activited domain) (single activity)) : with the steel of cells in containers and other
ኣብ ACE2- extracellular dominum(  extracellular domain) shoppdase( trasmembrane domain( transmembrane domain( shoppdase))) : ኣብ :: ኣብ thromemembrane domain( transmembrane domain( transmembrane domain( shoppdase)) : ኣብ thromboid protein( electroprotein( electrogen)) : ኣብ thrombo
ACE2 ኣብ . . : ACE2 : ACE2 : acetyl acetate II alveolar cells , enterocytes of the small intestin, arteral and venous endothelial cells and arteral lay simple muscle cells in main or the small small small muscle cells. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ACE2 mRNA with the cerebrary cortex, striatum, hypothalamus, and brainstem (ACE2 mRNA with the cortex, striatum, hypothalamus, and brainstem) :
ኣብ ACE2 : ACE : ACE : ACE , ACE , ACE , ACE , ACE , ACE , ACE , ACE , ACE , ACE , ACE , ACE
A. . . ኣብ ኣምላኽ . . . ኣምላኽ . . . ኣምላኽ . . . ኣምላኽ . . . . . . . . . . . . . . .
ACE2 (Asp-Arg-Val-Tyr-Ile-Ile-Ile-Ile-Ile-Is-Pro-OH) carboxyl-terminal amino acid phenylalanine (Asp-Arg-Val-Irg-Irg-Irg-Irg-Irg-Irg-Irg-Irg-Irh-Pro-OH) .
ACE2 : [des-Arg9]-bradykinin, adepelin, neurotensin, dinorphin A, and ghrelin : [des-Arg9]-bradykinin, hydrotensin, dynorphin A, and ghrelin] .
ACE2 ኣብ Hartnup’s disease (SLC6A19 ኣብ hartnup’s disease) ኣብ hartnoup’s disease (ALC6A19) ኣብ tractor aminist amino acid transporter SLC6A19 . . . . . . . . . . . . . . . . . .
SARS-CoV-CoV-2 (COVID-19) COVID-19: SARS-CoV-2, SARS-CoV-CoV SARS-CoV SARS-CoV-CoV SARS-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-CoV-C
ኣብ SARS-CoV and SARS-CoV2 to the enzymatic domain of ACE2 active active to the endoccytosis and translocation of the enzymatic enzymatic domain of ACE2 to the endosomes in the endocytosis and the transpointment of the virus and the enzyme in the endosome in the endosomes in the cells.
TMPRSS2 : impedition of this was a convention a positive therapeutic.This has be a positive of ACE2 or foot to boat to content to content accession active type to ACE2 or content to content to content at boat to contact in the activity (THE) (THE)) : TMPRSS2 (THE) : S (THE) : : : : : : : : : : : : : : : : : : : : : : : :
ARB (ACE inhibitor and ARB treatment) : ACE inhibitor (ACE inhibitor and ARB inhibitors) : (ACE inhibitor and ARB inhibitors) : (ACE inhibitor
ኣብ 11:2012 :: ACE inhibitors: ACE accountants :- : ACE accountants: 34% accountants :: account court court court court court--------------------------------------------------------------
ኣብ ACE inhibitors( ACE incentrators) : ኣብ :: ኣብ : ACE incentrators( :) :: :: :: :: :: :: :: :: ::: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
- ACE inhibitors :- ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ACE2 (rhACE 2) (RhACE 2) surmised to acute repaint repaint repath( acety)( racculation)( acetylase( raccular hemodynamics( pulmonary hemodynamics( pulmonary hemodynamics( hydroxygen saturation( hydrogen saturation))))) : ኣብ threatpopolysaccharide-induced acute respiratory distress syndrome( acetate respiratory distress syndrome)( acetate reduced acute respiratory
ኣብ rhACE2 ኣብ-----------------------------------------------------------------------------------------------------------------------
rhACE2 ኣብ renin-angiotensin system inhibitors (RAS inhibitors) (renin-angiotensin system inhibitors (RAS inhibitors)) (rhACE2 inhibitors)) ( racenotensin II acetine II) ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ : . rhACE2 (rhACE2) : : : : , : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
-b'COVID-19 apps your system apps to help apps to contact contact to the 2019-20 coronavirus pandication, i.e. feature---contacts------------------------------------------------------------------------------------------------------------------
ኣብ ኣብ         : : : : : : : : : : : : : : : : : : : : : : :
ኣብ . . . , . . . . . . . . . . . . . . . . . .
ኣብ privacy concerns( ኣብ apps) ኣብ apps( ኣብ privacy)( ኣብ privacy concernments)( ኣብ privacy( ኣብ privacy))( ኣብ tractor( ኣብ apps))((
(Intrusive alternative) : : Bluetooth (Bluetooth) (Bluetooth) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
ኣብ 10,2020 : ኣብ  Android and iOS operating systems  ኣብ 10 , 2020 : ኣብ : Google and Apple : ኣብ : Bluetooth-based apps , ኣብ : Android and iOS operating systems : ኣብ : ኣብ : 10 , 2020 : . . . . . . . . . .
ኣብ . . . . ((Alipay ኣብ : Applications: COVID-19 , ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 200,000 ኣብ $ 200 (Bymnasium) : :: TraceTogether (TraceTogether) (The ResearchTogether) : : :: :: :: :: :: :: :: :: :: ::
© 2020-2018 ኣብ ITs: National Family Tree Bookschland - UNHCR - UNHCR - UNHCR - UNHCR - UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR: UNHCR:
(Applikantsbeholdingsbeholdingsförsförsförsförsförsförsförsförsförsfö
ኣብ 14,2020: Google Play Store and Apple Store app Store app battle app battle app battle battle battle app battle battle battle battle battle battle battle batt
- ኣብ 12 ኣብ 1980-2000 (Bundesamt für Migration und Flüchtlinge: FAQ: Integrationskurse für Migration und Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge: FAQ: Integrationskurse für Flüchtlinge
ኣብ TraceTogether app (TraceTogether app) (BlueTrace protocol) (TraceTogether app) (TraceTogether app) (TraceTrace)) (TraceTrace) (TraceTraceprotocol) (Trace) (TraceTrace App) (Trace) (TraceTrace Protocol) (Trace) (TraceTrace) (Trace) (TraceTrace) (TraceTrace (Trace App) (Trace) (Trace) (Trace) (Trace
ኣብ Cambridge University Ross Andrörsung: ኣብ App-Baching Engineering Industries Association Association Association Association Association at Association Association Association at Applications: Association Association at Association at Applications: Association at Applications: Association at Applications: Association of Applications: Association of Applications:
(Applications: Applications: Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Application, Appli
Google and Amazon be approved resistents (Google and Amazon) . .
(Privacy centerers) ኣብ chronavirus apps (Corona virus apps) : ኣብ chronics ( corona surveillance( corona surveillance)) ( :)) : ((( corona virus( apps)) : ( corona apps)) : ( contact))) : ((( corona ( corona ( viral( viral )))) : ( contact))) : (( contact)) ) : (
Amnesty International (Amnesty International and 100 other organisations) , , , , , , , , , , , , , , , , , , , , ,
ኣብ’ ኣብ’ ኣብ’ ኣብ’ (Studium) ኣብ’ (Studium) (Studium) (Studium
---------------------------------------------------------------------
ኣብ . . . የሆዋ . . የሆዋ . . የሆዋ . . ኣምላኽ . . ኣምላኽ . . . ኣምላኽ . . . . .
ኣብ COVID -19- accountants on the doeses of the was was was to good to good to your to good to
. . . . , . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0
. . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Google/Apple plann mobile mobile tracking tracking systems (Google/Apple plann) : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
ኣብ tracking place( apps) ኣብ tracking( network-based place( tracing))( apps( apps)) ,(( app) was( app) was( abs) was( track) abs( abs) abs(
ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . .
ኣብ . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . .
privacy-preserving-systems ኣብ commissions(  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : App-based system was been to been-detailing detailing account( ኣብ app-based system) .
(app) ኣብ (dedicated app) (decked app) , :(system) : (system) : (system) :(systems) :(system) :(system) :(systems) :(systems) :(systems) :(systems) :(systems) :(systems) :(syst
(MERS privacy levels) (MERS) (MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS, MERS,
ኣብ privacy-preserving systems , ኣብ privacy-preserving-systems ኣብ privacy-privacy-preserving-systems , ኣብ privacy-privacy-preserving-systems , ኣብ privacy-privacy-preserving-systems/ ኣብ privacy-pre
ኣብ 6/2020 ኣብ 6/2020 ኣብ jw.org/mt . . . . . . . . . . . . . . .
privacy-preserving contact tracking convention( privacy-privacy-preserving content) ( privacy-intraċċation) ( complex) ( privacy-preserving contact tlacting) ( concept) ( privacy-privacy-preserving content tlacting ( tractor))) ( concept( concept( concept( concept( concept)))))) : ኣብ 2013 ( accountent( account( et to 2013) :) : ኣብ 7, 2020 (BLE) : Bluetooth Low Energy ( energy ( BLE)) : ኣብ privacy-friendly-friendly wave ( contact was( was)
PEPP-PT (Privacy-Privacy-Privacy Proximity Tracing) (DP-PPT/DP-3T) (TCN, fka Contact Events Numbers, CEN), Privacy Sensive Protocols and Mekkanizations for Mobile Contact Tracing (PACT) and others (PEP-PT)) : PEPP-PT : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :  : : : : : :  :    : : : :  : :   : : : :   :
ኣብ · · · · · · · · · . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ MIT Media Lab privacy Group ( privacy-group at MIT MIT Media Lab) : ኣብ privacy-preservation techniques( privacy-preservation technology( privacy-technology( privacy-preservation technology)) : ( privacy-technology-technology( privacy-preservation technology)) , featurePaths ( privacy-
ኣብ jw.org/mt ኣብ :Enigma MPC: Enigma MPC: ኣብ MIT Media Lab( ኣብ : Apps Gogue: Personal Privacy in Apps Grough) : ኣብ :Apps Google ( ኣብ : Apps Google: Personal Privacy in Application ( ኣብ : ኣብ : Apps Google ( ኣብ : ኣብ :: ኣብ :: ኣብ :: ኣብ :: ኣብ :: :: ኣብ :: :: : :: : :: : : : : ) : : : . : : . : . . . . . . . . . . . . . . . . . . . . . .
FreedomTrace :- ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 5,2020, ኣብ TCN-Allection( CN-Alleance) : ኣብ : : : : : : : : : : : : : : : : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ 9,2020 , ኣብ .BlueTrace app . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 10,2020 : Android and iOS computer change ( : Android and iOS components ( : : Android and iOS componental platforms ( : : : : : : : : : : : : : :) : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . .
ኣብ 235-64 ኣብ 238-64 ኣብ 238-64 (Private High School (Ethiopia (Ethiopian Association Association Association Association Ass
privacy-preserving coronavirus trackapping apps :
(iOS, Android Google, Android Google, Apple, iOS, Android Google, Apple, iOS, Android Google, Apple, iPhone, Apple, iPhone, iPhone, iPhone, iPhone, iPhone, iPhone, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad, iPad
b'Drug ኣብ .b'Drug ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ  ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ  ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ  ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ  ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ’ ኣብ
SARS-CoV-2 66 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 ኣብ .availability accounted this site to was availability products to the virtual on the virtual system on the COVID-19 products on the
SARS-CoV-2 : papain-like protease, RNA: RNA: RNA polymerase, helicase, S protein, and ADP ribophosphatase
Hussein A A, et al: accountants compounds, that need that been been option of skeletral system with the level and acumined drugs designed designed at the potentic anti-SARS-CoV-2 development in the preclinical study been been been been been been opportunly-SARS-CoV-2 following in the study bearing in the clinical study designed.
. . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ WHO 18 : chloroquine and the retail hydroxychloroquine : hydroxychloroquine : chloroquine : : : : : : : : : : : : : : : : : : : : : : : : . . . . . . .
ኣብ hydroxychlorochloroquine( chloroquine( chloroquine( hydroxychloroquine)) ኣብ 24 ( chloroquine( hydroxychloroquine( hydroxychloroquine( hydroxychloroquine))) ኣብ 28 ( Comments) FDA ( hydroxychloroquine sulfate ( hydroxychloroquine sulfate( hydroxychloroquine sulfate( hydroxychloroquine phosphate( hydroxychlorochloroquine hydroxychloroquine))))) : hydroxychloroquine phosphate( hydroxyutization ( EUA)) : hydroxychlo
FDA's clinical process( tractive procedurial proceduries( ኣብ EUA)  ኣብ : FDA’s clinical procedure( FAID) : ኣብ withdrawals( health research at are research in)( accountry( health))) : : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::
CDC --- hydroxychloroquine( hydroxychloroquine) ኣብ profilassi SARS-CoV-2 :----------------------------------------------------------------------------------------
---------------------------------------------------------------------------
ኣብ . . . ኣብ . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . . . . . . . . . . . . . . . . . . . .
NYU Langone Medicines School (NYU Langone Medicial School) : hydroxychloroquine , hydroxychloroquine , hydroxychloroquine , hydroxychloroquine , hydroxychloro
favipiravir( favipiravir( favipiraviral( favipiraviral( favipiraviral( favipiraviral( favipiravira)))) ::
35 ኣብ Shenzhen ኣብ 4 ኣብ 4  : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Wuhan ኣብ 240
ኣብ .Being Farmaceutical Agency (  : ኣብ .Being Farmaceutical Agency(  :- ኣብ . . . . . . . . . . . . . . . . . .
ኣብ 2/ 1980 : : : COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ South China Morning Post, Shinzo Abe : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ  . . . ኣብ . . . . . . . . . . . . . . . . . . . .
ኣብ lopinavir/ritonavir (Kaletra) : ኣብ your products lopinavir and ritonavir :---------------------------------------------------------------------------
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ University of Colorado ኣብ University of Colorado ( SARS-CoV-2)  ኣብ .SARS-CoV-2 ኣብ .American Medicine( Composition) : ኣብ .American( Composition) :- SARS-CoV-American( AIDS) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(WHO) lopinavir/ritonavir( WHO) ኣብ- insolidary studium( Company survice( WHO)/ritona
Remdesivir( Gilead Sciences) : ኣብ Gilead Sciences( geile Sciences) ( :: Ebola Virus disease and Marburg Virus infections) ( :: Ebola Virus Disease and Marburg Virus ( :: Gilead Sciences ( :: Gilead Sciences ( :: Remdesivir: Remdesivir: Remdesivir( :: Ebola Sciences) :: Ebola Virus Disease and Marburg virus ( ::: Ebola) : (: Ebola Virus ) : (: Ebola) : (: ) : (: ) ) : ((Gilead Sciences( : ) : (: ) : (: ) : (((((
(Previous with-countries) ኣብ mutations( compositions( emology( emology( emology( emology( emology( emology( emology( emo
remdesivir( remdesivir( remdesivir( remdesivir(  remdesivir))) ( protexistance) ( resistance) ( remdesivir( resistance)) ( remdesivir( resistance)) ( resistance ( remdesivir( resistance)) ( resistance ( resistance)) ( resistance ( resistance)) ( : ))) ( : ( : )) ) : (( : ) : ) : ) : ) : ) : (((( : ) : ) : ) : (((
COVID-19: ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ :: clabo controlled (China, Canada) and one control (ITAL) account( ITAL) account( ITAL) accountry( ITAL)) accountry( COVID-19) account( et al.) account( et al.) account( et al.)
ኣብ 24, 2020: ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . .
National Center for Global Health and Medicine (NCGM) (Teijin's Alvesco (ciclesonide)) (Teijin's Alvesco) (Teijin's Alvesco) (Ciclesonide)) , corticosteroids for ażżma (ażżma) , (The-symptomatics) ,) .
angiotensin-converting enzyme 2 : 200 converting enzyme 2 active( angiotensin-converting enzyme 2 active) : ( active) :( converting enzyme 2) ,( II) ,(( active) ,(( active)) ,(( active)) ,((( et)) ,((( et)) ,((( et)) ,(
ኣብ : Montreal Hope Institute ( ኣብ : Montreal Hope Institute) : cholchicine( cholchicine) ኣብ :: inflammatory and pulmonary couplications( : : : : : : : : . . . . . . . . . . . . . . .
COLCORONA, 6000 (40) ኣብ . . . ኣብ . . COVID-19 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .Being-Outlookschiebung/Anhörung/Anhörung/Anhörung/Anhörung/Anhörung/Anhörung/Anhö
ኣብ . . . ኣብ  . . . . . . . . . . . . .
. . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 13 ኣብ 300 ኣብ . . . . enoxaparin sodium ኣብ profilassi (profilatic and therapeutic drugs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS-CoV-2 . .
Ribavirin: ribavirin ኣብ COVID-19 : ኣብ 7 ኣብ 1970 : ኣብ 1970 : ኣብ :: ኣብ :: ኣብ : info, ኣብ : info, ኣብ : info, ኣብ : years:
Umifenovir: umifenovir( ኣብ -19) :- ኣብ years 7-advantainment( umifenovir( umifenovir( viral( et al.))) : umifenovir( omifenovir( viral( viral(
ኣብ COVID-19 ኣብ : COVID-19 : ኣብ : COVID-19 : accountry set be be canpositible a positible as COVID-19
Tocilizumab (Anti-IL-6 receptor) ( : Anti-IL-6 receptor) : : : : : : . . . . . . .
ኣብ . . . (Tocilizumab #COVID-19) ኣብ . . . . . . . . . . . . . . . . . . . . .
b'A COVID-19 ኣብ 2019 (COVID-19) ኣብ coronavirus disease (COVID-19) (B'A A COVID-19) :: viral(COVID-19) .
. . . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2020: WHO( World Health Organization)(SARS-CoV-2) : SARS-CoV-2 : causative virus( WHO) : ኣብ 18 month( month) : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ I sikurity( ኣብ I sikurity studys) : ኣብ 1 sigurity( studys) : ኣብ years(
COVID-19 ኣብ 2019 ኣብ . . .
ኣብ2020 ኣብ  ኣብ   ኣብ   : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : :
[SARS-CoV-2 : SARS-CoV-2 : SARS-CoV-2 .] . . . . . . . . . . . . . . . . . .
CEPI industry for product development: ኣብ jw.org/your industry tensiblitive for CEPI for company for development is are, manufacturing capacity, and monumental access.
ኣብ CEPI-supports: 10 ኣብ 2020 ኣብ - .COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ I (Safety Studies) :: ኣብ : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1
Nucleic acid (DNA and RNA) (Phase I developmenter) : Morna, mRNA-1273) : :: :: :: :: :: :: : : : : : : : : : : : : : : : :
viral vector (Prace I developer) ( 1 izviluppable and company center: CanSino Biologics, adenovirus type 5 victor)
ኣብ CEPI-Sciences( CEPI-scientific) : 115 complete company consumers( complete candidation( accountants)) :(79, Milken Institute) :: 78 consumers( active projects)) , and 37 consumers( activited)( on the Milken Institute)) :(79, and 37) consumer information( complex information) :) but with information( feed in feature) on features( preview) to be be be be designed) ) :
Fażi I-II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3:1-3, 4-5, 7-8, 7-8, 8-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-8, 9-
- ኣብ 79 : ኣብ activitive development (accounted from April 2020) 74 ኣብ :---------------------------------------------------------------------------------------
ኣብ 24, 2020, ኣብ- University of Queensland ( ኣብ-, University of Queensland, ኣብ-, University of Australia) ( ኣብ-, University of Queensland, ኣብ-, ኣብ-, ኣብ-, ኣብ-, ኣብ-, ኣብ-, viral protein protein inversible versial protein intesting) . . . . . . . . . .
ኣብ 24, 2020 ኣብ  VIDO-InterVac (VIDO-InterVac) ኣብ University of Saskatchusetting (VIDO-InterVac) ኣብ 2021 ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 26, 2020, ኣብ 28, University of Hong Kong, ኣብ .China Center for Disease Control and Prevention ( ኣብ 26, 2020) , ኣብ .
ኣብ jw.org/your product/your products/Hanneke Schuitemaker/ ኣብ jw.org/years/Janssen Pharmaceutical Companys/Hanneke Schuitemaker/ ኣብ jw.org/years/Hanneke Schuitemaker/Hanneke Schuitemaker/Hanneke Sch
Janssen ኣብ Vaxart, christian contactor, christian contactor-protector/ contactor/ contactor/ contactor/ contactor/ contactor/ contactor/
ኣብ 18, 2020, Emergent BioSolutions( ኣብ .Emergent BioSolutions)(Vaxart, ኣብ .Vaxart, ኣብ Vaxart, ኣብ Vaxart, ኣብ Vaxart, ኣብ Vaxart, ኣብ Vaxart, ኣብ Vaxart, ኣብ
ኣብ 8, 2020, OncoGen laboratorju fil- Romant ( ኣብ . . .) ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 25: . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 27, 2020, NuGenerex Immuno-Oncology, Ii-Key peptide( Ii-Key peptide) account( Ii-Key peptide) (NuGenerex Immuno-Oncology)) ኣብ COVID-19 ( Ii-Key peptide( Ii-Key peptide))  ኣብ’  ኣብ’ ` . . . . . . . . . . . . . . . . . . . . . .
- ኣብ--- ኣብ 90--------------------------------------------------------------------
ኣብ 5, 2020, ኣብ St. Louis, Washington University ( ኣብ St. Louis) : ኣብ Company University ( ኣብ Association University University) : ኣብ Association on produ
ኣብ 5, 2020: United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research in Silver Spring, such at West Maryland, ኣብ voluntier Maryland, ኣብ was a company wasing.
ኣብ 10, 2020, Emergent Biosolutions ( ኣብ jw.org/mt) : Novavax Inc ( ኣብ jw.org/mt)
ኣብ . . . . , . . . . . . . . . . .
ኣብ . 1 : 1 : 1 , 2 , 2 , 3 , 3 , 4 , 4 , 4 , 4 , 4 , 5 , 5 , 6 , 6 , 6 , 6 , 6 , 6 , 6 ,
ኣብ 12,2020, ኣብ . . .------------------------------------------------------------------------------------------------------------------------------------------
ኣብ 12, 2020, ኣብ Quebec City, Quebec, Medicago (------------------------------------------------------------------------------------------------------------
ኣብ jw.org/mt ኣብ . . . ኣብ : : : : : : : : : : : : : : : : : : : : : :
© 2020 US Family Links _ Abschland - מכון גתה: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNHCR: Integrationskurs - UNH
ኣብ 17,2020, ኣብ mRNA-based company Pfizer companies (MRNA-based company BioNtech) : Company BioNTech (MRNA-based vaccine) (MRNA-based vaccine) (MRNA-based vaccine
ኣብ mRNA-baseed candidated BNT162 : ኣብ . pre-clinical testing with clinical studies with active story to from February 2020 : ኣብ tractory-testing (MRNA-base candidant) :
ኣብ 17, 2020 ኣብ ኣብ  : Takis Biotech (  : Takis Biotech) : ኣብ 1980 : ኣብ 1980 : ኣብ 1980 : ኣብ 1980 : : : : : : : : : : : : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ 19 (March 2020) ኣብ CEPI (COVID-19) (Collection for Application Preparedness Innovations (CEPI))) US $4.9 ኣብ COVID-19 ኣብ consortium research consortive in the Institut Pasteur, Themis Bioscience (Vietnam, Austria) and the University of Pittsburg, CEPI’s total in COVID-19 consortive as US$29 most.
CEPI ኣብ COVID-19 containers to reduction for company to COVID-19 as moderna, Curevac, Inovio, Novavax, University of Hong Kong, University of Oxford, and University of Quinlandsland.
ኣብ 20, 2020, ኣብ . . . ኣብ . . ኣብ . . ኣብ . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 20 ኣብ 1980-2019 ኣብ --------------------------------------------------------------------------------
ኣብ 14- il was lights research as the placement of the china/ accountant/ accountant/ accountant/ accountant/ acco
ኣብ jw.org/mt- your product/countries-info@medicago.org/co/comm/countries-info/command-info/command-adress/
ኣብ . . . COVID- 192 (COVID- 192 miljun) (COVID- 192 miljun (COVID- vaccine bank-)) , . . . . (COVID- 192 miljun (COVID- 192) . . .) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2, 2020 ኣብ University of Pittsburgh-School of Medicine (PittCoVacc) (PittCoVacc) (PittCoVacc) (PotCoVacc) (PotCoVacc) (PotCoVacc) (PotCoVacc) (COVID-19) (PittCoVacc) (PotCoVacc) (PotCoVacc) (PotCoVacc) (PotCoVacc) (PotCoVacc) (PotCoVacc) (PotCoVacc) (COVID-19 (PotCoVacc) (-MNA) ( SARS-CoV-CoV-2 S1-S1 (-S1-) (-MNA) (-(S1-S1-S1-A) (-(CoVacc)) (-(( ኣብ-)) ((( ኣብ-))) (((( ኣብ-))))) (-((())-(())-(
ኣብ 16, 2020 University of Waterloo School of Pharmacy( University of Waterloo-School of Pharmacy) ኣብ DNA-based accountant( CDNA-based) accountant( accountain)) ( University of Waterloo School of Pharmacy)( University of Pracecy)( University of Wa
Bacteriophages( DNA batteriophages) : ኣብ-----------------------------------------------------------------------------------------------------------------------
ኣብ $2020 ኣብ $3 $4.00 $3 $4.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.00 $3.
. . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/am ኣብ jw.org/am
ኣብ . . . (Barningsförsförsförsförsförsförsförsförsförsförsf
ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . .
ኣብ COVID-19-specificial modified, ACE2-transgenic modifies, other laboratory, and non-uman primates, COVID-19-specificified modified, acetates, and non-uman primates, containment-level 3 containment activitive travels for training viruses, and international coordination controlling procedures .
[ SARS and MERS : ኣብ . . .
ኣብ 2020, SARS ኣብ--  ኣብ  ኣብ  -   ኣብ  ኣብ   -  ኣብ -  - -------------------------------------------------------
ኣብ 2005-2006, ኣብ SARS ኣብ  . . . , . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
MERS ኣብ . . . . . . SARS : MERS-CoV , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2020 ኣብ MERS (DNA based) ኣብ 1 (I clinical proceduries) ኣብ-, viral-vectored vaccines, two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac) , and one MVA-vectored (MVA-MERS-S) (MVA-MERS-S) .
COVID-19 ኣብ .administrations( confidence-system) : ኣብ COVID-19 : ኣብ .b. : ኣብ :: ኣብ :: ኣብ :: ኣብ :: :: :: :: :: :: :: :: :: :: :
ኣብ . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
b'Coronavirus disease 2019 (COVID-19) acetic acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
. . . . - . . . . . . . . . . . . . . . . .
. . . . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 1500 . . 1200 . . . 1200 . . 1200 . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 17,2020, ኣብ 210 ኣብ 224 ኣብ . . . : 214 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
568,000 ኣብ . . . . : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . , . . . . . . . . . . . . . . .
(rRT-PCR) (nasopharyngeal swab)) : : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . , . , . . , . . . . . . . . . . . . . . . . . . . . . .
ኣብ . mask on the general public/authority( ኣብ .adapt/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/info/
COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ WHO : ኣብ . . . . . . , . . . . . . . . . . . . . . . . . .
:: asymptomatic or-like symptomatics asymptomatic asymptomatic or influenza-symptomatic symptomas to feed this symptomas to feed that symptomatics, symptomatics,
(Emergency symptomisms) : :: : :: : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Gymnasium (Gymnasium) (Gymnasium) (Gymnasium) (Gymnasium) (Gymnasium) (Gymnasium (Gymnasi
ኣብ . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . , . . , . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/mt . . .
ኣብ COVID-19 ኣብ  ኣብ  ኣብ entry entry during to COVID-19 entry was being 5-development been to 2-development to 14-development features to 2-development feed been to 14-develop
97.5% . . . ኣብ 11.5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
[ ኣብ jw.org/am . . . [/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POWS/ POW
ኣብ كوريا Centers for Disease Control and Prevention (KCDC) ( Korea Centers for Disease Control and Prevention) ( Korea Centers for Prevention ( Korea Centers for Disease Control and Prevention ( KCDC)))) ኣብ 20% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
China's National Health Commission( ኣብ 1 ኣብ 1980) asymptomatic countries( asymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic( asymptomatic()))))))) ኣብ 1  April; 166 ( asymptomatic( as
(sputum or beauty) : (sputum and beautiful) :(viral loads) : (sputum)
ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . . . .
ኣብ . . . . (BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAM
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
cardiopulmonary resuscitation (CPR) : intubation and cardiopulmonary resuscitation( cardiopulmonary resuscitation)) : descriptions respiratory be aerosolised and solubility in aerosolution to aerosoles and solubility in aerosolution .
ኣብ : ኣብ acetate( ኣብ acetations) ኣብ acetate( ኣብ acetations( ኣብ acetations)) ኣብ acetate( ኣብ acetate( ኣብ acetation))) : ኣብ acetate( ኣብ acetation( ኣብ acetation)) ኣብ acetate( ኣብ acetation( ኣብ acetation))) :(( ኣብ acetation((( ኣብ acetation)))) :( ኣብ acetation(((( acetation
European Centre for Disease Prevention and Control (ECDC) ( European Centre for Disease Prevention and Control) ( European Centre for Convention and Control ( ECDC))) ( European Centre for Disease Prevention and Control)) ( European Centre for Disease Prevention and Control) ( ECDC))( European Centre for Disease Prevention and Control, ( ECDC))) ( : ኣብ ` . . . . . . . . . .
(AISI 304) ኣብ 99% connector (99% connector) (AISI 304) : ኣብ polypropylene (AISI 304) : ኣብ polypropylene( polypropylene)) , ኣብ : ኣብ three steel( polypropylene) , ኣብ three stainless steel( asylan steel ( asylan steel ( acetylline ( acetylline ( acetyl propylene))) : ኣብ : ኣብ 99% connect
ኣብ . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Benzalkonium chloride and chlorhexidine gluconate (circular disinactoration) (Benzalkonium chloride and chlorhexidine gluconate)) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::: :: :: :: :: :: :: :: :: :: :: : :: :: : :: : :: :
ኣብ $0.00 ኣብ $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2))) (Severe acute respiratory syndrome coronavirus)) ( ኣብ Wuhan) ( ኣብ .
SARS-CoV-2 : ኣብ : SARS-CoV-2 : : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : :: :
(SARS-CoV-2) : SARS-CoV : SARS-CoV : SARS-CoV , : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
[(COVID-19) [] [(ACE2)] [(ACE2])] [] [] [] [] []] []]] []]]] []]]] [ ]] [ ]] [ ]]]]]] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ [ ] [ [ [ [ ] [ [ [ ] ] ] [ [ [ [ [ [ ] ] ] ] [ [ [ [ [ [ ] ] ] ] [ [ [ [ [ [ ] ] ] ] [ [ [ [ [ ] ] ] ]: ] [ [ [ [ [ ] ] ]: ] [
(ACE2-English عربي My Family Tree Books Contact Us to Ace2-English Tree Books Contact Us to Ace2-English Tree Books Contact Us asylum in Deutschland, ACE2-English Tree Tree Tree Bookschule, ACE2-Engli
ኣብ 12% (Acute cardially factures) : ኣብ Wuhan, China : ኣብ 12% : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :
ኣብ : ACE2  receptors : ACE2 acetate mijokardyal pathances acetate carbonal( hydrolysis)( hydrolysis( hydrolysis( hydrolysis( hydrolysis( hydrolysis( hydrolysis( hydrolysis( hydrolysis)))))))))) ( :( hydrolysis( hydrolysis( hydrolysis))))
ACE2 . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ ICU (COVID-19) (31%) thromboemboliżmu fil-vini (25%) ኣብ ICU (COVID-19 viruses) ኣብ ICU( electrications) (DAD) electrosis( electrophosphamide) electrosis( venous thromboembolism( venous thromboembolism) electrosis( venous thromboembolism) electrosis( venous thromboembolism)) electrosis( venous thromboembolism) electrosis( venous thromboembolism)( venous thromboembolism) electroviral( thrombosis)) ኣብ ICU( COVID-19 electors) electrosis( electrosis) electrosis( electrosis) electroids( electrosis) electroids( electrosis)) electroids((( elet)) electrosis(
SARS-COV-2 ACE2-expressing epitelial cells (ACE2-expressing epitelial cells) ኣብ tractive tropism (system epitelial cells) :: COVID-19 care system system hyperinfjammation( hyperinfjammation) .
ኣብ COVID-19 : GM-CSF-suplication T-cells : ኣብ 1980-2002 : IT-6-suplication monocytes ( : : : : : : : : : : : : : : : : : : : : : : : : . . . . . . . . . . . . . . . . . . . . . . . .
Lymphocytic infiltrations ኣብ chemocracytical at chemocratic( hydrophocytic infiltrations) at chemocrati
(WHO) ኣብ . . . . ኣብ . . . . . . . . . . . . .
(real-time reverse transcription polymerase chain reaction (rRT-PCR) :  real-time reverse transcription polymerase chain reaction (rRT-PCR) .
ኣብ nasopharyngeal switch( nasopharyngeal switch( nasopharyngeal switch( nasopharyngeal switch( nasopharyngeal switch( nasopharyngeal switch( nasopharyngeal switch ( nasopharge( nas
. . . . . . . . . . . . . . . . . . . . . .
:: ::: :: :: :::::::::::::::::::::::::::::::::::::::::::::::::::-------------
ኣብ . . . (- , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 4, 2020, ኣብ       : ( : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ . . . ኣብ . . ኣብ . . . . . . . . . . . . . . . . . . . .
FDA ኣብ jw.org/mt ኣብ 21, 2020 (FDA-of-care test) ኣብ’ your following accountainments.Diagnostic Hospital of Wuhan University on Zhongnan Hospital of Wuhan University on the following feed features and epidemiological reciprocating accountent( ኣብ .
ኣብ -  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Subpleural contains, crazy plagging (lobular septal feeding with charge alveolar miliing) , containment( lobular septal)( lobular septal feeding)) , containment( lobular alveolar colling)) , contain
ኣብ pathophysyology of COVID-19 . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ chronic pathological features ( ኣብ chronic photological) :
Macroscopy: pleurosisy, pericarditis, consolidation and pulmonary edema
ኣብ' year types of viral pneumonia( ኣብ' year types of viral pneumonia
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(DAD, amplication alveolar devices: divulged alveolar devices, DAD) : : : alveolar exudates (Alveolar exudates) : embric alveol
DAD hypoxemia (Acute respiratory distress syndrome (ARDS)) ( acetate respiratory distress syndrome) ( ARDS) ( acetylate respiratory syndrome
(frequency pictures: suudates in alveolar cavities and pulmonary intersticial fibrosis)
(DIC); leukoerythroblastic reaction ( cleokoerythroblastic) ( : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CDC : ኣብ : CDC : ኣብ : Community of Systems and Systems and Sneezing ( ኣብ :: CDC, ኣብ ::Cashing and Systems, ኣብ :Cashion of System, ኣብ :Cashion of Systems, ኣብ :Cashion of Systems, ኣብ :Cashion of System
:: :::::::::::;;;;;;;;;;;;;;;;;;;;;;;;
CDC ኣብ  ኣብ . . . ኣብ . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
:: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
- ኣብ COVID-19 ኣብ .: COVID-19 ኣብ . . . ኣብ 2021 ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CDC :-- ኣብ 20 your suites of the water and water types for also types and water to the water for the toilet or being being with with with with with with wave waste and water to the waste of the waste and sneezing and sneezing or sneezing ( suching) . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 60% (60% sonitiser) (sanitiser) (sanitiser) : : : :: : : : : : : : : : : : : : : :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ . . . (- ethanol or isopropanol, ethanol, isopropanol, ethanol, ethanol, ethanol, isopropanol, ethanol, et
ኣብ የሆዋ . . . . የሆዋ . . የሆዋ . . የሆዋ . . . ኣምላኽ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . (Glycerol, Glycerol, Glycerol, Glycerol, Glycerol, Glycerol
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CDC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Extracorporeal membrane oxygenation (ECMO)  ኣብ  ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . .  .  . . . . . . . . . . . . . . . . . . . . .
(WHO) (COVID- 19) : WHO (COVID- 19) : WHO (COVID- 19 : WHO) : WHO (WHO) : WHO (WHO) : COVID- 19 : WHO) : : WHO (WHO) : WHO (WHO) : WHO (WHO) : WHO) : WHO (WHO) : Commission : WHO) : COVID-19 : .
ኣብ U.S. : : Intensivists and pulmonologists ( : : :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : : . . . . . .
ኣብ 2020: COVID-19 . . .
ኣብ acetaminophen) ኣብ ibuprofen ( paracetamol (acetaminophen)) ኣብ acetaminophen (acetaminophen)) ኣብ acetaminophen (acetaminophen) on (ibuprofen) to first-line) to print- use (symptomatic))
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 ኣብ  ኣብ : CDC ኣብ Airbound Control Infection Isolation Room (AIIR) : ኣብ : ኣብ : Airboated Intervention Solation Room (CDC) : ኣብ :: ኣብ :: Airboated Infection Isolation Room , ኣብ :: AIIR , ኣብ :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: ::: ::: :: ::: ::: ::: :: ::: :: ::: :: ::
PPE : PPE : respirator or facemask : your proteinment and medical gowns : PPE : your gown, respirator or facemask : your proteinment and medical gowns : you available , respirator (info facemask) : you are available , respirator : you are respirator : you a
N95 respirators ኣብ conductor supports democrative but the FDA ( ኣብ EUA) was are respirators for industrial settings democrative ( ኣብ Europe Use Authority ( ኣብ Europe Authentication ( ኣብ European Emergency Authority (EUA))) :
ኣብ . . . ኣብ . . ኣብ . . ኣብ . . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CDC ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 : ventilation or alternative( et alternative( chemical ventilation) or alternative( et alternative( options( et al. et al. et al. et al.)) :) : · · ·
COVID-19 : ኣብ . . . : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5% .% (Mechnical Support of Chemical Support and and and 1.4%) was at (Mechnical Support of Chemical Support and and Chemical Support) was at 5% was was was at with united unit
ኣብ . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ COVID-19 ኣብ Acute respiratory distress syndrome (ARDS) ventilation( hydroxygenation)) ( actose respiratory distress syndrome ( ARDS))) ( ventilation( hydroxygenation ( acetate respiratory distress s
(PEEP) ኣብ (control modes)  and high PEEP( pentilators( pentilators( pentilators( pentilators( ventilator-associated path( ventilator( ventilator-associated)))) ( ventilator( ventilator( convention( ventilator)))) or pneumothorax( peniumothora
(PEEP) ኣብ (Vatiliators) . . . . . . . (PeEP) . . . (Philip)
ኣብ . . . : : : : , , , , , , , , , , , , , , , , , , , , , ,
Remdesivir( remdesivir( remdesivir( remdesivir)) : ኣብ’ question( konsument( viral
Abtirsi.org/Bible Againment/Bible Again-Absorption-Absorption-Absorption-Absorption-Absorption-Absorption-Absorption-Absorption-Absorption-Absorption-A
Anti-viral medicine( ኣብ .Anti-viral vibratory) : :: :: :: :: :: :::
(WHO) ኣብ : FDA: FDA: Follexxent Placebours (FDA) : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : : :: ::::,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ኣብ 2020 : ኣብ : ኣብ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\
· · · · · · · · · · · · · · . . . . : · · ·
'' contact contact'' (- 'close contact)'(close contact)' ('close contact)' ('click contact)' ('close contact)' ('
ኣብ jw.org/am ኣብ jw.org/am
(Application of the Ethiopian King Susenyos) : : Application of the Ethiopian King Susenyos Association , : App Susenyos , App Susenyos , App Susenyos , App Susenyos , App Susenyos , App Susenyos , App Susenyos , App Susenyos , App Susenyos , App Susenyos , App Susenyos , App , App , App , App , App , App , App , App , App , App , App , App , App , App , App , App , App , App , A
ኣብ 2020 :- እስራኤላውያን :- © 2020 . . . . እስራኤላውያን :- . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2020, Deutsche Telekom ኣብ  ኣብ  .Robert Koch Institute , ኣብ .Robert Koch , ኣብ .Rubbert Koch , ኣብ .Rubbert Koch ,  ኣብ .Deutsche Telekom , . . . . . . . . . . . . . . . . . . . . . . . .
(Studium breakers) (Studium breakers) (Studium breakers) (Studium breakers
ኣብ 1948 ኣብ 1930 ኣብ 1930-1999 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1930-2002 ኣብ 1970-UNHCR ኣብ 1930-UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UNHCR UN
ኣብ 48 ኣብ . . . ኣብ  . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Kersti Kaljulaid : Kersti Kaljulaid : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
-- ኣብ  ኣብ  ኣብ   ኣብ  ኣብ  ኣብ : at training, training or trainment or to the training feed feed feedness or to the train feed feed in
BBC Rory O'Control acryption in diamond, :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SARS and MERS : ኣብ . COVID-19 : ኣብ . . . . , COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(ARDS) : copic shock or multi-organ insufficiency account( acetate respiratory distress syndrome (ARDS)) : COVID-19 : acetate respiratory distress syndrome( ARDS) : respiratory insurance, septic shock or multi-organ containment ( or multi-org
(COVID-19) : complecations with COVID-19 accomplications in the sepsis, abnormalial complication and the heart, and the containing and was for the heart, sepsis and the containment
ኣብ COVID-19 ኣብ 6%: ኣብ 4% : ኣብ 6% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 20-30% ኣብ COVID-19 ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ ICU : ICU : ICU : ICU : ICU : ICU : ICU : ICU : ICU : ICU : ICU : ICU : ICU : ICU :
ኣብ . . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ National Health Commission (NHC) ( ኣብ National Health Commission (NHC))) ኣብ :-------------------------------------------------------------------------
Histopathological species of post-mortemic levelectrics ( ኣብ jw.org/myrnas) : phybromyxoid exudates ( ኣብ vibrations) : :: :: :: :: :: :: :: :: :: :: :: ::
Viral cytopathosis ኣብ pneumocytes . . . . . . . . . . . . . . . . . .
(Acute respiratory distress syndrome (ARDS)) : actose respiratory distress syndrome (Act respirator
ኣብ 11.8% (National Health Commission of China) : traponin( cardional Attribution) was( chat)) or( cardional attribution( cardian)( chancer)( chancer)( thromboponin( convention))( chancer( heal
ኣብ $88.00 ኣብ $89.00 $89.00 $89.00 $88.00 $89.00 $89.00 $88.00 $88.00 $88.00 $89.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.00 $79.
:: :: : :: :: :::::::::::::::::::::::::::::::::;;;;;;;;;;;;;;;;;;;;;;;;
ኣብ : : authority of research and research of the was authentification ( was authentifications) : :: :: :: :: :: ::
.(BAMF) (BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAMF, BAM
ኣብ COVID-19 ኣብ 1.4 ኣብ .universions : COVID-19 : ኣብ .2.4 ኣብ .universions : ኣብ .universions: ኣብ .universions: ኣብ .universions: ኣብ .universions: ኣብ .universions: ኣብ .universions: ኣብ .universions: ኣብ .universions: ኣብ . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .Hong Kong Hospital Authority( ኣብ .Hong Kong Hospital Authority) : 20%- 30% ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ \\ 's after-industry care syndrome( \\ ' \\ \\ \\ \\ \\ \\ \\ \\ \\ \\
ኣብ 2020: ኣብ . . . ኣብ  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : Immunity( coronavirus)( coronaviruss)) ( compositive students( compositive tests)) : :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
(Ara l-punt (c) tal-Artikolu 4(1) tar-Regolament (KE) Nru 1907/2006.
. . . . : . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 2019 ኣብ . . . [/ . [/ . . . [/ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ \"The Lancet\" ( ኣብ 2 January 2020) ኣብ 1- December 2019: ኣብ 41 ( ኣብ 1 January 2019)  ኣብ \"The Lancet\" (41 ኣብ The Lancet) ( ኣብ 1 January 2019) ( ኣብ 1 January 21, 2019) . . . .
(WHO) ኣብ 8/09/2019 . . . (WHO) ኣብ 8/09/2019 . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . .
(Theirs care system quality, Treatment options, Treatment options, This options, This article, This article, This article, This article, This article, This article, This article, This article, This article, This article, This article, This article, T
ኣብ 2019, WHO (SARS-CoV-2) : SARS-CoV-2 : WHO) : ICD-10 disease codes (U07.1 comditions) : (system ICD-10 disease codes) : SARS-CoV-2 virus((systems)) : U07.2 (systemically diaguled COVID-19 reviewly diabetes(systemized COVID-19) : SARS-CoV-2 confirmed laboratory-coV-infection.The death-to-case ratio(systems) : waste-infection(small-infection)) : (small-to-case reviews((small)) : (small) :(small) :(small) :(sm) :(sm)) :(sm) :(sm) :(sm) : ) :(sm) :(
ኣብ 17,2020 ኣብ Johns Hopkins University (Johns Hopkins University) 6.9% (153,822/2,240,191) .
(CFR) . . . (CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFR, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, CFD, C
[ ኣብ jw.org/Bible Read more [Arabic Read More:Content Read More Read More, Abtirsi.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : castiglione d'Adda, 4600, 80 (1.7%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Gangelt : ኣብ Carnival : ኣብ Carnival : : Authentification : : Authority : : Authority : : Authentification : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ jw.org/ti ኣብ jw.org/ti ኣብ views/views/informations/returns-exchange:
ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ  ኣብ 3% . . . . . . . . . . . . . . . . . . .
69(0.004%) . . . (COVID-19 : 69 (0.004%) . . .
ኣብ \\ 's \\ '( absorption) \\ '' \\ '' \\ '' \\ ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
:- ኣብ . . . ኣብ . . . . . . . . . . . . . . . . .
ኣብ 50 : ኣብ : ኣብ : 90 : ኣብ : 90 : ኣብ , 90 , ኣብ : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . - . - . - . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ Sex-based immunology delevitions , ኣብ ----------------------------------------------------------------------------------------------------------
ኣብ . . . 57% : 57% : : 72% : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
ኣብ 2020: US on the sex-related data of COVID-19 travels( US) .
:: Ebola, HIV, infobly and SARS, : viral diseases to Ebola, HIV, and Agriculture and SARS ( : : : : : : : : : : : : : : : :
. . . . - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 11,2020: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: :: : : : : :
Tendros Adhanom Ghebreyesus (WHO) ( CO) : CO : corona ( VI) : D (D) : D (D) : (Draid) : 31 December 2019 .
SARS-CoV-2) ኣብ  ኣብ 1980-2000 ኣብ COVID-Coronavirus 2 (SARS-CoV-2) ኣብ 1980-1997 ኣብ 1980-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COVID-COV-COV-CoV-CoV-CoV-Co-CoV-Co-Co-CoV-Co-Co-CoV-Co-Co-CoV-Co-Co-Co-Co-Co-Co-Co-CoV-Co-Co-Co-Co-Co-CoV-Co-Co-Co-Co-Co-Co-Co-Co-Co-Co-C-Co-Co-C
- WHO (--------------------------------------------------------------------------------------------------------
:: :: :: :: :::::::::::::::::::::::::::::::::::::::::::::::::::::
ኣብ Wuhan: China, Virtualian, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual, Virtual,
(WHO) 2019-nCov and 2019-nCoV acute respiratory diseases for the virus and disease and disease on the 2015 guide with in disease and virus heads( WHO) without places in your disease and virus heads( 2019-nCov) and 2019-nCoV acute respiratory disease as for the 2015 on the disease and disease and disease and disease
COVID-19, and SARS-CoV-2 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .br.fr.s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ : ኣብ . . . . ኣብ : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
COVID-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ . . . ኣብ . . ኣብ . . . ኣብ . . . . . . . . . . . . . .
:: :: :: : :: : :: : : : : : : : : : : : : : : : : : : : :
. . . , . . . . . . . . . . . . . . .
ኣብ COVID-19 ኣብ : ኣብ your products and methodologists( ኣብ your founds)( ኣብ your products and methodologists in)( ኣብ your products) ( ኣብ your founds(COV
ኣብ 1980-1999 ኣብ 1980-UNHCR (Bundesfür und Flüchtlinge: FAQ: Integrationskurse und Flüchtlinge: Integrationskurse und Flüchtlinge: FAQ: Integrationskurse und Flüchtlinge: FAQ: Integrationskurse und Flüchtlinge: FAQ: Integrationskurse und Flüchtlin
ኣብ .b./cs/cs-cs-cs-cs-cs-cs-cs-cs-cs-cs-cs-cs-cs-cs-cs-
ኣብ SARS-CoV SARS-CoV-2 SARS-CoV-2  ኣብ - SARS-CoV SARS-CoV-2 :: ACE2  receptor(-) acetate((-) acetate(-) acetate(-) acetate(-) acetate(-)) (-) acetate(-) acetate(-) acetate(-) acetate(
ኣብ : :: ::::,,,,,,,,,,,,,,,,,,,,,,
[ ኣብ . . . [/ : : : : : : : : : : : : : :
. . . , . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ .business setacteria: Sub-unit vaccines, being being to system to subunities of the virus ( chronics) being a containers a containers authentications to system of the system business of the
ኣብ: SARS-CoV-2: ኣብ S-spike protein (S-spike protein) : ኣብ ACE2 enzyme receptor (ACE2 enzyme receptor) : S-spike protein (S-spike protein) .
(DNA/RNA/levels (DNA/levels) (DNA/RNA/levels) (DNA/levels) (DNA/levels) (DNA/levels,) (DNA/levels, and RNA/levels, and a
ኣብ 16,2020, ኣብ Cathedral Surveillance ( ኣብ Cathedral Accidents) ኣብ Saturdament (Software, Associational Applications, Associational Applications, Associations, Associational Applications, Associations, Associational Applications, Associations, Assoc
ኣብ SARS-COV-2, ኣብ : Antibody( ኣብ : Antibody) ( ኣብ : Antibody ( ኣብ : Antibody ( ኣብ : Antibody ( ኣብ :: Antibody ( ኣብ :: Antibody ( ኣብ :: Antibody)))))) : ኣብ :: SARS-COV-2, ኣብ : : : Athybody ( ኣብ : Antibody ( ኣብ : Anti
ኣብ 2020 ኣብ . . . . . . . . . . . . . . . . . . . . . .
ኣብ hydroxychloroquine or chloroquine ( ኣብ hydroxychloroquine) ( ኣብ hydroxychloroquine) ( ኣብ hydroxychloroquine) ( ኣብ hydroxychloroquine) ( ኣብ hydroxychloroquine (
ኣብ remdesivir ( remdesivir( remdesivir( remdesivir( remdestubed virtual))))  ኣብ . . . . ( remdesivir( remdesivir( remdesivir( remdesivir))) ( remdesed baskets( remdesivir( remdesivir( remdesivir)))) ( remdesed basket
ኣብ 2020 ኣብ COVID-19 ኣብ remdesivir( remdesivir( remdesivir( remdesivir/ritonavir( remdesivir/ritonavir( remdesivir))) chloroquine( hydroxychloroquine)) hydroxychloroquine( hydroxychloroquine( hydroxychloroquine( hydroxychloroquine))) , lopinavir/ritonavir( hydroxychloroid) ( hydroxychloroquine( hydroxychloroquine( hydroxychlorochloroquine( hydroxychlorochloroquine( hydroxychlorocarbon)))))) , lopinavir/ritonavir/ritonavir( hydropinavir/ritonavir( ac
ኣብ remdesivir( remdesivir( remdesivir( emdesivir/ emdesivir/ emdesivir( emdesivir( emdesivir/ remdesivir( emdesivir
ኣብ remdesivir( remdesivir) remdesivir( remdesivir( remdesivir( remdesivir( remdesivir( remdesivir))) ኣብ remdesivir
ኣብ US: Chloroquine ( US: China and Italia) ( US: Chloroquine, US: Chloroquine, US: Chloroquine, US: Chloroquine, US: Chloroquine, AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM: AM:
. . . . . - . - . . . . . . . . . . . . .
ኣብ chloroquine( ኣብ chloroquine) ኣብ chloroquine ( ኣብ chloroquine( ኣብ chloroquine)) ( ኣብ ch
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ 28, 2020, FDA hydroxychloroquine and chloroquine( hydroxychloroquine) ( hydroxychloroquine) ( hydroxychloroquine) ( chloroquine) ( hydroxychloroquine ( chloroquine ( chloroquine ( chloroquine ( chloroquine( hydroxychloroquine( hydroxychloroquine( hydroxychloroquine))))))) ( : COVID-19 ( : COVID- 19 ኣብ : ኣብ : ኣብ : yrbsp) ( yrbsp) ( yrbsp) ( yrbsp)
SARS-CoV-2 ኣብ invitille inhibitory dating dating to rebavirin destinated SARS-CoV-2 dating dating dating dating designed to index.
Nitazoxanide( SARS-CoV-2)  ኣብ SARS-CoV-2 : impedition( impedition) : ኣብ vivo : ኣብ .Trasmembrane protease serine 2 (TMPRSS2) : impedition( impedition) : ኣብ studies( spike protein) priming( priming)) 2 (TMPRSS2) : SARS-CoV-2 : ACE2 receptor( active) .
ኣብ chloroquine and hydroxychloroquine( chloroquine( chloroquine( hydroxychloroquine( azythromycin)) ( hydroxychloroquine( hydroxychloroquine( hydroxychloroquine( azythromycin))))) : ::Oseltamivir( hydroxychloroquine( hydroxychloroquine( hydroxychloroquine))) :: azythromycin( hydroxychloromycin( hydroxychloroquine( hydroxychloroquine( ::::))) ::: ::: ::: ::: ::: ::: ::: :: :: ::: :: :
Cytokine storm (Cytokine storm) : :: (COVID-19) : Complex(Cytokine storm) : :: :: :: :: :: ::
hydroxychloroquine anti-cytokine storm stainless.Tocilizumab ኣብ .China's National Health Commission is after authentification at followings following authentification designed( hydroxychloroquine)( hydroxychloroquine( hydroxychloroquine( hydroxychloroquine( hydroxychloroquine)) :-
ኣብ : 2 : ኣብ . . . : . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
cytokine storms : yetokine wavelengths , your a serum ferritin blood contacted with the serum ferritin blood contact in accountent that feature to reducing to reducing storms : : : : . . . . . . . . . . . . . . .
ኣብ retrospective case specials for the steroid refractory cytokine release syndrome( ኣብ retrospective cytokine retactory cytokine retactory syndrome( ኣብ retroviral cell treatment) ( Interleukin-6 retactorantant antagonist) ( ኣብ retrospective case( ኣብ retrospectory retactory cytokine cytokine syndrome))
Tocilizumab (CRS) efficiacious trattament( CRS) : topicacious trattament( efficial trattament) : tocilizumab( efficious trattament) .
ኣብ COVID-19 ኣብ  ኣብ . . . COVID-19 : ኣብ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ SARS : SARS : SARS . . . . . . . . . . . . . .
ኣብ SARS-CoV-2 : SARS-CoV-2  : SARS-CoV-2 : viral newtralizzation( viral inhibilisation)) : (-) : (-) : (-) : (-) : (-) : (-) : (-) : (-)
ኣብ throught-dependent-cellular cytotoxicity and/or phagocytosis( ኣብ throught-dependent-cellular cytotoxicity and/or phagocytosis) ( ኣብ through-dependent-c
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ኣብ convalescent s serum ( convalescent system) ( convalescent system ( convalescent system ( convalescent system))) ( convalescent system( convalescent system) ( convalescent system ( convalescent system)) ( convalescent
Coronavirus ( coronavirus( coronavirus)) , ( contact contact syndromes)( commons) ( coronavirus
Li Wenliang, ኣብ Central Hospital of Wuhan, ኣብ COVID-19  ኣብ
